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ABSTRACT 
 
 
Prebiotic oligosaccharides and polymers are a form of dietary carbohydrate that are selectively 
fermented by the microbiota of the lower gastro intestinal tract and confer a health benefit to the host 
other than that of nutrition. Galacto-oligosaccharides (GOS) are a prime example of a dietary prebiotic 
and closely imitate human milk oligosaccharides. They consist of galactose moieties, often linked to a 
terminal glucose. GOS promote the growth of beneficial bacteria that aid in the prevention and 
treatment of gastro intestinal dysbiosis which has been linked to various diseases such as auto-immune 
disorders, certain cancers and metabolic disorders. They are often synthesised from lactose by the 
glycoside hydrolase enzyme, β-galactosidase. A cheap substrate for the production of GOS is whey 
permeate, an industrial waste product. Another prebiotic dietary carbohydrate is Fructo-
oligosaccharides (FOS), which consist of fructose moieties often linked to a terminal glucose, and much 
like GOS is associated with the numerous health benefits of prebiotics. FOS is synthesised from the 
substrate sucrose by fructosyl-transferases. There is a great demand for new enzymatic biocatalysts 
with improved capabilities of producing GOS and FOS. In this study the construction and screening of 
numerous metagenomic libraries for prebiotic oligosaccharide and polymer synthesising enzymes are 
presented. The metagenomic DNA was sampled from locations rich in the substrate used for the 
production of the before mentioned prebiotics. The isolation, amplification and in silico analysis of three 
novel genes encoding proteins belonging to the Glycoside Hydrolase families 1, 2, and 68 are presented 
here. Their respective polypeptides were heterologously expressed in E. coli, purified and subsequently 
characterised biochemically in vitro through various means, and so too their respective products. 
Glycoside hydrolases often have two innate but distinct activities namely hydrolysis and trans-
glycosylation. All three the glycoside hydrolases described here, MS-βGluc1, HW-βGal1 and SAS-Ls, had 
high trans-glycosylation activity apart from their hydrolytic activity. They are all excellent candidates for 
the industrial production of prebiotics, whether it be GOS (MS-βGluc1 and HW-βGal1) or FOS (SAS-Ls). 
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OPSOMMING 
 
Prebiotiese oligo-sakkariede en polimere is ’n tipe voedings koolhidraat wat selektief gefermenteer 
word deur die mikro-biota van die laer gastro-intestinale sisteem, en lewer ’n positiewe gesondheids 
eienskap bydrae aan die gasheer anders as die oog op liggende voedings waarde. Galakto-
oligosakkariede (GOS) is ’n uitstekende voorbeeld van prebiotiese oligo-sakkariede en is ’n nouliks 
nabootsing van menslike melk oligosakkariede. Hulle bestaan uit opeenvolgende galaktose eenhede wat 
baie keer aan ’n terminale glukose molekuul gekoppel is. GOS bevorder die groei van voordelige 
bakterieë wat help met die voorkoming en behandeling van gastro-intestinale disbiose wat verwant hou 
met verskeie siektetoestande soos auto-immuniteit wanorde, sekere kankersoorte asook metaboliese 
wanorde. GOS word vervaardig vanaf melk laktose deur die glikosied hidrolase ensiem β-galaktosidase. 
’n Goedkoop substraat vir die produksie van GOS bestaan in die vorm van industriële wei invulling. Nog 
’n goeie voorbeeld van ’n prebiotiese voedings koolhidraat is Frukto-oligosakkariede (FOS), wat bestaan 
uit opeenvolgende fruktose eenhede wat dikwels gekoppel is aan ’n terminale glukose molekuul. Net 
soos GOS word FOS geassosieer met die verskeie gesondheids voordele van prebiotiese aanvulling. FOS 
word gesintetiseer vanaf die substraat sukrose deur ensieme genaamd fruktosiel-transferases. Daar is 
’n groot aanvraag vir nuwe bio-katalise met verbeterde eienskappe vir die produksie van GOS en FOS. 
In hierdie studie lê ons ten toon die konstruksie en toetsing van verskeie meta-genoom biblioteke 
waarvan die meta-genoom DNA verkry is van gebiede wat ryk is in die substrate vir die produksie van 
prebiotiese oligo-sakkariede en polimere, naamlik laktose en sukrose. Vêrder beskryf ons ook die 
isolasie, amplifikasie en in silico analise van drie eensoortige glikosied hidrolase familie 1, 2 en 68 
proteïene, onderskeidelik. Die drie proteïene genaamd HW-βgal1, MS-βgluc1 en SAS-Ls is heteroloog 
uitgedruk in E. coli, gesuiwer en biochemies gekarakteriseer tesame met hul onderskeie substraat 
produkte. Glikosied-hidrolases het dikwels twee ingebore onafhanklike en onderskeibare aktiwiteite 
genaamd hidrolise en trans-glikolisering. Al drie die glikosied-hidrolases wat hier beskryf word, het 
besondere hoë trans-glikolisering aktiwiteite hetsy vir GOS (MS-βGluc1 and HW-βGal1) of vir FOS 
(SAS-Ls), wat hul uitstekende kandidate maak vir industriële implementering en toepassing. 
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 General Introduction 
 
 Background 
  
The human microbiota refers to the collection of micro-organisms that reside either on, or in the human 
body and is composed of bacteria, fungi, archaea and their interacting viral particles. It has become 
increasingly evident that both the composition of the microbiota inhabiting the human gastrointestinal 
tract (GI), and its interaction with its surrounding environment, plays a pivotal role in human health [1]. 
Perturbations of the healthy biota due to various factors including, but not limited to, host genetics, 
antibiotics, diet and infection, can result in reduced microbial diversity and/or the loss of beneficial 
microbes as well as pathobiont expansion. This is referred to as dysbiosis [2].  
Over the last decade numerous scientific studies have linked dysbiosis of the gut microbiota to the 
pathogenesis of various intestinal and extra-intestinal diseases and disorders. These include 
inflammatory bowel diseases (IBD) like Crohn’s disease, ulcerative colitis, eczema, allergies, colorectal 
cancer, chronic fatigue syndrome, obesity and a range of autoimmune disorders including celiac disease, 
multiple sclerosis and rheumatoid arthritis [3]. Even cardiovascular health and autistic spectrum 
disorders have been linked with dysbiosis [4, 5], as have disorders of cognitive state like depression, 
anxiety and Alzheimer’s disease [6]. 
The intestinal microbiota varies between healthy and diseased individuals and in excess of 25 diseases 
and syndromes have been scientifically associated with an altered intestinal microbiome [7]. The major 
anaerobic bacterial genera associated with the GI tract are Bacteroides, Eubacteria, Fusobacterium, 
Bifidobacterium, Peptostreptococci, Clostridium, Lactobacillus and Streptococcus, with a higher 
representation of Bifidobacterium and Lactobacillus species being associated with a healthy and 
beneficial GI microbiota [8]. By targeting the intestinal microbiota novel avenues for the prevention 
and/or treatment of the above mentioned diseases could potentially become available. There are two 
broad means by which the composition of the intestinal microbiota can be altered, namely probiotics 
and prebiotics. 
Probiotics are defined as “live microorganisms that when administered in adequate amounts confer a 
health benefit to the host” [9]. With probiotics, contrary to popular belief, the effects are mostly 
transient as the administered microbes only rarely establish self-propagating cultures if a favourable 
environment is also created. None the less, the advantages and health benefits of probiotics are 
numerous and have been extensively reviewed [10-15]. 
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An alternative and/or additive approach to microflora management via diet is by means of prebiotics. 
These are defined as “selectively fermented ingredients that are non-digestible by the host, that result 
in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring 
benefits upon host health” [16]. Any dietary material that enters the GI tract that is non-digestible by 
the host is a potential prebiotic and this includes complex carbohydrate polymers and oligosaccharides. 
The difference between these are that oligosaccharides are defined as carbohydrates having a degree 
of polymerisation (DP) of between three and nine saccharide units, while polymers have a DP of ten or 
more. However, current prebiotic research mainly focuses on non-digestible oligosaccharides as these 
have been shown to have a fermentative bias towards Lactobacillus and Bifidobacterium, the two main 
genera associated with a healthy microbiota [11, 14, 17].  
The health benefits associated with prebiotics are numerous and wide ranging. They include anti-
inflammatory, anti-carcinogenic and immunomodulatory effects, as well as the lowering of 
cardiovascular risk factors and positive cognitive and mental health modulation [17-19]. They have also 
been associated with enhanced bio-availability and mineral uptake and the promotion of satiety and 
weight loss and the prevention of obesity [17, 20]. 
Fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS), lactulose, malto-oligosaccharides and 
inulin together with its hydrolytic derivatives, are the major prebiotics. Such prebiotic oligosaccharides 
can be obtained by three different means namely (i) extraction from plants, (ii) microbial/enzymatic 
synthesis, and (iii) enzymatic hydrolysis of polymers [21]. Plant sources of prebiotics include onions, 
chicory, garlic, bananas, asparagus, artichokes, leeks and tomatoes. FOS and GOS are currently the 
leading prebiotics available. GOS is synthesised from the simple sugar lactose by means of a 
β-galactosidase that also possess trans-galactosylation activity, whilst FOS is synthesised from sucrose 
by fructofuranosidase/invertase that also possess trans-fructosylation activity [22, 23]. The respective 
enzymes are utilized in either whole cell, free or immobilized formats for the production of prebiotic 
oligosaccharides [24].  
Functional foods are defined as foods that, by virtue of the presence of physiologically active 
components, provide a health benefit beyond basic nutrition [25]. They were previously based primarily 
on the fortification of foods with vitamins and minerals, however more recently they have shifted 
towards the addition of probiotics and prebiotics due to their synergistic effect on human health. 
Conventional prebiotics have Generally Regarded As Safe (GRAS) status and novel ones need only be 
generally assessed for risk only if they differ substantially [26]. The global prebiotic market is developing 
in a multi-billion dollar industry, driven largely by infant formula due to prebiotic oligosaccharides 
becoming one of its major components in an attempt to imitate human milk oligosaccharides (HMO) 
[27]. The search for novel prebiotics and the enzymes that make them, greatly add to this field. 
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 Brief review of objectives and methodological approach  
 
This study set out to discover and characterise enzymes that produce novel polymers and/or 
oligosaccharides comprised mainly of either galactose or fructose. The enzymes that facilitate this 
belong to the glycoside hydrolyse type family proteins and possess both hydrolytic as well as 
trans-glycosidic activity. They act on simple sugars like lactose and sucrose by transferring a glycosyl 
moiety to an acceptable donor after the initial hydrolysis.  
The search for these enzymes were mediated through the construction and use of metagenomic 
libraries from niche environments that have an abundance of either galactose or fructose present. In 
the case of galactose the first environment was one where milk and whey are disposed and which 
consequently contains ample amounts of the galactose containing disaccharide lactose. Secondly, a site 
of kelp degradation was sampled which contains structural and functional macro algae polysaccharides 
consisting primarily of galactose. With regards to galactose containing saccharides and polymers, the 
screening of these metagenomic libraries were facilitated by the use of a novel mutagenised 
Escherichia coli strain that has no endogenous β-galactosidase protein. Metagenomic libraries where 
screened using the ∆β-Gal mutant on minimal media plates, containing lactose as the sole carbon 
source. Only cells with metagenomic inserts that contain open reading frames (ORF) encoding proteins 
capable of hydrolysing the β-1,4 glycosidic linkage between the glucose and galactose moieties, should 
be able to grow.  
For fructose containing environments a metagenomic library constructed from process runoff at a sugar 
refinery was screened for novel enzymes producing fructose containing polymers and/or 
oligosaccharides. Screening for these enzymes were done solely based on the visual phenotype of a 
laboratory E. coli strain grown on sucrose. 
 
 Dissertation layout 
 
CHAPTER ONE is a brief introduction which aims to provide an overview of the relevant research field 
as well as the aims and objectives of this research project. It furthermore provides a chapter outlay of 
this dissertation. 
CHAPTER TWO is a literature review that aims to give a comprehensive exploration of the relevant 
literature with regards to prebiotic oligosaccharides and polymers, their properties and uses, as well as 
the enzymes that synthesise them. 
Stellenbosch University  https://scholar.sun.ac.za
 4 
 
CHAPTER THREE is a results chapter that describes the initial library construction, screening and clone 
selection, as well as the preliminary analysis of the positive clones for their potential 
oligosaccharide/polymer production capabilities. Of the sixteen positive clones and their resultant 
translational protein products and concomitant catalytic products, that were rudimentary characterised 
in this chapter, three were selected for further detailed characterisation. The next two chapters will 
therefore focus on the three before mentioned clones and be presented for purposes of publication. 
CHAPTER FOUR: is titled ‘The biochemical characterisation of two novel glycoside hydrolases, a 
β-galactosidase and β-glucosidase, belonging to the Glycoside Hydrolase families 1 & 2 respectively, 
both with high trans-galactosylation activity.’ This chapter focuses on two of the novel enzymes 
discovered through the metagenomic library approach described in chapter three, and entails a more 
in depth characterisation of the purified enzymes and their products. They both have high 
trans-galactosylation activity when incubated with the substrate lactose, and produce GOS. Both 
enzymes have potential industrial relevance for the production of prebiotic oligosaccharides. Of the 
two, the β-glucosidase is most promising and the article rendered will possibly submitted to the journal 
‘Applied Microbiology and Biotechnology’ [ISSN: 01075-7598 (pint); 1432-0614 (web)] for publication. 
CHAPTER FIVE: is titled ‘The characterisation of a novel levansucrase with high trans-fructosylation 
activity.’ This chapter focussed on the only clone isolated from the metagenomic libraries that exhibits 
significant trans-fructosylation activity. In this chapter the levansucrase enzyme is further purified and 
characterised in vitro, and so too its product. The data is significant resultant article will again be 
submitted to ‘Applied Microbiology and Biotechnology’ [ISSN: 01075-7598 (pint); 1432-0614 (web)], or 
alternatively to the journal ‘Bioscience, Biotechnology, and Biochemistry’ [ISSN: 0916-8451 (print); 
1347-6947 (web)] for publication. 
CHAPTER SIX is the final and concluding chapter. This chapter provides a critical discussion of the 
research conducted and results achieved. It provides an in depth review of the metagenomic approach 
employed together with its advantages and challenges, compared to other viable approaches. It places 
the research in the broader scientific context of what’s already ‘out there’ and discusses future research 
and potential alternative application. 
BIBLIOGRAPHY at the end of this dissertation the bibliography is presented for all the literature cited. 
The bibliographic style is based on the ‘BMC Biochemistry’ journal, published by Biomed Central. For 
author guidelines refer to http://www.biomedcentral.com 
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 Literature Review 
  The human microbiota and microbiome 
 
The microbiome comprises all the genetic material within a specific microbiota and can also be referred 
to as the metagenome of the microbiota. Technically speaking, the human microbiome is a reference to 
all the genes of the microorganisms and viruses that reside either on or in our bodies, however it is 
colloquially a reference to the metagenome of the microbiota, and its associated viral particles, of the 
lower GI tract. The distal GI tract is the most densely populated natural occurring microbial community 
known to man.  
Only since the advent of affordable next generation sequencing platforms, has the scientific community 
become fully aware that the commensal microorganisms residing in our bodies are intractably linked to 
our well-being and physiological functioning. This topic has spilled over into the mainstream media in 
seeing that it is relevant and current (see Fig 2-1). Recent revelations of the role of the microbiome in 
our health have begun to shake the foundations of medicine and nutrition. Some would argue that a 
paradigm shift is in occurrence. Many scientist now view humans as collective supra-organisms and that 
our biology is determined by both the genes of our genome as well as those of the microbiome meaning 
that, from this perspective, human health is a form of ecology [28]. A compelling argument can be made 
for this as the human body contains tenfold (1014) more microbial cells than human cells 
(approx. 30x1012) and the microbiome exceeds the number of human genes by at least two orders of 
magnitude [1, 29]. The importance of the GI microbiota to our health is further supported by the 
presence of human milk oligosaccharides (HMO) in human milk. HMO, which are short chain 
oligosaccharides of varying lengths and composition, can make up to 20% of the total nutritive value of 
human milk [30]. They are however non-digestible by human infants and serve as prebiotics to mostly 
bifidogenic bacteria. Therefore, in the earliest and most vulnerable stage of infant life, one fifth of the 
total nutritive component of human milk is dedicated towards the growth and maintenance of the 
human microbiota [31].  
The research interest in the human microbiome and its effects on humans have led to the establishment 
of international consortiums dedicated towards its investigation. Large projects such as the Human 
Microbiome Project (HMP) and Metagenomics of the Human Intestinal Tract (MetaHIT) were specifically 
established to investigate the microbiota and its microbiome as well as its influence on human health 
[32-34]. 
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Figure 2-1 The respective covers of Nature (Vol 464 Number 7285), Scientific American (Vol 306 Issue 6), Science (Vol 336 Issue 
6086) and The Economist (Aug 18th 2012), indicating the relevance of the human microbiota and microbiome. 
 
 The core Microbiota / Microbiome 
 
The complex communities of microbiota that inhabit the lower GI tract have been demonstrated to have 
a direct impact on human health, which can be either beneficial or adverse. The bacterial biomass of 
the entire GI tract ranges from 102 to 1011 cells/ml [35]. Recently, studies via culture independent 
sequencing techniques have revealed that, while the exact GI microbiota composition is highly 
individual specific, fewer than ten bacterial phyla dominate the make-up of the GI tract in humans [32, 
36]. Of these, Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Verrucomicrobia, 
constitutes the majority of the microbiota by far, with the first two being most prominent constituting 
almost 90% of the total microbial gene catalogue [32, 37].  
The human intestinal core microbiota is defined as the number and the identity of bacteria that are 
shared among different individuals [37]. Schippa et al. (2014) hypothesised that deviations from, and 
altered abundance in the core microbiota is associated with the development of complex diseases like 
atherosclerosis, type 2 diabetes, obesity, and colorectal cancer, yet defining the exact makeup of the 
core has proven to be difficult [38]. 
On a species level Peer Bork et al. (2011) hypothesised the existence of three cluster types (enterotypes) 
based on comparative metagenome sequence analysis of different individuals, from different countries 
on different continents [39]. They found that enterotypes are not dictated by age, gender, body weight, 
or national divisions, but there are indications that long-term diet has a large influence. Type 1 is 
characterized by high levels of the Bacteroides species (diet high in animal protein and saturated fat), 
type 2 has few Bacteroides but Prevotella species are common (diet high in carbohydrates), and type 3 
has high levels of Ruminococcus species (diet rich in alcohol and polyunsaturated fats) [40]. However, 
the year after the publication of that article new research brought into question the clear-cut 
boundaries of the ‘enterotypes hypothesis’ [41]. 
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Perhaps, if a functional core cannot be adequately defined by the presence of certain species, it would 
be better served on a genetic level. Qin et al. (2010) as part of the Human Metagenome Project, 
catalogued a common ‘functional core’ of genes, conserved in each subject and among different 
bacterial species [32]. This reflects the genes that relate to the survival of the gut microbiota and also 
those major microbial functions that relate to human health [32]. For example, some of the functions 
included in the ‘core of genes’ are linked to the degradation of complex polysaccharides, synthesis of 
short-chain fatty acids (SCFAs), amino acids and vitamins. The core microbiome is present in all humans, 
but a smaller subset of genes known as the ‘variable microbiome’ is only associated with certain subsets 
of the human population. The variable microbiome depends mostly on host-specific factors, such as 
genotype, physiological status, host pathologies, lifestyle, diet, and also environmental factors [32, 42]. 
Together, the core and variable components of the human microbiome influence a multitude of 
different aspects of human health, all of which is of major scientific interest and at the forefront of 
current research (see Fig 2-2). 
 
Figure 2-2 The core human microbiome (red) is the set of genes present in the majority of humans. The variable human 
microbiome (blue) is the set of genes present in smaller subset of humans. This variation could result from a combination of 
factors such as host genotype, host physiological status, host pathobiology (disease status), host lifestyle, host environment 
and the presence of transient populations of microorganisms that cannot persistently colonize a habitat. 
 
  Contribution of the core towards health 
 
The gut microbiome contributes towards human health through various mechanisms that can be 
broadly categorised under (i) metabolic, (ii) mucosal epithelium defence barrier and, (iii) immune 
modulation. In the following sections each of the sub-headings will be discussed briefly. 
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 Metabolic Functions 
 
The gut microbiota can be seen as a ‘metabolic organ’ that interacts with the human host and impacts 
on a myriad of essential functions and helps maintain human health [43]. Humans lack the necessary 
enzymes to degrade the bulk of dietary fibres, which pass through the upper digestive tract to the lower 
one where these complex carbohydrates are broken down and fermented to mainly SCFAs and gasses 
(carbon dioxide and methane) [44]. SCFAs are saturated aliphatic organic acids that consist of one to six 
carbons of which acetate (C2), propionate (C3) and butyrate (C4) are the most abundant (≥95%) in the 
gut [45]. The ratio of acetate: propionate: butyrate is normally 3:1:1, however this may vary depending 
on the initial dietary carbon source of fermentation, the dominant microbiota as well as host specific 
factors [44]. To the microbial community SCFAs are a necessary waste product required to balance redox 
equivalent production in the anaerobic environment of the gut, to humans however they are much 
more [45]. Approximately 95% of SCFAs are absorbed by the human body and only 5% is secreted in the 
faeces [45]. SCFAs are absorbed in the colon and have been shown to play a role in regulation of the 
immune system, colonic gene expression, gut motility, anti-carcinogenesis, obesity, insulin resistance 
and metabolic regulation [11, 43].  
On the most rudimentary level SCFAs serve as an energy source to the human host. In diets that are 
high in legumes, fruits and vegetables the dietary fibre content may reach approximately 60 grams per 
day. Fermentation of this fibre will yield roughly 400–600 mmol SCFAs per day, which accounts for about 
10% of the adult human caloric requirements [45]. Acetate, butyrate and propionate are absorbed 
through the intestinal lumen. Colonocytes are epithelial cells that form the primary barrier between the 
lower GI lumen and human body and it has been estimated that between 60-70% of the total energy 
requirements of colonocytes are derived from SCFA oxidation, specifically butyrate [45]. After acetate 
is absorbed it can be not only metabolised in the liver for energy production, but also serves as substrate 
for the synthesis of cholesterol, long-chain fatty acids, glutamine and glutamate. Propionate acts as an 
precursor for gluconeogenesis in the liver [46].  
SCFAs also play a role in regulating the balance between fatty acid synthesis, fatty acid oxidation, and 
lipolysis. Fatty acid oxidation is activated by SCFAs, while its synthesis as well as lipolysis are inhibited 
by them, resulting in a reduction of free fatty acid plasma concentrations and, ultimately a decrease in 
body weight [45]. Apart from fatty acid metabolism, SCFAs also lead to a decrease of plasma glucose 
levels via multiple mechanisms [47]. Furthermore, SCFAs have also been shown to reduce plasma 
concentrations of cholesterol in rodents and humans [48, 49]. 
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Other than its effects on primary metabolism, the GI microbiota produce vitamins, synthesize amino 
acids, influence ion absorption and transform potentially carcinogenic compounds to inactive forms 
[28].  
 
 Mucosal epithelium effect and defence barrier 
 
Enterocytes are the epithelium barrier cells of the small intestine and also act as nutritive adsorptive 
cells. Together with the colonocytes of the colon they make up the barrier of the GI tract. The GI 
microbiota contribute towards maintenance of intestinal epithelial barrier integrity not only through 
SCFAs but also through direct signalling, active maintenance of cell-to-cell junctions, promotion of 
epithelial repair, as well as playing a role in the regulation of enterocytes and colonocytes turnover [50]. 
A healthy microbiota furthermore creates a “colonisation resistance” which can be described as the 
ability of the microbiota to prevent pathogenic colonisation by competing for attachment sites and 
nutrients and through the production and secretion of antimicrobials [51]. 
 
 Host immune modulation 
 
The microbiota plays a critical role in the establishment, adaptation, maintenance and proper function 
of the human immune system through a multitude of complex and dynamic host/microbiota 
mechanisms (for review see [52]). It is this unique set of immune-regulatory mechanisms that prevent 
the unnecessary activation of the immune system against non-injurious antigens, including the 
commensal microbiota themselves. Pivotal to this immune homeostasis is the interface and interplay 
between epithelial/mucosal barrier and microbiota [3]. As mentioned previously, the microbiota 
contribute towards the innate immune system directly through modulating this epithelial mucosal 
barrier. However, intestinal antigen presenting cells (APCs), macrophages, neutrophils and natural killer 
cells (NKCs) are all modulated by the intestinal microbiota [11]. Autoimmune and inflammatory diseases 
are associated with dysregulated immune responses and are often linked to disruption of this barrier 
[53]. Keeping a delicate balance in the immune system by eliminating invading pathogens, while still 
maintaining self-tolerance to avoid autoimmunity, is critical for health. The GI microbiota also influence 
the adaptive immune system in that they play an important role in the development of CD4+ T cells, 
both within and outside the intestine [53]. Some of the best evidence of the pivotal role the microbiota 
plays in the immune system comes from studies utilising germ-free (GF) and gnobobiotic mice. GF 
animals are sterile with regards to intestinal microbiota whilst gnobobiotic ones have been seeded with 
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a singular bacterial species allowing investigation of species related traits [53]. It has also been 
suggested that the microbiota plays a pivotal role in the production of antibodies in the intestinal 
mucosal membranes. It is estimated that 0.8g of Immunoglobulin A (IgA), which are antibodies 
associated with mucosal membranes, are secreted per day per meter intestine by Peyer’s patch 
immunoglobulin secreting plasma cells [54]. Significant reductions in IgA and plasma cells were 
observed in GF-mice, which was restored once the gut was recolonized with microbiota demonstrating 
that the gut microbiota is the driving force for mucosal IgA production and is therefore pivotal to the 
intestinal immune response [55].  
 
 Dysbiosis  
 
There is mounting evidence for the association between various intestinal and extra-intestinal disorders, 
and the dysbiosis of the gut microbiota. Intestinal disorders are usually associated with over-reactive 
inflammatory responses characteristic of diseases like irritable bowel syndrome (IBS), coeliac disease 
and Crohn’s disease. Extra-intestinal disorders include allergy, asthma, obesity, metabolic syndrome and 
cardiovascular disease. Even disorders of the cognitive state have been associated with the conversion 
of certain dietary compounds (by a subset of microbiota) to metabolites that are absorbed and which 
then affect the phenotype of the host and influence the risk of disease [56]. 
As mentioned above, even though the association between dysbiosis and health have been proven, it is 
none the less difficult to establish precise relations with the occurrence and relative abundance of 
specific microbial species. In future though, specific changes in compositional or functional diversity 
may serve as biomarkers for health or specific diseases. Below is a brief discussion of dysbiosis in disease 
under the headings of (i) Effect of microbial metabolites on health, (ii) Dysbiosis and GI tract disorders, 
(iii) Dysbiosis and systemic diseases, and (iv) Dysbiosis and central nervous system disorders. 
 
 Effect of microbial metabolites on health 
 
The complimentary effect of SCFAs to host health was discussed above, however metabolic 
fermentation products of other microbiota have been associated with the development of diseased 
states in humans. In recent years, the gut-liver axis and the impact of intestinal microbiota on liver 
function has come to the forefront. The liver receives approximately 70% of its blood supply from the 
intestinal portal vein and is, therefore, the organ that is exposed first to the absorbed metabolites and 
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antigens produced by the gut microbiota. Non-alcoholic fatty liver disease (NAFLD) is a prevalent and 
severe disease that can lead to cirrhosis, liver carcinoma and ultimately death. It has a prevalence of 
16-30% among the general populace and between 50-90% in obese individuals [57]. Several 
mechanisms relate NAFLD, and its concomitant deposition of hepatic fat, to dysbiosis and the 
microbiota. These include the dysregulation of gut permeability, bile acid metabolism, immune balance 
and low-level inflammation. In addition, increases in endogenous ethanol production by bacteria, most 
notably through the metabolism of choline are also thought to play a role [58]. Mice fed a high-
protein/high-fat diet had a higher rate of metabolising choline to methylamines. Due to this conversion 
by the microbiota, the bioavailability of choline is reduced, resulting in the inability to synthesise 
phosphatidylcholine giving rise to the accumulation of triglycerides in the liver. This mimics choline-
deficient diets which have been consistently associated with hepatic steatosis. The bacterial 
methylamines are absorbed and transported to the liver where they are oxidised to trimethylamine 
N-oxide (TMAO). TMAO is a pro-atherogenic compound and used as an indicator for cardiovascular 
disease [59].  
 
 Dysbiosis and GI tract disorders 
 
Crohn’s disease (CD) and ulcerative colitis (UC) are the most prevalent forms of inflammatory bowel 
disease (IBD), characterised by recurrent or chronic inflammation of the mucosal intestinal barrier. IBD 
is a class of autoimmune disease, in which the body's immune system attacks elements of the digestive 
tract giving rise to the inflammatory response. CD is generally associated with the upper GI tract whilst 
UC is associated more with the colon, but sometimes a definitive diagnosis cannot be made due to 
idiosyncrasies in the presentation. The exact causation of either disease is unknown but there is 
increasing evidence that intestinal microbial dysbiosis has a role in the development of IBD [60]. Both 
diseases are characterised by an overall decrease of between 30-50% in microbiota diversity most 
specifically Firmicutes, and an increase in Bacteroidetes and other facultative anaerobes such as 
Enterobacteriaceae [61]. People with IBS are at higher risk for developing colorectal cancer and can also 
present with extra-intestinal manifestations such as liver problems, arthritis, skin manifestations and 
eye problems [56]. 
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 Dysbiosis and systemic diseases 
 
Worldwide obesity is on the rise and has reached epidemic levels [62]. According to the World Health 
Organisation (WHO) globally in 2014, 39% people older than 18 years were overweight and 19% of the 
total global population were obese. Obesity manifests its comorbidities in metabolic syndrome which 
includes increased risk for coronary heart disease, diabetes mellitus type 2, high blood pressure, high 
blood cholesterol, insensitivity to insulin, high triglyceride levels, and various cancers [63]. Obesity is 
most commonly caused by a combination of excessive food energy intake embodied in the ‘western 
diet’, sedentary lifestyle, lack of physical activity and, to a lesser extent, genetic susceptibility [63, 64].  
Gut microbiota have been linked to obesity [65] based on two observations. Firstly, the ratio of the two 
dominant bacterial genera, namely Bacteroides and Firmicutes, are altered in obese people (fewer 
Bacteroides than Firmicutes) compared to lean people (more Bacteroides than Firmicutes) [65]. 
Secondly, the observation that obesity phenotype could be triggered by transplanting microbiota from 
obese animals to germ free mice [66, 67]. The intestinal microbiome affects glucose and lipid 
metabolism as well as satiety. Germ-free and conventionally colonised mice differ in that conventional 
mice have higher serum glucose levels, higher triacylglycerol levels in the liver and, also, higher levels of 
the hormones leptin and insulin which are positively correlated with body weight and with adipose 
mass. These data support the idea that the microbiota could potentially contribute to weight gain [64]. 
Two mechanisms have been hypothesised for the link between weight-gain and the GI-microbiota. 
Firstly, fermentation of indigestible carbohydrates by intestinal microbiota leads to an increased 
absorption of SCFAs followed by increased hepatic lipogenesis. Secondly, high-fat diets trigger an 
increased transfer of bacterial lipopolysaccharides (LPS) from the intestinal lumen to the blood causing 
metabolic endotoxaemia and low-grade inflammation [64] which, in turn, contributes to adipose 
deposition. The role of SCFAs on metabolism and plasma glucose levels were discussed above. 
Theoretically SCFA adsorption could contribute to obesity development; however epidemiological 
studies indicate that a diet rich in fibre correlates with a lower incidence of obesity and symptoms of 
the metabolic syndrome [17, 68]. This apparent paradox is further supported through studies linking 
dietary fibre to increased satiety, reduced weight gain, increased metabolic rate, increased insulin 
sensitivity, decreased serum cholesterol levels, overall beneficial impact on health and the presentation 
of fewer markers for metabolic syndrome and its associated comorbidities (for review see [17]).  
In healthy individuals the intake and expenditure of metabolic energy is balanced, but there is evidence 
that the microbiota can influence this [64]. Current scientific evidence indicates that high-fat diets 
contribute towards the development of a microbiome that promotes increased harvest of energy over 
its expenditure from the diet, thereby promoting obesity [64]. The SCFAs produced by fermentation can 
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either provide additional energy to the host and can be channelled towards lipogenesis and 
gluconeogenesis, or, can lead to increased satiety and insulin sensitivity as well as reduced overall 
energy intake and increased expenditure. Which of these effects predominates, and how they are 
affected by the type of dietary fibre, is under current investigation. 
 
 The gut-brain-axis: Dysbiosis and central nervous system disorders 
 
The enteric nervous system (ENS) consists of approximately 500 million neurons and is embedded in the 
lining of the GI-tract, forming a mesh-like system of neurons. It governs the function of the 
gastrointestinal system and is often referred to as the second brain. The link between the CNS and ENS 
is referred to as the ‘gut-brain-axis’. There is bidirectional communication between the CNS and ENS, 
thereby linking the emotional and cognitive centres of the brain with the GI tract. The mechanisms 
underlying gut-brain-axis communication involve neural pathways as well as immune and endocrine 
mechanisms. Recent research describes the importance of gut microbiota in influencing these 
interactions and intestinal dysbiosis has been associated with diseases that impact on the ‘gut-brain’ 
axis and thereby effecting on the central nervous system [69].  
Perhaps some of the best evidence of the impact of microbiota on behaviour comes from animal studies. 
The occurrence of locusts congregating in vast swarms that can devastate crops is dependent on 
pheromones. Dillon et al. (2000) identified that locust gut microbiota were pivotal in the production of 
these swarming pheromones [70]. Germ free locusts did not produce the pheromones but once the 
bacterium Pantoea agglomerans was introduced into the gut, pheromone production was restored [70]. 
Even in humans the gut microbiota can act as a source of various biologically active molecules normally 
associated with neurotransmission and GABA, serotonin, melatonin, histamine, and acetylcholine have 
all been shown to be produced by bacteria [71]. In a study by Sharon et al. (2004) two isolated 
populations of Drosophila fruit flies were reared on two different feeding mediums, one containing 
molasses and the other starch. When the isolated populations were mixed, molasses fed flies showed a 
preference to mate with other molasses fed flies, while the starch fed flies showed a preference for 
other starch fed flies. The differential mating preference occurred after only one generation of rearing 
on the separate growth media and could be maintained for at least thirty seven generations. Antibiotic 
treatment abolished the diet-induced mating preference, but it was re-established when the flies were 
seeded with the original gut microbiota. These data suggest that the fly microbiota was responsible for 
the preferential diet-induced mating phenomenon [72]. Through the study of germ free and gnobobiotic 
mice several studies have shown that microbiota influences stress reactivity and anxiety-like behaviour 
[73]. Furthermore, germ-free mice demonstrated decreased memory function as well as increased 
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serotonin turnover [74, 75]. In humans there is also evidence of microbiota influencing anxiety and 
depressive-like behaviours. Research suggests early developmental association with beneficial 
microbiota is crucial later on in life to reduce the risk of depression and anxiety related disorders [76, 
77]. So too has dysbiosis in autistic patients shown to present specific microbiota alterations in 
accordance to the severity of the disease [78, 79]. The topic is, however, very contentious and research 
is ongoing. 
 
 Manipulating the gut microbiota to maintain health and treat disease 
 
As has been mentioned, the intestinal microbiota composition varies between healthy and diseased 
individuals. Generally, high microbial diversity is thought to be associated with healthy gut microbiota, 
while loss of diversity seems to correlate with disease [7]. Although the relationship between the 
alterations in the gut microbiota and disease is not always clear-cut, targeting the intestinal microbiota 
might offer new possibilities for preventative health and treatment. 
There are three possible mechanisms by which the microbiota of the gut can be modulated, namely the 
administration of probiotics, prebiotics and lastly microbial transplants. Dietary prebiotics will be 
discussed in depth in the next section whereas probiotics and microbial transplant will be discussed 
briefly as sub-headings in this section. 
 
 Probiotics 
 
Since ancient times lactic acid bacteria has been utilized to preserve milk and improve its digestibility. 
An early Persian translation of the Bible credits the prophet Abrahams’ longevity to the daily 
consumption of sour milk. Legend also has it that the French king Francois 1st cured his chronic diarrhoea 
with the use of a Turkish ‘yogurt’. Even Hippocrates, the father of modern medicine famously stated 
that ‘all disease begin in the gut’ [80]. During the First World War Alfred Nissle isolated a non-pathogenic 
strain of Escherichia coli from a battlefield soldier, who was one of a few that did not fall ill during a 
severe outbreak of Shigellosis. This strain E. coli Nissle 1917 (EcN) has since been used to treat a variety 
of gastrointestinal diseases including salmonellosis and shigellosis, thereby heralding the modern era of 
probiotic treatment [81]. A multitude of publications have shown that specific probiotic strains (or 
combinations of them) can be utilized to treat different diseases. For example Oxalobacter formigenes 
is the key bacterium responsible for the degradation of oxalate in humans, the accumulation of which 
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is the main cause of kidney stone formation [82, 83]. The bacterium is extremely sensitive to antibiotics 
and individuals who have undergone antibiotic treatment in their lifetime often contain reduced level 
of O. formigenes. Probiotic treatment with O. formigenes have been shown to temporarily reduce serum 
levels of oxalate [84]. Currently the dominant species of probiotics used for human and animal livestock 
are from the genera Lactobacillus, Streptococcus and Bifidobacterium [85]. By transiently colonizing the 
GI tract, probiotics serve to correct dysbiosis that contributes to disease. The effects that these bacteria 
exert can either be direct via the probiotic bacterium itself, or indirect via its interaction with the 
commensal microbiota. These include the secretion of antimicrobial peptides and bacteriocins, 
modulation of lumen pH, influencing quorum sensing in other bacteria which alters their virulence and 
pathogenesis, enhancing the production of mucins from gut epithelial cells, exerting an 
anti-inflammatory effect in the gut and promoting the secretion of IgA which binds pathogens  [7, 18, 
81]. It should be noted however that, in all likelihood, the probiotics exert their effect in the small 
intestine and not the lower GI tract of the large intestine. In the small intestine there is a lower 
concentration of microbiota, for the relative small number of dietary acquired probiotika to exert an 
effect during their transit. In the large intestine the probiotics will be vastly outnumbered by the 
resident microbiota and, even though they can still have an effect, its efficacy will be greatly diminished. 
 
 Microbial faecal transplants 
 
A faecal microbiota transplant (FMT) is the process of transplantation of faecal bacteria from a healthy 
individual into a recipient so as to restore a healthy microbiota [86]. Evidence for the use of faecal 
bacteriotherapy dates back to the 4th century AD when it was reported that nomadic Bedouin used 
camel dung for the treatment of diarrhoea [7]. More recently FMT came to prominence for the 
treatment of recurrent Clostridium difficile infections [87]. Today, C. difficile is a debilitating disease and 
the leading cause of antibiotic associated diarrhoea and pseudomembranous colitis. Antibiotic 
treatments fail in up to 30% of cases and it can be a life threatening illness. Mortality rates are as high 
as 24% in cases involving critically ill patients, especially the elderly, and it has reached epidemic levels 
in North America and Europe [87]. So effective is FMT for the treatment of resistant C. difficile infection 
that the original double blind placebo controlled study was halted, for ethical reasons, so that the 
placebo group could also receive the treatment. In the firsts trial 85% were effectively cured and of the 
remaining 15% a further 90% were cured with a second treatment [88]. Due to the above mentioned 
success FMT is being investigated for the treatment of other dysbiosis associated diseases most notably 
inflammatory bowel diseases as well as metabolic and cardiovascular diseases [86]. Furthermore, the 
federal Food and Drug Administration (FDA) of the United States of America (USA) now recognizes FMT 
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as an ‘Investigational New Drug’ (IND) and have published proposed guidelines for its use and called for 
comments (http://www.regulations.gov) [89] 
 
 Prebiotics  
 
The current definition of a prebiotic states that, a prebiotic is a selectively fermented ingredient that 
results in specific changes in the composition and/or activity of the GI microbiota, thereby conferring 
benefits upon host health [16]. Contrary to probiotics which aim to introduce new bacteria, prebiotics 
stimulate the growth and activity of particular bacteria that are already present in the GI tract and, for 
this reason, is considered to be one of the more effective modulators of the GI microbiota [90]. The 
main genera that are stimulated by prebiotics are Bifidobacterium and Lactobacillus, and the effect that 
prebiotics exert is often referred to as the bifidogenic effect. Inulin type polysaccharides, fructo-
oligosaccharides (FOS), galacto-oligosaccharides (GOS) and lactulose are the dominant prebiotics that 
have garnered the most scientific attention thus far [17, 91]. Other molecules that have recently been 
classified as prebiotics are lactitol, mannitol, maltodextrin, raffinose, lactulose, sorbitol, isomalto-
oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides (XOS) and wheat bran derived 
arabinoxylo-oligosaccharides, all of which is currently under investigation as putative and promising 
prebiotics [90]. Different prebiotics can selectively stimulate the range of beneficial bacteria to varying 
degrees. FOS were less selective than GOS as a fermentative growth substrate, while even fewer 
bacteria were able to use starch and long-chain inulin for fermentation [92]. It has also emerged through 
the metagenomic studies of the human microbiome that there is a higher representation of genes 
encoding GOS degrading enzymes compared with those encoding FOS degrading polypeptides [93]. The 
positive effect promoted by prebiotics mostly relates to SCFAs (as discussed above) and include, 
immunomodulation, anti-inflammation, contribution towards cardiovascular health, enhancement of 
the bioavailability and uptake of minerals and vitamins, promotion of satiety and weight loss, prevention 
of obesity and prevention of certain cancers [94, 95]. 
 
 Synbiotics 
 
Synbiotics is the combination of prebiotics and probiotics, that then work in a synergistic way, so as to 
beneficially effect the host by improving the survival of the live microbial probiotic dietary supplement, 
in the GI tract. This is achieved by the prebiotics selectively stimulating the growth and/or metabolism 
of one or more of the health promoting probiotic bacteria [96, 97]. Synbiotics were especially developed 
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to overcome the before mentioned (section 2.5.1) limitations of prebiotic survivability through the 
upper GI tract as several factors like pH, H2O2, organic acids, oxygen and moisture stress has been shown 
to effect the viability of probiotic supplementation [98]. The health benefits claimed by synbiotic 
treatment includes, (i) increased levels of Lactobacillus, Bifidobacterium species and an overall balanced 
gut microbiota (ii) improvement of liver function in cirrhotic patients, (iii) improvement of 
immunomodulating function, (iv) and prevention of bacterial translocation and reduced incidences of 
nosocomial infections in surgical patients [99]. 
 
 Introductory review of Prebiotic synthesis by microbial enzymes and their classification 
 
As mentioned in section 2.5.3, prebiotics enhance the growth of beneficial bacteria in the GI system, 
thereby establishing all the beneficial properties listed above. The specific prebiotic properties of 
oligosaccharides and polymers are determined by their monosaccharide composition, glycosidic 
linkages and degree of polymerisation [100]. Due to the scientifically backed health benefits already 
reviewed, there is a high demand for functional food prebiotics leading to a constant drive to develop 
more efficient and affordable methods of production for these types of compounds. There is also a drive 
to identify novel prebiotics with unique properties [101]. The two substrate sources of disaccharide 
carbohydrate often envisaged to be used in the production of more complex carbohydrate compounds 
are whey permeate and cane sugar [102]. Whey permeate is a by-product from cheese manufacturing 
and is high in lactose. Annually, millions of tons of cheese are manufactured leading to whey water often 
becoming an industrial pollutant if not adequately disposed of. Therefore, its use makes not only 
economic sense but is also environmentally beneficial. So too sugar, which is isolated predominantly 
from sugarcane throughout the tropics and sub-tropics, is a readily available and cheap source. It is 
therefore not coincidental that the use of the above mentioned substrates for the production of more 
complex derivatives of lactose and sucrose is currently the focus of research and is an on-going challenge 
for industry.  
The production of prebiotics by means of enzymatic synthesis has great potential as they generally 
exhibit high yields, substrate specificity as well as regio-and stereo-specificity [21, 103]. Such enzymes 
can be obtained from a variety of sources including microorganism, plant and animal sources. In general 
however, microbial enzymes are preferred for industrial application for various reasons including (i) 
ease of microbial handling and extraction, (ii) higher microbial enzymatic yields, (iii) high microbial 
enzymatic product synthesis, (iv) ease of use of microbial genes in recombinant technology relative to 
those of higher complex eukaryotic genes, (v) economic feasibility in terms of fermentation biology, (vi) 
versatility with regards to acceptor substrate, (vii) better enzymatic stability and finally (viii), regularity 
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of supply in that it’s not dependent on seasonal availability of extraction source [24, 101, 104, 105]. 
Consequently many bacterial, yeast and fungal enzymes have been utilized in the production of dietary 
oligosaccharides and polymers and the dominant ones are summarised in table 2-1. 
With regards to the classification of enzymes two systems predominate, namely the International Union 
of Biochemistry and Molecular Biology (IUBMB) enzyme nomenclature, and the Carbohydrate active 
enzymes database (CAZy). Commonly and traditionally though, enzymes involved with the synthesis of 
bioactive polymers and oligosaccharides are colloquially referred to as glycoside hydrolases (GHs) 
and/or glycosyltransferases (GTs) with the two terms often interchanged depending on which 
nomenclature system are being employed. These enzymes are capable of transferring a glycosyl moiety 
from one compound (donor) to another compound (acceptor) thereby elongating the 
oligosaccharide/polymer [106].  
With the IUBMB system it is the reaction, rather than the enzyme itself, that are classified and this is 
done primarily on the basis of their substrate specificity which is expressed as the Enzyme Commission 
(EC) number of the enzyme (http://www.chem.qmul.ac.uk/iubmb/enzyme/). In accordance to this 
system GHs/GTs (enzymes which hydrolyse compounds containing O- and S- glycosidic bonds) are given 
the serial code 3.2.1.X where X is representative of the substrate specificity but can also occasionally be 
indicative of either the enzymatic molecular mechanism or the glycosidic linkage type [107]. These 
GHs/GTs can further be subdivided into groups according to the glycosyl moiety that they actually 
transfer i.e. hexosyltransferases (EC. 2.4.1), pentosyltransferases (EC 2.4.2) and those transferring other 
glycosyl moieties (EC 2.4.99) [108]. There are however several limitations to the IUBMB system of 
enzyme classification, most notably that the numbering system does not allow for enzymes which act 
on more than one substrate. It also does not relay any inherent structural information or give insight to 
the actual mechanistic action of the enzyme [109]. The GHs/GTs were then further classified into three 
mechanistic groups, based on the characteristics of the donor substrate. Firstly (i) there are the Leloir-
type glycosyltransferases which require activated sugar nucleotides to synthesise elongation e.g. 
monosaccharide di-phosphonucleotides. Secondly (ii), there are the non-Leloir type 
glycosyltransferases which utilise substrates like sugar- phosphates, sugar-pyrophosphates as well as 
the respective polyprenol phosphates and pyrophosphates. Finally (iii) are the transglycosidases which 
employ non-activated disaccharide sugars like lactose and sucrose and consequently utilise the energy 
released from the initial hydrolysis to catalyse the transfer of the sugar moiety to the donor [110]. 
Contrary to the IUBMB, the CAZy system of nomenclature and classification exploit amino acid sequence 
similarities rather than the reaction characteristics in order to group enzymes in families. Henrissat et 
al. (1991, 1997) hypothesised that in principle sequence and structure are inherently related and, 
therefore, structural and mechanistic properties of enzymes can be inferred by means of this sequence 
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based system [111, 112]. Henrissat’s initial system of classification evolved into the CAZy database 
(http://www.cazy.org) which describes the different families with structurally related catalytic and 
functional domains (Carbohydrate Binding Domains, BDMs) to which the various enzymes involved in 
the degradation, modification and/or creation of glycosidic bonds belong [113]. Currently CAZy 
describes over 300 protein families which can be further subdivided into classes of carbohydrate active 
enzymes enzymes namely (i) Glycoside Hydrolases (GHs, hydrolyses and/or rearrangement of glycosidic 
bonds), (ii) Glycosyltransferases (GTs, formation of glycosidic bonds), (iii) Polysaccharide lyases (non-
hydrolytic cleavage of glycosidic bonds), (iv) Carbohydrate esterases (hydrolysis of carbohydrate esters), 
and (v) Auxiliary Activities (redox enzymes that work in conjunction with CAZymes).  
It is noteworthy that in accordance with CAZy, but not with the IUBMB nomenclature system, a clear 
distinction is being made between glycoside hydrolases and glycosyltransferases. The former refers to 
the original transglycosidases (utilising disaccharides as substrates) with the latter being a combination 
of the Leloir (nucleotide sugars) and non-Leloir (sugar derivatives) transferases as described in the 
three-pronged mechanistic and substrate donor based IUBMB denoted system [109]. Even though 
bi-enzymatic systems utilising glycosyltransferases have been reported, it is glycoside hydrolases which 
are most often employed in the production of prebiotic oligosaccharides and polymers as they do not 
require rare activated sugar nucleotides or monosaccharide derivatives for synthesis [114]. 
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Table 2-1 Microbial glycoside hydrolase enzymes most frequently used for the synthesis of food bioactive oligosaccharides (adapted from Diez-Municio et al 2014 [101] 
 
 
 
Structure / linkage a Enzymes  EC number b Enzyme source  GH family b Substrate References 
Fructo-
oligosaccharides 
(Fruc)n-Glc [(β-2,1),(β-2,6)] β-Fructofuranosidase 
Inulosucrase 
Levansucrase 
EC 3.2.1.26 
EC 2.4.1.9 
EC 2.4.1.10 
Fungi ( Aspergillus niger; A japonicus; A.oryzae; 
Aureobasidium pullulans; Penicillium citrinum  
Bacteria (B. macerans; Z. mobilis; Lactobacillus 
reuteri; Arthrobacter sp. 
32, 68, 100 Sucrose  
(transfructosylation) 
 [115, 116] 
Galacto-
oligosaccharides 
(Gal)n-Glc or (Gal)n-Gal 
[(β-1,3),(β-1,4),(β-1,6)] 
β-Galactosidase EC 3.2.1.23 Fungi (A.oryzae; A. niger; A. aculeatus) 
Bacteria (Bacillus sp.; Streptococcus thermphilus; 
L. acidophilus; L. reuteri; Bifidobacterium sp.) 
Yeast (Kluyveromyces lactis; K. marxianis; 
Saccharomyces fragilis; Cryptococcus laurentii) 
1,2,3,35, 42, 50 lactose  
(transgalactosylation) 
[24, 117, 
118] 
Galacto-
oligosaccharides 
(Gal)n-Fruc or (Gal)n-Gal or (Gal)n-Fruc-
Gal [(β-1,1),(β-1,4),(β-1,6)] 
β-Galactosidase EC 3.2.1.23 Fungi (A. oryzae; A. aculeatus) 
Yeast (K.lactis) 
1,2,3,35, 42, 50 lactulose 
(transgalactosylation) 
[119, 120] 
Lactosucrose 
derived from 
lactulose 
(β-Gal-1,4)-(α-Glc-1,2)-β-Fruc β-Fructofuranosidase 
Levansucrase 
β-Galactosidase 
EC 3.2.1.26 
EC 2.4.1.10 
EC 3.2.1.23 
Bacteria (Arthrobacter sp. K-1; Z. mobilis; Bacillus 
subtilus; B. natto; B. circulans) 
32, 68, 100, or 1, 
2, 3, 35, 42, 50 
transfructosylation of 
lactose or 
transgalactosylation of 
sucrose 
[121-125] 
Lactulosucrose (β-Gal-1,4)- (β-Fruc-2,1)-α-Glc Dextransucrase EC 2.4.1.5 Bacteria (Leuconostoc mesentroides) 70 lactulose and sucrose 
transglucosylation 
[126] 
2-α-glucosyl-lactose (β-Gal-1,4)-(α-Glc-2,1)-α-Glc Dextransucrase EC 2.4.1.5 Bacteria (Leuconostoc mesentroides) 70 lactulose and sucrose 
transglucosylation 
[127] 
Isomalto-
oligosaccharides 
(Glc)n-[α-1,6] A) α-Amylase with 
Pullulanase 
B) α-Glucosidase 
 
Fungi (Aspergillus sp.; Aureobasidium pullulans) 
Bacteria (Bacillus subtilis; B. licheniformis; B. 
stearothermophilu) 
A) 13, 14, 57, 119 
( B) 4, 13, 31, 63, 
97, 122 
Starch [hydrolysis (A) and 
transglucosylation (B)] 
[128, 129] 
Gluco-
oligosaccharides 
(Glc)n-[(α-1,6),(α-1,3), (α-1,4), (α-1,6)] Dextransucrase EC 2.4.1.5 Bacteria (L. mesentroides; L. citreum) 70 Maltose and sucrose 
(transglucosylation) 
[130-132] 
Gentio-
oligosaccharides 
(Glc)n-[β-1,6] β-Glucosidase or 
Gluco-endo-1,6-β-Glucosidase 
EC 3.2.1.21 
EC 3.2.1.75 
Fungi (Penicillium multicolor; A. oryzae) 1, 3, 5, 9, 30, 116 
or 5, 30 
Pustulan (hydrolysis) or 
Gentiobiose 
(transglucosylation)  
[133, 134] 
Pectic-
oligosaccharides  
(GalA)n-[α(1,4)] (GalA-Rha)n-[α(1,2); 
α(1,4)] *GalA can be partially esterfied 
and Rha ramified 
Polygalacturonase 
Rhamnogalactronan 
galacturonohydrolase 
EC 3.2.1.15 
EC3.2.1.173 
Fungi (Fusarium moniliforme; Aspergilus 
pulverulentus; A. aculeatus; Kluyveromyces 
fragilis) 
Bacteria (B. licheniformis) 
28 Pectin (hydrolysis) [135, 136] 
Xylo-
oligosaccharides 
(Xyl)n [β(1,4)] Endo-1,4-β-xylanase EC 3.2.1.8 Fungi (Trichoderma sp.; A. oryzae) 5, 8, 9, 10, 11, 12, 
16, 26, 30, 43, 44, 
51 
Xylan (hydrolysis) [128] 
Maltosyl-fructosides (Fruc)n-Malt [β(2,1), β(2,6)] β-Xylosidase 
Levansucrase 
Inulosucrase 
EC 3.2.1.37 
EC 2.4.1.10 
EC 2.4.1.9 
Bacteria (B. subtilis; Lactobacillus gasseri) 32, 68 Maltose and sucrose 
(transfructosylation) 
[137, 138] 
a. Glc, glucose; Fruc, fructose; Gal, galactose; GalA galacturonic acid; Rha rhamnose; Xyl, xylose; Malt, maltose  
b. According to the CAZy database
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 21 
 
 Structural characteristics and catalytic mechanisms of microbial Glycoside Hydrolases 
 
The mode of action and substrate specificity of GHs are determined by their tertiary, rather than their 
secondary structure [112]. In this regard three dimensional structural studies by means of 
crystallography are crucial in identifying the relevant amino acid residues involved in catalysis and, 
therefore by default the mechanistic action of any enzyme. Furthermore, site directed mutagenesis 
studies have established that a few crucial amino acids in the active site of GHs are crucial with regards 
to establishing linkage specificity [139]. More detailed structural and catalytic mechanisms will be 
discussed in the following section under either fructose or galactose containing oligosaccharides and 
polymers. 
 
 Fructose, Fructans and Fructo-oligosaccharides (FOS), sources and synthesis 
 
Fructose (C6H12O6) is a hexose monosaccharide and a ketose type reducing sugar. In comparison with 
fructans, fructose either in its free form or as part of sucrose can be metabolised by humans. Before the 
advent of the modern diet the only sources of fructose were from fruits and honey, both of which 
contain relatively low levels. The western diet however is high in refined sugars, fructose sweeteners 
and high-fructose corn syrup (HFCS) [140]. A high fructose diet is associated with insulin resistance and 
many other features of the metabolic syndrome including obesity, inflammation and increased risk of 
type-II diabetes and cardiovascular disease [141]. Once fructose and glucose are absorbed, they are 
translocated to the liver where the hepatic enzyme system metabolises fructose, converting it into 
glyceraldehyde and dihydroxyacetone phosphate (DHAP). This is the point where fructose and glucose 
metabolism converge (Fig.3) and the most fundamental difference between these is that glucose 
metabolism does not rely on the activity of phosphofructokinase (PFK-1)(Fig.3). PFK-1 converts fructose 
6-phosphate to fructose 1,6-bisphosphate and is a pivotal regulatory step in the glycolytic flow being 
governed by allosteric control. The PFK-1 enzyme is regulated by the concentration of the metabolites 
AMP, ADP and fructose 2,6-bisphosphate which act as activators and ATP, phosphoenolpyruvate (PEP) 
and citrate that inhibit it. Furthermore in contrast to glucose metabolism, insulin is unable to influence 
the hepatic metabolism of fructose and its subsequent conversion to triose phosphates. Therefore, 
fructose enters the glycolytic pathway unabated and generates excess energy caused by the low Km of 
the enzyme fructokinase and the lack of negative feedback from ATP or citrate. The end result is that 
the triose phosphates produced from fructose can be converted into pyruvate and oxidized to CO2 and 
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H2O in the tricarboxylic acid cycle, or can be converted to fatty acids before entering de novo lipogenesis 
(Fig 3). 
 
Figure 2-3 The comparative and integrated hepatic metabolism of glucose and fructose: ATP (adenosine triphosphate); ADP 
(adenosine diphosphate); DHA (dihydroxyacetone); DHAP (dihydroxyacetone phosphate); fruc-1-P (fructose-1-phosphate); 
fruc-6-p (fructose-6-phospahte); fruc-1,6-bisP (fructose-1,6-bisphosphate); G-6-P (glucose-6-phospahte); Glc-6-Pase (Glucose-
6-phosphatase); FDPase (Fructose-1,6-diphosphatase); GAP (D-glyceraldehyde 3-phosphate); PFK-1 (phosphofructokinase); Pi 
(phosphate) 
 
It is necessary that a clear distinction be made between dietary ‘free fructose’ (HFCS, sucrose and fruit 
sugars) together with its negative health associations described above, and that of fructans, as the two 
are often confused by the general public. Fructans are regarded as functional foods and have been 
shown to act as prebiotics and are therefore, not metabolised by the human gastric system, but instead 
fermented by the GI microbiota. By definition fructans are homopolymeric oligo-and polysaccharides 
comprised of fructose. They have varying chain lengths and are generally synthesised using a starter 
sucrose unit which then takes the place of the reducing terminus. The structure of fructans is unusual 
in the sense that the sugar rings are to the exterior of the polymeric chain of carbon and oxygen atoms 
[142]. The five membered furanose rings of the chain are linked by -O-CH2 groups, rendering the 
structure more flexible than that of the six membered pyranose rings linked by an solitary oxygen, as is 
found in starch [143]. Apart from the enhanced flexibility induced by the ring structure, it also confers 
a left-hand twist on the tertiary helix structure [144]. Fructans can also differ from each other based on 
their structural isomerism linkage types [91]. Together the plethora of different structural 
characteristics of fructans gives rise to their unique biological characteristics. Broadly speaking a wide 
range of health benefits have been ascribed to them, including inducing satiety sensing and 
Stellenbosch University  https://scholar.sun.ac.za
 23 
 
counteracting lipogenesis in the liver together with all the other prebiotic benefits described above, as 
well as anti-viral and antioncogenic traits [91]. Recently fructans have also been recognised as having 
antioxidative properties and may be useful in disease prevention by actively reducing concentrations of 
reactive oxygen species (ROS) [145]. 
With regards to structure there are five main fructan subgroups which differ on the basis of the 
positional placement of the glucose moiety and on the linkage type between their fructosyl residues. 
The five sub-classes that can be discerned are, inulin (linear), levan (linear), graminan (branched), 
neo-inulin (branched) and neo-levan type (branched) fructans. The tri-saccharides 1-kestose, 6-kestose, 
neokestose as well as the tetra-saccharide bifurcose, are building blocks from which higher degree of 
polymerization (DP) fructans are synthesized. The five main fructan subgroups and the enzymes that 
synthesise them are as follows and are illustrated in Figure 2-4. 
I. The best known and well characterised fructan is inulin, which consists of a terminal glucose and a 
series of β-2,1 linked fructosyl units (Fig 2-4). 1-Kestose is the primary building block of these type 
of fructans and is formed when a fructosyl moiety is transferred to an acceptor sucrose substrate 
from a suitable donor by the enzyme sucrose: sucrose 1-fructosyl transferase (1-SST). Fructan: 
fructan 1-fructosyl transferase (1-FFT) then polymerizes 1-kestotriose into higher DP inulin-type 
fructans by continuously adding fructosyl residues in a β-2,1 linkage (Fig 2-4). The best dietary food 
sources of inulin are garlic, leeks and onions which can contain between 3-18% of their fresh weight 
as inulin. 
 
II. The enzyme fructan: fructan 6G-fructosyl transferase (6G-FFT) synthesizes 6G-kestotriose 
(neokestose) from 1-kestotriose as donor substrate and sucrose as acceptor substrate, thereby 
forming an internal glucose molecule flanked by two fructosyl moieties. Elongation of neokestose 
by 1-FFT leads to the formation of inulin neo-series type fructan which is abundant in asparagus.  
 
III. Neokestose is formed as above, but when it is elongated by 6-SFT it leads to the formation of levan 
neo-series type fructans.  
 
IV. Fructan: fructan 6-fructosyl transferase (6-FFT) transfers a fructosyl moiety from sucrose to the first 
fructosyl monomeric unit of 1-kestotriose, thereby producing 1,6-kestotetraose (bifurcose). 
Bifurcose is the smallest graminan-type fructans of mixed linkages and is most commonly found in 
cereals. Bifurcose can subsequently be further extended by 6-FFT and 1-FFT leading to higher degree 
of polymerization (DP) graminans. 
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V. Linear levan-type fructans are found in animal feed grasses. In plants levan type fructans are not 
nearly as abundant as the inulin type [142]. Much like inulin, levan in plants is synthesised by two 
distinct enzymes sucrose: sucrose 6-fructosyl transferase (6-SST) which forms the initial 6-kestose 
upon which 1-FFT elongate the fructan chain in a β-2,6 manner. Levan is however also produced by 
certain bacteria and yeast by the enzyme levansucrase. Levansucrase can be seen as having both 
6-SST and 1-FFT innate activity in that it initially transfers a fructosyl moiety from a sucrose donor 
to another sucrose molecule thereby forming 6-kestotriose, after which it elongates the linear levan 
with 6-FFT activity in a β-2,6 manner.  
 
 
Figure 2-4 Fructan biosynthesis of the five sub-types of fructans in plants: Glc (glucose); Fruc (fructose); 1-SST (sucrose: sucrose 
1-fructosyl transferase); 1-FFT (fructan: fructan 1-fructosyl transferase); 6G-FFT (fructan: fructan 6G-fructosyl transferase); 6-
SST (sucrose: sucrose 6-fructosyl transferase); 6-FFT (sucrose: fructan 6-fructosyl transferase). Note that bacterial and yeast 
levansucrase activity (red box and arrows) is seen as a combination of 6-SST/6-FFT activity when compared to that of plants. 
 
Fructans and FOS in human diets comes mainly from plant sources most notably wheat (Triticum 
aestivum), rye (Secale cereale), barley (Hordeum vulgare), oat (Avena sativa), leek (Allium 
ampeloprasum), lettuce (Lactuca sativa), Belgian endives (Cichorium intybus), salsify (Scorzonera 
hispanica), onion (Allium cepa), garlic (Allium sativum), globe artichoke (Cynara scolymus) and 
asparagus (Asparagus officinalis) [58]. The latter four species contain high fructan concentrations and 
have been extensively researched and utilized in medicine with reported immunomodulatory and 
antiviral properties [91].  
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Fructans are recognized as one of the principle storage forms of energy in approximately 15% of higher 
plants [146]. In dicots, inulin accumulates as a long term reserve carbohydrate in underground roots 
and tubers whereas in grasses, graminan, levan, and neokestose-derived fructans function 
predominantly as short-term storage compounds [142]. Of all the fructans, by far the most researched 
is that of the plant derived inulin, especially with regards to its prebiotic and other health associated 
benefits [147]. Inulin is commercially manufactured from chicory root, where it comprises roughly 
one-fifth of the fresh weight of which approximately 55% has a DP range of 2-19, 28% has a DP of 20-40 
and 17% has a DP higher than 40, giving it a good polydispersity index (PDI) [115]. This is a measure of 
distribution of molecular mass within a given polymer sample and is calculated by the weight average 
molecular weight divided by the number average molecular weight. Different chain lengths of inulin are 
fermented at different rates according to their DP [148]. Inulin type oligosaccharides and inulin with a 
lower DP are fermented rapidly in the proximal part of the colon where they exert the characteristic 
bifidogenic effect. Higher DP inulins are fermented more slowly and are able to reach the distal parts of 
the colon where readily fermentable carbohydrates are in short supply [149]. This creates a low 
carbohydrate environment where the microbiota experiences a metabolic shift towards predominantly 
proteolytic fermentation due to protein being the only remaining nutrient supply, resulting in the 
production of toxic putrefactive metabolites. High DP fructans are able to reduce the proteolytic activity 
in favour of a beneficial saccharolytic activity in these areas [150, 151].  
An alternate method of obtaining both FOS and high molecular weight fructans is through microbial 
production of levan with the enzyme levansucrase (EC 2.4.1.10). Whereas in plants the functional role 
of fructans relates to bridging the temporal gap between resource availability and energy demands, in 
microorganisms their evolutionary role relates more to exopolysaccharide production for microbial 
biofilm formation in response to environmental and competitive stressors [152]. Plants require at least 
two distinct and separate enzymes namely sucrose: sucrose 6-fructosyl transferase (6-SST) and Sucrose: 
fructan 6-fructosyl transferase (6-SFT) to catalyse the initial priming and subsequent chain elongation in 
the synthesis of levan type fructans (Fig 2-4). The low availability of these in plants compared with inulin 
makes plants an unfeasible source for commercial extraction. Microbial levan biosynthesis, however, is 
catalysed by the single enzyme, levansucrase, which simultaneously both primes and elongates using 
sucrose predominately as a substrate. This, therefore, makes it a great deal more attractive for industrial 
application [153, 154]. Numerous levansucrases that produces either levan or levan type FOS have been 
identified from a wide range of microorganisms [155]. They can be utilized either in a crude cell extract, 
partially or completely purified, produced in a recombinant system, or immobilized to produce levan on 
an reactor based scale [156]. The levan yield as well as the DP and polydispersity index vary greatly 
depending on the source of levansucrase, and the specific reaction conditions such as temperature, pH, 
initial substrate concentration and ionic strength [154, 157, 158]. 
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As mentioned above, in comparison with β-2,1 linkages of inulin obtained from plant sources, microbial 
levan consist primarily of β-2,6 linked fructosyl units, leading it to have additional and different 
biological and commercial characteristics. Together with its popular properties, such as renewability, 
flexibility, bio-degradability and industrial application as a natural adhesive and surfactant, levan also 
has numerous biomedical properties. These include acting as anti-inflammatory, anti-viral, 
anti-carcinogenic, fibrinolytic, hypolipidemic, immunostimulatory and anti-oxidant agents as well as 
being a hyperglycaemic inhibitor [159-164]. Furthermore levan has found applications in the food and 
cosmetic industry as emulsifiers and thickening agents and, in addition, levan type FOS are being utilized 
as a health beneficial artificial sweeteners [165]. Recently more novel applications for levan has been 
proposed in terms of nanotechnology based drug delivery systems and wound dressings [155]. By 
utilising a combination of synthetic biology and microbial fermentation techniques levan can also be 
effectively converted to biofuel [166]. One of the most useful characteristics of levansucrase is that it 
has been shown to hold a broad range of acceptor specificities to which it can transfer the fructosyl 
moiety after the initial sucrose hydrolysis. These include numerous other monosaccharides, 
disaccharides and oligosaccharides, thereby creating scope for the synthesis of valuable, novel or rare 
fructosylated saccharides e.g. lactosucrose (lactose-Fruc) and sucrose analogues (D-Gal-Fruc, 
D-Man-Fruc, D-Xal-Fruc and D-Fruc-Fruc) [155]. Other fructosylated compounds can also be formed 
when the fructosyl moiety is transferred to donors other than saccharides and the synthesis of 
alkyl-fructosides (methyl-fructoside) and the fructosylation of aromatic alcohols like hydroquinone have 
been reported [123, 167, 168]. 
With regards to levan as a prebiotic substrate surprisingly little research has been conducted compared 
to that examining inulin, with only six recent papers addressing the subject [144, 169-173]. The prebiotic 
potential of any complex carbohydrate is dependent on numerous factors including, but not limited to, 
its degree of polymerization, monomeric composition, linkage type, crystallinity, solubility and it 
relationship with other substrates [174]. From a microbial perspective the most rudimentary 
requirement is whether or not the resident microbiota are in possession of the necessary metabolic 
machinery to degrade the complex carbohydrates. Among GI microbiota, the Bacteroidetes, Firmicutes 
and Actinobacteria phyla are the most prominent in the degradation of plant fibre polysaccharides. 
Indeed, inulin administration has been shown to increase Bifidobacterium populations both in vivo and 
in vitro, but this would be expected as Bifidobacterium are known to possess β-fructofuranosidase 
activity that specifically cleaves the β-2,1 linkage type of inulin [175, 176]. Whether the same metabolic 
machinery is available for the degradation of microbial derived β-2,6 linked levan is still being 
investigated, although compelling evidence has been presented. As mentioned above microbial levan 
can either be in the form of FOS or larger polymers than can have a DP of several thousand [177]. Several 
studies have concluded that FOS with β-2,6 linkage type selectively enhance Bifidobacteria and 
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Lactobacilli numbers presumably by providing a good growth substrate that consequently lead to the 
production of lactic and acetic acid (For review see[144]). In addition, certain Bacteroides species has 
been shown to possess extra-cellular endo-levanase activity capable of degrading the longer chain levan 
into oligosaccharides which are more readily fermented [178]. Visnapuu et al. (2015) hypothesised that 
even if some probiotic microbiota cannot hydrolyse the longer chain β-2,6 fructans, they are still 
stimulated by it due to the ability of Bacteroides species and/or other bacteria with extracellular 
levan-degrading capabilities to break it down [144]. To further substantiate levan’s proposed application 
as a prebiotic, Adamberg et al. (2015) showed most recently that high molecular weight levan enhances 
the associated growth of levan-degrading (e.g. Bacteroides) and butyric acid-producing (e.g. 
Faecalibacterium) taxa in levan supplemented media and that the main products of levan metabolism 
were acetic, lactic, butyric, propionic and succinic acids as well as carbon dioxide [173]. 
Therefore levan has a broad array of applicability including that of a prebiotic fibre. The search for novel 
enzymatic catalysts with enhanced activities and specificities that synthesise them has great potential 
to improve their functionalities. 
 
 Galacto-oligosaccharides (GOS) as prebiotic, sources and synthesis. 
 
The hydrolysis of lactose in milk is one of the most important technological procedures in the food 
processes industry. The reasons for this are several fold namely (i) to diminish problems of lactose 
intolerance that are present in more than half the global adult population [179, 180], (ii) formation of 
galacto-oligosaccharides so as to enhance the growth of beneficial intestinal microbiota [181], (iii) 
enhancement of the sensorial characteristics of hydrolysed milk products (milk with high lactose content 
crystallise in ice-cream and the hydrolysed glucose sweetens the milk) [182, 183], and (iv) improvement 
of the degradability of hydrolysed waste whey water [184]. Lactose can be hydrolysed either by means 
of acid hydrolysis or enzymatically using β-galactosidase, however it is only by means of the latter that 
GOS can be synthesised [182]. Additionally the enzymatic process doesn’t add any by-products or alter 
the nutritional content or colour of milk, making it the preferred method. Several advances have been 
made in the field and lactose can be hydrolysed/transformed either with the addition of whole cell 
extracts, or by immobilised β-galactosidase on membranes by means of cross-linking, thereby making 
the enzymes reusable [183, 185, 186]. 
The enzyme β-galactosidase (EC 3.2.1.23) is of special historical significance in molecular biology. It 
played a pivotal role in Jacob and Monod’s development of the operon model for the regulation of gene 
expression and today the lac operon is synonymous with transcriptional regulation [187]. Furthermore, 
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its ability to phenotypically manifest its presence by producing an easily recognizable blue/indigo 
product through its activity on X-gal has made it a workhorse in molecular cloning via blue/white colour 
selection. The basis of screening on X-gal is α-complementation in the presence of IPTG. In early studies 
of β-galactosidase, it was observed that deletion of certain amino acid residues near the amino-terminus 
caused the tetrameric enzyme to dissociate into inactive dimers thereby abolishing activity. By 
co-expressing some or all of the missing peptide residues it was possible to reconstitute the tetrameric 
form of the enzyme and thereby its inherent catalytic activity [188]. 
There are two intrinsic competitive activities inherent in β-galactosidase namely those of hydrolysis and 
trans-galactosylation.  
 
Figure 2-5 β-galactosidase activity mechanism: EnZ (enzyme); EnZ-Lactose (enzyme lactose complex); EnZ-Gal+ (enzyme and 
galactose covalently bonded); EnZ-Gal-O-Sug (enzyme and galactose as well as acceptor molecule covalently bonded) Sug-OH 
(sugar acceptor molecule presenting –OH group). 
 
The trans-galactosylation reaction usually takes place in the presence of a high lactose substrate 
concentration [189]. Three distinct steps can be discerned for the general reaction mechanism of 
β-galactosidase, the last of which allows for either hydrolysis or trans-galactosylation (Fig 2-5): 
1. enzyme + lactose                          →   enzyme -- lactose (complex) 
2. enzyme -- lactose (complex)       →   galactosyl -- enzyme + glucose 
3. galactosyl -- enzyme + acceptor →   galactosyl – acceptor + enzyme 
In the first step the lactose substrate is docked in the active site of the tetrameric enzyme and an enzyme 
substrate complex is formed. In the second step, an amino group in the active site acts as a general acid 
and donates a proton to the glycosidic oxygen. Within the active site there is also another negatively 
charged group that then stabilizes the positively charged carbonium galactosyl intermediate by forming 
a temporary covalent bond [181]. The third and final step of the reaction mechanism involves the 
galactosyl transfer to a nucleophilic acceptor molecule. All reducing sugars can act as acceptors resulting 
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in a final mixture of di-, tri-, tetra-, and even higher saccharides. However, acceptor molecules act in a 
competitive manner and, if H2O is the acceptor molecule, hydrolysis occurs. 
As described above, GOS are galactose containing oligosaccharides that usually take the form of 
α-Glc-1,4[β-Gal-1,3/4/6]n, where n = 2-9. The initial acceptor molecule is primarily lactose, to which 
consecutive galactosyl moieties are added through the trans-galactosidase activity of the enzyme 
β-galactosidase [181]. However, Galn-Gal structures have also been shown to be formed when a 
galactosyl moiety is transferred to free galactose and branched structures of GOS have also been 
identified. Di-, tri-, tetra-, and penta-saccharides are the main end products with the disaccharide 
allolactose (βGal-1,6-Glc) and galactobiose (βGal-1,6-Gal) making up the majority of the 
trans-galactosylation product [190]. 
The concentration and yield of GOS obtained, as well as the different structural linkage types formed 
during their enzymatic synthesis, depend on various factors, most notably the reaction conditions and 
the specific enzyme used. The overall efficiency of the trans-galactosylation reaction is kinetically 
controlled and depends on the specific biochemical attributes of the enzyme. The GOS themselves are 
potential substrates and can be hydrolysed by the enzyme. The enzymatic reaction eventually 
hydrolyses all lactose and reaches an equilibrium with the resultant mixture of monosaccharides, 
disaccharides and oligosaccharides dependent on the conditions and enzyme used [191]. To produce 
GOS of a higher DP the enzyme would need to have a higher propensity to catalyse the 
trans-galactosylation reaction relative to that of the hydrolysis reaction and, and/or have a lower affinity 
for the hydrolysis of the already formed GOS relative to that of lactose [181]. 
As already noted GOS can differ in their saccharide composition, type of regio-chemical glycoside 
linkages, as well as the degree of polymerization [189]. These differences impart physicochemical and 
biological attributes that affect their prebiotic capabilities and are also relevant to other food 
applications. In vitro evidence suggests that the prebiotic microbiota differentially ferment 
oligosaccharides with different structures [192]. All prebiotics enhance the growth and/or activity of the 
beneficial microbiota but GOS has, furthermore, been shown to be a potent receptor decoy to prevent 
adherence of pathogenic bacteria [193]. Most recent research has emphasised the profound effect GOS 
have on inflammation, hypercholesterolemia as well as its ant-carcinogenic effects [194-198]. Special 
interest is also given to GOS as they closely resemble human milk oligosaccharides (HMO) and all 
evidence indicate that they have a large bifidogenic effect if added to infant formula. The GI microbiota 
of infants receiving GOS supplemented formula, more closely resemble that of breastfed infants [27, 
199]  
As mentioned the preceding sections there are two possible enzymatic systems for the production of 
GOS from lactose, namely glycosyltransferases (EC 2.4) and glycoside hydrolases (EC 3.2.1). 
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Galactosyltransferases catalyse the transfer of sugar moieties from an activated sugar nucleotide to an 
acceptor molecule leading to an increasing DP [114]. Galactosyltransferases are highly selective with 
regards to acceptor molecules and bond formation and can produce high yields of GOS and longer chain 
polysaccharides [200]. Even though novel bi-enzymatic systems have been developed with regards to 
incorporating the nucleotide sugar production systems, as well as the galactosyl-transferase system, 
their combined metabolic burden makes the requirement too cumbersome for it to be feasible on an 
industrial level [114].  
Many organisms exhibit endogenous β-galactosidase activity and it can be extracted from a variety of 
sources including microorganisms, plant and animal cells [118] The β-galactosidase utilized by industry 
originates from various microbial sources. Torres et al. (2010) compiled a comprehensive list of both 
the fungal and bacterial sources of enzymes as well as their optimum reaction conditions and yield [117]. 
Traditionally the main sources are the yeast Kluyveromyces lactis and the fungus Aspergillus oryzae., 
due to their easy cultivation and GRAS status [118]. However, increasingly bacterial sources are being 
investigated especially in regards to recombinant DNA technology. Bifidobacterium, Lactobacillus and 
Bacillus species are some of the bacteria utilized thus far (Table 2-2). There remains, however, a need 
to find or develop better production mechanisms for prebiotic GOS as well as FOS and longer chain 
polysaccharides. One way of accomplishing this is through the construction and screening of 
metagenomic libraries for enzymes with improved capabilities.  
As mentioned already in section 1.2. of the general introduction the aim of this study was for the 
discovery and subsequent objective characterisation of enzymes that produce novel polymers and/or 
oligosaccharides comprised of either galactose or fructose. The enzymes that facilitate this belong to 
the glycoside hydrolyse type family proteins and possess both hydrolytic as well as trans-glycosidic 
activity as already reviewed. The search for these enzymes was mediated through the construction and 
use of metagenomic libraries from niche environments that have an abundance of either galactose or 
fructose present. 
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Table 2-2 Bacterial sources of glycoside hydrolases used in the production of GOS (adapted from Torres et al.,2010 [117]) 
Bacteria  Enzyme & preparation Synth. GH T/ oC pH L0. Ymax Ref 
 → Actinobacteria         
Saccharopolyspora rectivirgula β-Galactosidase, purified  GH2 70 7.0 60 44 [201] 
Bifidobacterium adololescentis crude enzyme fraction   55 7.0 30 43 [202] 
Bifidobacterium angulatum crude enzyme fraction   55 7.5 5-30 44 [202] 
Bifidobacterium bifidum β-Galactosidase (BIF3), mutated  GH2 37 6.0 10-40 44 [203] 
Bifidobacterium bifidum crude enzyme fraction   55 7.5 30 38 [202] 
Bifidobacterium bifidum Cells, resting cells   39 6.8 50 20 [204] 
Bifidobacterium bifidum Cells, toluene treated, resting cells   40 6.2-6.8 45-50 44 [205] 
Bifidobacterium bifidum Cells, toluene treated, resting cells   40 5.0-5.5 Whey, 47 38 [206] 
Bifidobacterium longum s. inafantis β-Galactosidase(Bgal I), cloned  GH2 30 6.5 36 49 [207] 
Bifidobacterium longum s. inafantis β-Galactosidase(Bgal II), cloned  GH2 30-60 7.5 20-30 68 [208] 
Bifidobacterium longum s. inafantis β-Galactosidase(Bgal III), cloned  GH42 37 7.5 20 10 [209] 
Bifidobacterium longum s. inafantis crude enzyme fraction   55 7.5 30 48 [202] 
Bifidobacterium longum s. inafantis Cells, in culture   60 7.5 Milk, 35 43 [210] 
Bifidobacterium longum  crude enzyme fraction   45 6.8 5-50 35 [211] 
Bifidobacterium pseudolongum crude enzyme fraction   55 7.5 30 27 [202] 
→ Deinococcus-Thermus         
Thermus sp.  β-Glucosidase, cloned  GH1 70 7.0 7.5-30 40 [212] 
Thermus caldophilus β-Glucosidase (BglA), cloned  GH1 70-80 6.0 30-50 77 [213] 
→ Thermotoga         
Thermotoga maritima β-Galactosidase (LacZ), cloned  GH2 80 6.0 20-50 19 [214] 
→ Firmicutes         
Bacillus circulans β-Galactosidase (I), purified   40 6.0 4.6 6 [215] 
Bacillus circulans immobilized enzyme extract SG GH2 40 6.0 4.3 40 [216]  
Bacillus circulans β-Galactosidase (I), purified  GH3 40 6.0 4.6 41 [215] 
Bacillus circulans immobilized enzyme extract SG, PBR GH4 40 6.0 4.6-20 48 [217] 
Bacillus circulans immobilized enzyme extract PR, PBR GH5 40 6.0 4.6 35 [216] 
Bacillus circulans crude enzyme fraction   40-55 6.0 6.5-36 43 [218] 
Bacillus sp. crude enzyme fraction   50-55 5.0 33-36 43 [219] 
Bacillus sp. immobilized enzyme extract Chitosan  55 5.5 36 41 [220] 
Geobacillus stearothermophilus β-Galactosidase (BgaB), cloned  GH42 37 6.5 17 2.4 [221] 
Geobacillus stearothermophilus β-Galactosidase (BgaB), mutated  GH42 37 6.5 17 30 [221] 
Caldicellulosiruptor saccharolyticus β-Glucosidase (Bgla), cloned  GH1 65-80 6.3 10-72 63 [222] 
Lactobacillus acidophilus β-Galactosidase (LacL+LacM), cloned  GH2 30 65.0 21 39 [223] 
Lactobacillus reuteri β-Galactosidase (LacL+LacM), cloned  GH2 23 6.0 21 26 [224] 
Lactobacillus reuteri β-Galactosidase (LacL+LacM), purified  GH2 30-37 6.0-6.5 4.6-21 38 [225] 
Lactobacillus reuteri immobilized enzyme extract CMAR GH3 37 6.0 21 29 [226] 
Streptococcus thermophilus β-Galactosidase (LacZ), purified  GH2 37  Milk, 5.3 25 [227] 
→ Proteobacteria         
Enterobacter agglomerans β-Galactosidase (LacZ), cloned  GH2 50 7.5 5 to 13 38 [228] 
Enterobacter cloacae β-Galactosidase (Bga/LacZ), cloned  GH2 50 6.5 28 49 [228] 
Enterobacter cloacae Cells, resting cells   50 6.5 28 55 [229] 
Escherichia coli β-Galactosidase (LacZ), purified  GH2 30 to 37 
6.5 
to7.2 2.2 to 24 56 [230] 
Escherichia coli immobilized enzyme extract RM   37 7.5 2.2 44  [230] 
GH, glycoside hydrolase family. Synth., synthesis method. L0, initial lactose concentration (%,w/v). Ymax, maximum GOS yield 
reported (%) = GOS concentration/L0 x 100. SG, immobilized support gel. PR, phenol-formaldehyde resin. PBR, packed bed reactor. CMAR, 
membrane assisted reactor. RM, reverse micelles.
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 Metagenomic library construction, screening and preliminary analysis. 
 Introduction 
 
Despite their promising performance in the laboratory, the application of enzymatic biocatalysts on 
industrial or semi-industrial level often ends in failure [231]. This limitation is primarily due to the lack 
of availability of microbial enzymes that can perform the desired chemical reactions under industrial 
conditions. Even if a catalytic specific enzyme is available, the enzymatic fitness itself may be inadequate 
and the industrial processes redesigned so as to fit the characteristics of that enzyme [232]. Therefore, 
the quest for suitable, robust and need specific enzymatic biocatalysts is constant. 
Over the last decade, the ever advancing next generation sequencing platforms together with their mass 
data acquisition and concurrent bioinformatic sequence analysis has taken centre stage, resulting in 
over 190 billion nucleotides of sequence data being available in the public domain by 2010 [233]. 
Currently there are over a trillion nucleotides on GenBank and tenfold more from whole genome 
sequencing projects (Genbank statistics; https://www.ncbi.nlm.nih.gov/genbank/statistics/).  
However, several limitations do exist with regards to the search for functional biocatalysts via next 
generation sequencing. Accurate functional assignment of genes is a major challenge with mass 
bioinformatic analysis. Direct comparison of functional and metagenomic analyses have laid bare these 
limitations in that functional misannotation or over-representation often results in true positives being 
missed. Although environmental metagenome sequencing is being conducted by means of 
next generation platforms, the majority of next generation sequencing taking place is on the single 
organism level. Most industrial enzymes currently being utilized are of microbial origin, however fewer 
than 1% of bacteria present in most environments can be cultured under standard laboratory 
conditions, resulting in many potential targets being missed. Taking all of the above into consideration, 
it is not surprising that the functional screening of metagenomic libraries still plays a prominent, and 
often central, role in enzyme discovery [234]. 
Metagenomic library construction and screening is however not without its own set of limitations. The 
probability of identifying a specific gene depends on multiple factors including, source metagenomic 
DNA, host system, vector system, target gene size, its relative abundance in the source metagenome, 
efficiency of heterologous gene expression in host and, most importantly, the functional screening 
method itself [234].  
The most critical consideration for the construction of a successful and functional metagenomic library 
is the sampling site, in order to maximise the likelihood of the presence of the desired genetic elements. 
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For the purposes of this study the main interest lies in glycoside hydrolases that demonstrate both 
hydrolytic and trans-glycosidic activities, thus bypassing the need for complex bi-enzymatic systems 
utilising glycosyltransferases and activated sugar nucleotide substrates. Therefore, in the pursuit of 
microbial glycosidases that produce either a galactose or fructose containing oligosaccharide/polymer, 
logic dictates that environments that are abundant in disaccharidic substrates containing the desired 
monosaccharides moieties i.e. lactose and sucrose should be targeted. In addition to targeting substrate 
rich environments, environments where desirable enzymatic characteristics (like temperature stability 
and a broad pH range) could develop would serve as the main parameter for environmental sampling 
selection. 
For the construction of metagenomic libraries most researchers utilise E. coli as a host system. Almost 
all laboratory strains of this bacterium lack the homologous recombination genes recA and recBC, as 
well as the functional restriction enzyme genes mcrA and mcrBC, making it useful for cloning modified 
foreign DNA. Its main drawback though, is that even though E. coli is efficient for the expression of a 
great quantity of microbial genes, the functional expression of eukaryotic genes is often low or absent 
due to introns. Therefore, functional screens in E. coli using metagenomic libraries constructed from 
environmental samples will mainly identify prokaryotic genes. 
The choice of a vector depends largely on the size of the inserts and whether single genes or whole 
operons are targeted. Plasmids are suitable for cloning genetic fragments up to 12 kb, while cosmids 
(20-35 kb), fosmids (20-40 kb) and BACs (50-200 kb) are used to clone larger fragments. The targets for 
novel enzyme discovery are usually single genes thus making plasmid based bacteriophage library 
systems the method of choice for most gene discovery. Plasmid vector systems can also have the 
advantage of having a high copy number and strong promoters [235, 236].  
The methodology used to functionally screen metagenomic libraries can also be critical in terms of 
identifying industrially useful enzymes. Enzymatic activities are usually assayed on agar plates 
supplemented with specific substrates. By plating a metagenomic library on the before mentioned 
plates, positive clones can be identified through visual screening for the presentation of a phenotype or 
colour reaction.  
For the purposes of this study a dual approach was taken towards the screening of the metagenomic 
libraries based on the dual nature of the required glycosidases, i.e. it’s hydrolytic and trans-glycosylation 
activities. Firstly, depending on the source of the library, it will be screened on minimal media plates 
containing either lactose or sucrose as the sole carbon source. Cells should only grow if they contain an 
inserted sequence that encodes a functional enzyme capable of hydrolysing the disaccharides, thereby 
liberating the glucose hexose moiety that can enter glycolysis. The simultaneous presence of an 
exopolysaccharide, caused by polymer formation using the residual monosaccharide obtained from the 
Stellenbosch University  https://scholar.sun.ac.za
 34 
 
disaccharide after hydrolysis, will further serve to identify a positive phenotype. Additionally, with 
regards to screening for glycoside hydrolases that utilise lactose as a substrate, the well-known 
molecular technique of blue/white screening on X-gal will be exploited. In normal molecular techniques 
blue/white selection is utilized to establish whether a vector containing the coding sequence for the 
lacZ-alpha monomer is uninterrupted, or if a sequence of DNA has been inserted into it. If it is 
uninterrupted then a functional peptide is expressed and the LacZ-alpha protein forms a hetero-enzyme 
complex with LacZ-omega, consequently restoring activity and giving the cell the ability to hydrolyse 
X-gal resulting in the phenotypic indigo blue colour [188]. In this study, an E. coli mutant was constructed 
lacking both the LacZ-alpha and LacZ-omega subunits, thereby abolishing any and all β-galactosidase 
activity even if a vector derived α-subunit were to be present. Colour formation on X-gal will only occur, 
therefore, if an exogenous coding sequence is present in the library derived vector, capable of its 
hydrolysis. 
Once positive clones have been identified and confirmed, they can be sequenced through conventional 
methods, after which they can be cloned and partially characterised so as to to establish potential 
suitability for industrial applications. 
 
 Materials and Methods 
 
All chemicals were of molecular biology grade. Restriction endonucleases, DNA ligase, and RNAse were 
purchased from Thermo Scientific (Waltham, Massachusetts, United States). GoTaq was purchased 
from Promega (Madison, Wisconsin, United States). Galactose dehydrogenase/mutatarose, 
hexokinase/glucose-6P-dehydrogenase were obtained from Megazyme (Bray, Ireland). All other 
chemicals were purchased from Sigma (St. Louis, Missouri, United States). 
 
 Sample collection and DNA isolation 
 
Several libraries were constructed from metagenomic DNA extracted from environmental samples. For 
galactose containing polymers/oligosaccharides soil was collected at the Faircape dairy farm located in 
the Western Cape province of South Africa during early autumn on the 25th April 2014. Sampling was 
done at a place where milk runoff occurs from a storage container into the soil (GPS coordinates: 
33°45'01.2"S 18°36'44.9"E). The ambient temperature was approximately 20oC . Several  ‘interesting’ 
sub-sites were sampled in and around the general site, and collected and sealed in plastic containers 
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(Fig. 3-1). Samples were taken to the lab where their pH’s were measured individually at room 
temperature, before being amalgamated into one general sample for each respective library. For the 
second library, sampling was done at an intertidal zone where galactose containing coastal kelp 
degradation takes place at Gansbaai on the Western Cape coast, South Africa (GPS coordinates 
34°34'26.9"S 19°20'45.2"E). Samples were collected during autumn on May the 15th 2014, early 
afternoon. The ambient temperature during time of sampling was approximately 19oC. Much like the 
sampling for the previous library, several samples around the general sampling site were collected and 
taken to the laboratory for further analysis and extraction (Fig 33-1). For the library constructed for the 
purposes of screening for fructose containing polymers/oligosaccharides samples were collected from 
onsite runoff occurring at the Illovo sugar refinery Durban, KwaZulu-Natal, South Africa (GPS 
coordinates: 30°05'28.5"S 30°49'30.8"E) during September 2013. It should be noted that the author 
himself didn’t conduct the sampling of the latter site, and no other physical parameters are known other 
than the fact that the refinery conditions are generally hot and humid with temperatures usually in 
excess of 30oC. 
A modified protocol was utilized for the extraction of all genomic DNA based on the protocol of Verma 
et al. (2011) and Dos Reis Falcão et al. (2008) [237, 238]. A total of 100 g of soil/sludge was extracted 
for each sample. In brief; Soil (1 g) was suspended with activated charcoal (0.4 g) and 20 μl of 
proteinase K (10 mg.ml−1) was added together with 2 ml of modified extraction buffer [(1%; w/v) 
N,N,N,N-cetyltrimethylammoniumbromide (CTAB), (2%; w/v) polyvinyl-polypyrrolidone (PVPP), 1.5 M 
NaCl, 100 mM EDTA, 0.1 M TE (Tris-HCL EDTA) buffer (pH 8.0), 0.1 M sodium phosphate buffer (pH 8.0), 
and 100 μl RNase A (10 mg.ml-1]. The sample was incubated at 37oC with orbital shaking at 200 rpm for 
a total of 30 min. Subsequently, 200 µl of SDS (10%; w/v) was added to the homogenate and further 
incubated at 60oC for 2 hrs with intermittent shaking. DNA was precipitated by adding 1 ml PEG 8000 
(30%; w/v in 1.6 M NaCl) and left at room temperature for an hour. The precipitated DNA was collected 
by centrifugation at 12,000 xg at 4oC. The supernatant was discarded, and the pellet resuspended in 
1 mL TE buffer (pH 8.0) after which 100 µl of 5 M potassium acetate was added and incubated at 4oC for 
30 min. The supernatant was collected after centrifugation at 12,000 xg and twice extracted with an 
equal volume of a phenol-chloroform : isoamyl alcohol (25:24:1; v/v). This was followed by another 
extraction with an equal volume of a chloroform/isoamyl alcohol (24:1; v/v) only, before being 
centrifuged at 10,000 xg for 15 min. The aqueous layer was transferred to another tube and treated 
with a 0.7 volume of isopropanol for 1 hour at room temperature. The DNA was pelleted by 
centrifugation at 12,000 xg for 20 min at 4oC after which the supernatant was decanted and the 
remaining pellet carefully washed with 1 ml of 70% (v/v) ethanol and then briefly dried at room 
temperature. The dried pellet was resuspended in 100 μl of sterile Milli Q water. To further purify and 
remove polysaccharide contamination an equal volume of GHCl extraction buffer [6.5 M guanidinium 
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hydrochloride, 100 mM Tris-HCl (pH 8.0), 0.1 M sodium acetate (pH 5.5), 0.1 M β-mercaptoethanol, 0.2 
M KOAc] was added and gently mixed. The sample was then centrifuged at 12,000 xg for 15 min to 
selectively precipitate the polysaccharides, and the supernatant transferred to a new tube. The DNA 
was again precipitated with two volumes of ethanol, pelleted by centrifugation at 12,000 xg for 15 min 
and suspended in 100 μl ddH2O. After DNA extraction the quality and quantity of the DNA was assessed 
by agarose gel electrophoresis on a 1% gel. The purity was assessed spectrophotometrically and 
nuclease activity on the extracted DNA was qualified visually by restriction enzyme (RE) digestion of 3 
µg of extracted DNA with 3 units XhoI in the supplied 1X buffer in a final volume of 50µl. 
 
 Metagenomic library construction and in vivo mass excision 
 
Libraries were constructed with the Lambda ZAP express pre-digested vector kit according to the 
manufacturer’s recommended protocol (Agilent Technologies). In brief: 5 µg genomic DNA was digested 
with Bsp143I RE ranging between 0.2 u.µl-1 and 0.0125 u.µl-1 in a final 15 µl reaction volume for 30 min 
after which it was heat inactivated at 70 oC for 10 min and then chilled on on ice. One unit of enzyme 
activity is defined as the amount of enzyme needed to digest 1 µg of DNA in a 50 µL volume in one hour. 
The digestion products were separated by agarose gel electrophoresis (1%; w/v) in order to identify the 
correct enzyme concentration for optimal partial digestion, where the majority of the digested 
fragments were larger than 2 kb in size. After establishing the desired RE to DNA ratio in the correct 
volume, the reaction was up-scaled so as to digest 100 µg of total DNA. The digested DNA was then 
fractionated on a 20 cm long 1 ml Pasteur pipette, packed with Sepharose CL-2B, by the gravity fed 
method. The column was pre-washed with 10 ml of STE buffer (100 mM NaCl, 1 mM EDTA, 10 mM 
Tris-HCl pH 8.0). The sample was loaded together with 1 µl of saturated bromophenol blue solution to 
serve as a tracking dye. Three drop fractions were collected in microfuge tubes up until the dye ran 
through the column.  Five microliter of each fraction was analysed by agarose gel electrophoresis 
(1%; w/v). Fractions containing DNA of the appropriate size (2 kb and higher) were pooled, precipitated 
with 2 volumes ethanol, washed with ethanol (70%; v/v) and reconstituted in 20 µl Tris buffer (5 mM; 
pH 7.5). A total of 4 µg of size fractured DNA (avg. size ~ 3 kb) was ligated with a roughly estimated 
equimolar amount of lambda ZAP vector in an overnight reaction, so as to attain the ligated 
concatemeric DNA required for optimal packaging, with the aid of T4 DNA ligase. The ligation reaction 
was then heat inactivated at 60oC for 10 min and immediately cooled down on ice. Commercial 
packaging extracts were used to encapsulate recombinant lambda phage DNA with high efficiency 
within their proteinaceous viral capsules. The extract itself is an extremely temperature sensitive viral 
protein preparation that is free of any foreign DNA. It is restriction minus thus allowing methylated DNA 
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to be packaged (HsdR- McrA- McrBC- McrF- Mrr- ). The ligated DNA was packaged with Gigapack III 
packaging extract according to the manufacturer’s recommended protocol (Agilent technologies). In 
brief: the packaging extracts were removed from the -80oC freezer and briefly thawed between the 
finger tips before being placed on ice. The ligated DNA preparation was carefully added to the packaging 
extract and gently stirred with a pipette tip whilst taking care not to introduce any bubbles. The tube 
was briefly spun down and incubated at 22oC for two hours. The reaction was stopped by adding 500 µL 
of SM buffer [25 mM Tris-HCl (pH 7.5), 100 mM NaCl, 8 mM MgSO4, gelatin (0.01%; w/v)], and 20 µL of 
chloroform. The tube was briefly spun down to sediment debris. The primary library was now ready for 
tittering and stored at 4oC until needed.  
The primary library was titered and amplified using the XL1 blue MRF’ E. coli strain according to the 
manufacturer’s recommended protocol (Agilent technologies). In brief: lysogeny broth (LB) 
supplemented with 10 mM MgSO4 and maltose (0.02%; w/v) was inoculated with a single colony from 
a fresh overnight streak of XL1 blue MRF’ cells that was grown on LB agar tetracycline (30 µg.mL-1) 
plates. The cells were then grown with rigorous shaking at 37oC until an OD600 of 1.0 was reached, and 
spun down at 500 xg for 5 min. The supernatant was decanted and the cells gently resuspended in 
10 mM MgSO4 and diluted down to a final OD600 of 0.5 (approx. half the original volume). Five sequential 
2x serial dilutions of the primary library was prepared, of which 1 µL of each were incubated with 200 µL 
of the diluted XL1 Blue MRF’ cells in a 37oC water bath for 15 min, so as to allow the phage to attach to 
the cells. Three millilitres of LB top agar (0.7%; w/v) at approx. 48oC were added to the cell preparation, 
briefly vortexed, and spread out on pre-warmed LB agar plates. The plates were incubated upside-down 
overnight at 37oC following which the plaques were counted to determine the titer in plaque forming 
units per millilitre (pfu/ml).  
After the primary library was titered it was amplified so as to attain a stable high-titer stock of the library. 
In brief: a fresh culture of XL1 Blue MRF’ cells in MgSO4 (OD600 = 0.5) was prepared as previously 
described. Aliquots of the primary library, each containing approx. 5x104 pfu of bacteriophage, were 
incubated with 600 µL of XL1 Blue MRF’ cells at 37oC in a water bath for 15 min following which 6.6 mL 
of NZY top agar [0.5% NaCl (w/v); 0.2% MgSO4 (w/v); 0.5% yeast extract (w/v); 1% NZ amine (w/v) 0.7% 
agar (w/v) at approx. 48oC] was added, briefly vortexed, and then spread out on 150 mm diameter 
freshly poured NZY agar plates. To amplify 1x106 plaques, a total of 20 aliquots (each containing 5x104 
plaques/150 mm plate) needs to be plated. The inverted plates were incubated at 37oC for 8 hrs. The 
plaques should not be larger than 1-2 mm and should just be touching. Each plate was overlaid with 
10 ml of SM buffer and gently rocked at 4oC on an orbital inclinator-shaker overnight, allowing the phage 
to diffuse into the SM buffer. The phage containing buffer was decanted and incubated with chloroform 
(5%; v/v) for 15 min at RT. Cellular debris were removed by centrifugation at 5,000 xg for 5 min. The 
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supernatant was recovered and chloroform added (0.3%; v/v) and stored at 4oC. For long term storage 
aliquots were stored with DMSO (7%; v/v) at -80oC. 
The ZAP express vector is designed to allow simple efficient in vivo excision and recircularization, of the 
cloned DNA insert, into the pBK-CMV phagemid vector thereby effectively converting lambda phage 
DNA into a utilizable plasmid based vector [236, 239]. The protocol to achieve this is detailed in the 
following paragraph, whilst this paragraph aims to describe the process itself. This complex and 
ingenious operation of in vivo excision is dependent on the placement of the cloned DNA within the 
lambda phage, and the presence of a variety of proteins, including certain filamentous (M13) derived 
bacteriophage proteins. These M13 proteins recognizes two important regions of the ‘origin of 
replication’ on the lambda DNA, namely the (i) site of initiation of, and (ii) termination of DNA synthesis. 
The target lambda DNA (Lambda ZAP) is made accessible to the before mentioned M13 proteins by 
simultaneously co-infecting an E. coli strain with both the Lambda ZAP phage vector, and the M13 helper 
phage. Within the E. coli the M13 derived ‘helper’ proteins recognize the initiation site and then nicks 
one of the DNA strands and initiates rolling replication downstream of the 3’ nicking site. DNA synthesis 
continues through the cloned DNA region, up until the the termination sequence downstream of the 3’ 
nicking site is reached. The ssDNA is then circularized by the gene II product of the M13 helper phage, 
thus forming the complete single stranded pBK-CMV phagemid vector that contains the cloned DNA as 
well as all the necessary phagemid genes, including the f1 origin of replication. Signals for the packaging 
of the newly created phagemid is linked to the f1 origin sequence, resulting in the circularized ssDNA 
being packaged into phagemid particles and secreted by the E. coli. Following secretion, the E. coli used 
for in vivo excision can be killed by heat treatment at 70oC. The encapsulated phagemids aren’t affected 
by the heat and can be utilized for downstream processes including single strand DNA rescue. The 
phagemids can also be used to infect E. coli, upon which it will be converted to its double stranded 
plasmid form, and can then be plated on selective media to form colonies. The plasmid DNA from the 
colonies can be extracted and used for analysis of the insert DNA including DNA sequencing, sub-cloning 
and restriction mapping. 
After the primary library was amplified it was again titered as described previously and in vivo mass 
excision conducted according to the manufacturer’s recommended protocol (Agilent technologies). The 
ExAssist helper phage in combination with the E. coli XLOLR strain were specifically designed to 
efficiently excise the pBK-CMV phagemid vector from the ZAP Express vector, while eliminating 
problems associated with helper phage co-infection. The ExAssist helper phage contains an amber 
mutation that prevents replication of the helper phage genome in a non-suppressing E. coli strain such 
as XLOLR. This allows only the excised phagemid to replicate in the host, removing the possibility of 
co-infection from the ExAssist helper phage. The protocol in brief are as follow: both XL1-Blue MRF’ and 
XLOLR cells were grown till log phase, pelleted through centrifugation at 5,000 xg,  and resuspended in 
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10 mM MgSO4 at an final OD600 of 1.0 (approx. 8x108 cells.mL-1). In a 50 mL conical tube bacteriophage 
from the amplified library was combined with XL1-Blue MRF’ cells at an multiplicity of infection (MOI) 
of 1:10 lambda ZAP phage-to-cell ratio. A hundred fold more lambda ZAP phage was excised, than was 
the primary size of the library, so as to ensure proper statistical representation of the excised clones. To 
the same conical tube the ExAssist helper phage was added to a MOI of 10:1 helper page-to-cell ratio, 
thus ensuring that every cell is co-infected with both lambda ZAP phage and helper phage. The tube was 
incubated at 37oC in a water bath for 15 min following which 20 mL of LB broth with supplements 
[10 mM MgSO4, 0.2% maltose (w/v)] was added, and then subsequently shaken at 37oC in an incubator 
for 2.5 hrs. The tube was heated to 70oC for 20 min to lyse the cells and then briefly cooled on ice. The 
cellular debris was pelleted by centrifugation at 10,000 xg for 10 min and the supernatant decanted to 
a sterile tube. To titer the phagemid, 1 µL of three sequential 5x serial dilutions of the phagemid 
preparation were combined with 200 µL of the previously prepared XLOLR cells in a microcentrifuge 
tube, and incubated at 37oC in a heating block for 15 min. Forty microliters of a 5x NZY broth were then 
added (final concentration 1x) and shaken at 37oC for 1 hrs to allow for the kanamycin resistance gene 
to be expressed before 100 µL was plated out on selective media (50 µg.mL-1 kanamycin).  
After the titer was accurately obtained and noted, a large scale transduction of the phagemid into the 
XLOLR cells was performed. Cells were plated out on multiple large LB agar square plates (28x28 cm) 
and care was taken to achieve at least 10x higher clonal representation as the original library size. The 
colony density was such that the colonies just touched, but weren’t overgrown in a complete matt, 
allowing for approximately a hundred thousand colonies per large plate. After the overnight incubation 
at 37oC the plates were cooled at 4oC for several hours and the cells then scraped of with a scalpel blade 
and pooled, taking care to avoid excess agar.  
The phagemid plasmids were then extracted from the cell mass by means of large scale alkaline lysis as 
described by Sambrook et al. (2001) to yield a final plasmid library that can be used later with the aid of 
conventional transformation methods, e.g. electroporation and chemical, to screen in either the 
constructed ∆β-gal mutant or E.coli strains [240]. The protocol in brief: After the cells were scraped, 
they were first washed by suspending them in 200 mL 0.1x TE  (1 mM Tris-HCl, 0.1 mM EDTA; pH 8.0). 
The cell suspension was equally divided between 50 mL conical tubes to facilitate ease of use. The cells 
were pelleted at 10,000 xg and the supernatant decanted. The cell pellets were suspended in 5 mL 
ice-cold solution I [50 mM glucose; 25 mM Tris-HCl (pH 8.0), 10 mM EDTA] and vigorously vortexed. To 
this, 10 mL of freshly prepared solution II (0.2 N NaOH; 1% SDS) were added and gently inverted several 
times making sure all the surface area got covered. The tubes were stored on ice for 15 min. Seven and 
a half millilitres of solution III (3M KOAc, pH 6.0) were then added and the tubes gently inverted several 
times, and again stored on ice for 10 min. The tubes were centrifuged at 12,000 xg for 15 min and the 
supernatant carefully transferred to a new tube. The solution was the twice extracted with an equal 
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volume of phenol-chloroform : isoamyl alcohol (25:24:1), and once only with an equal volume of 
chloroform. The DNA was precipitated with 2 volumes of ethanol, briefly air dried and suspended in 200 
µL of TE (pH 8.0). The quality and quantity of the isolated DNA was ascertained by gel electrophoresis 
(1%; w/v) and spectrophotometric analysis. 
 
 β-galactosidase mutant construction 
 
The E. coli DH5α strain employed for the screening of the metagenomic libraries seeking galactose 
containing oligosaccharides/polymers was mutated so as to contain no endogenous β-galactosidase 
sequence at all, through lambda red recombineering according to the methodology of Datsenko and 
Wanner (2000) [241]. To modify the target DNA, one needs to electroporate a linear donor dsDNA into 
E. coli expressing the ʎ-red enzymes. These ʎ-red enzymes then catalyse the homologous recombination 
of the donor DNA with that of the target DNA, based on their shared flanking homologous sequences, 
that was incorporated into the donor DNA trough the polymerase chain reaction (PCR). Expressing the 
lambda red genes from a plasmid allows for a mobile recombineering system, but tight regulation of 
expression is required for a successful experiment, otherwise non specific recombination can occur. The 
pKD46-RecA (Nature Technology) plasmid utilized in this procedure carry the ʎ-red genes behind the 
araBAD promoter, which allows for rigid expression control. Expression of the ʎ-red genes is sufficiently 
induced by adding L-arabinose (0.1%; w/v) to the culture media. The plasmid itself is 
temperature-sensitive and can be cured from the strain by growing it at elevated temperatures above 
30oC. By transforming any E. coli K-12 strain with pKD46-RecA it will be turned into a highly efficient 
recombineering strain when grown in the presence of arabinose.  
The recombineering plasmid pKD46-RecA was transformed into chemical competent CaCl2 DH5α cells 
that was prepared according to the methods of Tu et al. (2005) [242], taking care though never to 
elevate the the culture temperature above 30oC, once the cells were transformed with the plasmid. For 
the chemical competent cell preparation ‘Chemical Competent’ (CC) solution (10 mM Pipes, 55 mM 
MnCl2, 15 mM CaCl2, 250 mM KCl) was prepared by mixing all components except for MnCl2, and 
adjusting the pH to 6.7 with KOH. Only then was the MnCl2 added and the CC solution filter-sterilized 
through a pre-rinsed 0.45 µm filter unit, and stored at 4oC until later use. For the preparation of the cells 
a fresh DH5α colony from an overnight streak was inoculated into SOC broth [bacto-tryptone (2%; w/v), 
yeast extract (0.5%; w/v), 10 mM NaCl, 2.5 mM MgCl2, 10 mM MgSO4, 20 mM glucose], and incubated 
at 37oC with vigorous shaking till an OD600 of 0.4 was reached. The cells were pelleted through 
centrifugation at 5,000 xg for 5 min at 4oC, and resuspended in one-half volume of sterile ice-cold CC 
solution, and incubated on ice for 30 min. The cells were again pelleted through centrifugation at 
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5,000 xg for 5 min at 4oC and resuspended in one-tenth the volume CC buffer. Cells can be stored at 4oC 
for up to 3 days, or sterile glycerol added (20%; w/v) and then aliquoted and stored at -80oC for later 
use. For the transformation with pKD46-RecA, 1 µL of plasmid was added to 100 µL competent cells 
together with 1 µL DMSO, and incubated on ice for 30 min. The cells were heat shocked at 42oC for 90 s 
in a heating-block and placed back on ice for 2 min, after which 400 µL of SOC medium was added and 
shaken in an incubator at 30oC for 1 hrs. The transformation mixture was spread on prewarmed SOC 
agar plates containing 100 µg.mL-1 ampicillin and incubated overnight at 30oC. 
For the actual recombineering event electrocompetent cells need to be prepared from the previously 
generated DH5α cells containing the pKD46-RecA plasmid. This was done according to the methodology 
of Sambrook et al. (2001) [240]. The protocol in brief: an overnight colony from a freshly streaked 
DH5α (pKD46-RecA) grown on LB agar (100 µg.mL-1 ampicillin) at 30oC, was inoculated into selective SOC 
broth with arabinose [100 µg.mL-1 ampicillin; 0.1% arabinose (w/v)] into a baffled flask, and grown with 
vigorous shaking at 30oC till an OD600 of 0.6 was reached. The flask was immediately submerged into an 
ice-water slurry and kept there for 10 min with occasional swirling. The cells were pelleted through 
centrifugation at 5,000 xg for 5 min at 4oC, and then resuspended in one-seventh the original volume 
ice-cold sterile ddH2O. The cells were washed twice more with ice-cold sterile ddH2O and then 
reconstituted in one-twentieth the original volume of ice-cold ddH2O containing 10% glycerol. The cells 
were again pelleted as described above and resuspended in one-hundredth the original volume 10% 
glycerol. The cells were either immediately used for electroporation or stored at -80oC for later use. 
Primers were designed using the CLC-genomics workbench software suite (Qiagen, Hilden, Germany) 
and synthesised by Inqaba Biotech (Pretoria, South Africa). Both the forward and reverse primer 
contained two important sequential sequence segments namely (i), on the 5’ end of each primer a 70bp 
sequence homologous to the region adjacent the E. coli β-galactosidase sequence to be removed. 
And (ii), on the 3’ of each primer a 23 bp sequence homologous to the flanking sequence of the 
chloramphenicol resistance gene on the pKD3 donor plasmid, that allows for amplification by PCR of the 
chloramphenicol resistance gene that will replace the β-galactosidase sequence on the E. coli genome 
in the actual recombination event (Table 3-1).  
For the recombineering event, the linear dsDNA PCR product was cleaned using the PCR purification kit 
(Qiagen, Hilden, Germany) and electroporated (pulse controller = 200Ω; capacitor = 25 µF; voltage  = 
2.5 kV)  into the DH5α(pKD46-RecA) cells with a Bio-Rad Gene Pulser Xcell electroporator 
(Bio-Rad Industries, USA), using disposable 1 mm cuvettes. Warm 30oC SOC broth with arabinose 
(0.1%; w/v) were immediately added to the cuvette, before being transferred to a conical tube and 
incubated in an incubator-shaker at 30oC for 1 hour with vigorous shaking before being plated-out on 
selective LB agar plates (10 µg.ml-1 chloramphenicol and 50 µg.mL-1 ampicillin) and grown for two days 
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at 30oC. Positive colonies were tested by PCR for the presence of β-galactosidase utilizing primers 
internal to the sequence that was homogenously removed. The temperature sensitive pKD46 plasmid 
was cured by inoculating a single colony into liquid culture and incubating overnight at 40oC. Cells were 
streaked out on selective plates (10 µg.ml-1 chloramphenicol) and subsequently negatively tested by 
streaking out individual colonies on plates containing 50 µg.mL-1 ampicillin plates. Cells that did not grow 
were taken to have dropped the plasmid. The ∆β-gal mutant was further assayed for the complete 
abolition of any endogenous β-galactosidase activity, even through α-complementation, by 
transforming the pBluescript (sk-) plasmid into the newly generated mutant and testing on X-Gal. Once 
it was confirmed that Δβ-gal was a complete null-mutant for any endogenous β-galactosidase activity, 
and it did not contain the pKD46-RecA recombineering plasmid anymore,  both chemical competent 
and electrocompetent cells were prepared as described previously and stored at -80oC for later use. 
 
Table 3-1 Primers used for the LacZ lambda red recombination. The underlined blue text is the annealing sites for the 
amplification of the chloramphenicol resistance gene on the pKD3 donor plasmid, whilst the preceding sequence is the 
β-galactosidase recombineering recognition sequence. The lacZ-frw and lacZ-rev are internal β-galactosidase internal annealing 
sites to pcr test for the presence of β-galactosidase. 
Primer name Sequence Tm (oC) Binding site NCBI ACNO 
LzF Recomb ATCCCATTACGGTCAATCCGCCGTTTGTTCCCACGGAGAATCCGACGGGTgtgtaggctggagctgcttc 58.1 317-366 NC_000913.3 
LzR Recomb CTTCCAGCGTTCGACCCAGGCGTTAGGGTCAATGCGGGTCGCTTCACTTAatgggaattagccatggtcc 54.8 2387-2436 NC_000913.3 
lacZ-frw TCGATGAGCGTGGTGGTT 56.8 839-856 NC_000913.3 
lacZ-rev GCTGCTGGTGTTTTGCTT 54.3 1859-1876 NC_000913.3 
 
 
 Library screening and media used 
 
For the screening of the metagenomic libraries, the in vivo mass excised pBK-CMV plasmid libraries were 
electroporated into either the Δβ-gal DH5α mutant, or normal DH5α electrocompetent cells. The before 
mentioned choice was dependant on whether screening for β-galactosidases or fructosyltransferases. 
Technically speaking all of the screening could have been conducted in the Δβ-gal mutant as the removal 
of the endogenous β-galactosidase activity should have no bearing on screening for fructosyltransferase 
activity, but so as to avert any imperceivable consequence this protocol was adhered to, even though 
the libraries were cross-screened for the different activities.  
The pBK-CMV plasmid preparation was desalted prior to electroporation with a Amicon Ultra 0.5 mL 
centrifugal filter according to the manufacturer’s recommendations (Merck-Millipore, Massachusetts, 
USA). After electroporation (pulse controller = 200 Ω; capacitor = 25 µF; voltage  = 2.5 kV) 1 mL 
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prewarmed SOC broth was immediately added to the cuvette before being transferred to a conical tube 
and incubated in an incubator-shaker for 40 min at 37oC with vigorous shaking. Cells were immediate 
placed on ice for several minutes to halt growth before being pelleted at 5,000 xg for 5 min at 4oC, and 
then resuspended in an equivolume minimal MDA-5052 media (see paragraph below). The cells were 
titered on normal LB agar selective plates (50 µg.mL-1 kanamycin) so as to establish a representative 
matt plate-out titre where individual colonies can barely be distinguished from the lawn of cells. The 
cells suspension can be kept at 4oC for 10 days without the loss of cell viability or the titre being affected.  
All minimal and auto-induction media used for library screening and heterologous protein expression, 
were prepared according to methodology of Studier et al. (2014) [243]. Several stock solutions were 
made from which all final media preparations were composed. For convenience all of the preparation 
of the stock solutions employed in the Studier methodology are described here. All stock solutions were 
autoclaved and stored at RT unless specified otherwise. In brief:  
− 50 x M: 80 ml water, 17.75 g Na2HPO4, 17 g KH2PO4, 13.4 g NH4Cl, 3.55 g Na2SO4. 
1x concentration: 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, (pH ~6.7). 
− 50 x 5052: 25 g glycerol (weigh in beaker), 73 ml water, 2.5 g glucose, 10 g α-lactose 
monohydrate. 1x concentration: 0.5% glycerol, 0.05% glucose, 0.2% α-lactose. 
− 25% aspartate: 84 ml water, 25 g aspartic acid, 8 g NaOH (pH ~7). 
− 50% lactose: 500 g lactose, warm ddH2O to 1 L. Stirred until dissolved with occasional heating. 
Either filter sterilised or autoclave. Can be reheated if crystallisation occurs, but not once added 
to final media composition. 
− 30% sucrose: 300 g sucrose, warm ddH2O to 1 L. Stirred until dissolved with occasional heating. 
Either filter sterilised or autoclave. Can be reheated if crystallisation occurs, but not once added 
to final media composition. 
− 40% glucose: 40 g glucose, ddH2O to 100 mL. 
− 1M MgSO4: 24.65 g MgSO4-7H2O ddH2O to 100 mL. 
− 1000x metals: 50 mM FeCl3, 20 mM CaCl2, 10 mM MnCl2, 10 mM ZnSO4, 2 mM CoCl2, 
2 mM CuCl2, 2 mM NiCl2, 2 mM Na2MoO4, 2 mM Na2SeO3, 2 mM H3BO3. The trace metal mix 
was assembled from autoclaved stock solutions of the individual components except for FeCl3, 
which was added from the 0.1 M acid solution (see immediately below), do not autoclave once 
added together. 
− 0.1 M FeCl3: in ~0.12 M HCl: 99 ml water, 1 ml concentrated HCl (~12 M), 2.7 g FeCl3-6 H2O, do 
not autoclave. 
− ZY: 1 litre ddH20, 10 g N-Z amine (casein hydrolysate), 5 g yeast extract. 
− X-gal: 200 mg in 10 mL DMSO, aliquot and store at -20oC. 
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− Kanamycin: 1 g kanamycin sulphate in 10 mL ddH2O, aliquot and store at -20oC. 
For the final preparation of the minimal media agar plates either containing 30% lactose (MDA-lac; w/v) 
or 20% sucrose (MDA-suc; w/v), 17 g agar was autoclaved in approx. 250 mL ddH2O and allowed to cool 
to ~60oC, following which, components of the sterile pre-prepared stock solutions were then added. 
Bellow are the final compositions of the solid and liquid media used in subsequent experiments. A more 
in-depth review of the auto-induction methodology will be conveyed in chapter five. 
− MDA-lac defined minimal selective medium:  2 mL 1 M MgSO4, 200 µl 1000x metals, 4 mL 
25% aspartate, 20 mL 50xM, 600 mL 50% lactose, 2 mL X-gal, 1 mL kanamycin, autoclaved 
ddH2O to 1 L. Final composition: 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 
2 mM MgSO4, 0.2x metals, 0.1% aspartate, 30% lactose (w/v), 40 µg.mL-1 X-gal, 100 µg.mL-1 
kanamycin. 
− MDA-suc defined minimal selective medium:  2 mL 1 M MgSO4, 200 µl 1000x metals, 4 mL 
25% aspartate, 20 mL 50xM, 667 mL 30% sucrose, 1 mL kanamycin, autoclaved ddH2O to 1 L. 
Final composition: 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 
0.2x metals, 0.1% aspartate, 20% sucrose (w/v), 40 µg.mL-1 X-gal, 100 µg.mL-1 kanamycin. 
− MDA-5052 defined minimal media 2 mL 1 M MgSO4, 200 µl 1000x metals, 4 mL 25% aspartate, 
20 mL 50xM, 20 mL 50x 5052, 2 mL X-gal, 1 mL kanamycin, autoclaved ddH2O to 1 L. Final 
composition: 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 
0.2x metals, 0.1% aspartate, 0.5% glycerol, 0.05% glucose. 
− ZYM-5052 complex auto-inducing medium: 957 mL ZY, 2 mL 1 M MgSO4, 200 µl 1000x metals, 
20 mL 50 x 5052, 20 mL 50 x M. Final composition: 1% N-Z-amine, 0.5% yeast extract, 25 mM 
Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.2x metals, 0.5% glycerol, 
0.05% glucose, 0.2% α-lactose. 
The minimal selective agar media with their respective carbon sources were poured in large square 
plates (28 x28 cm) and allowed to cool. The previously prepared titered cells were plated out at the 
desired titre and the plates were incubated at 37oC for several days. The experiment was repeated 
several times and incubated at varying temperatures (4oC, 10oC and 20oC) once the colonies were 
formed, to screen for differential activity. All positive colonies that either presented a blue colour for 
X-gal hydrolysis or presented a visible phenotype in terms of exopolysaccharide production, were 
isolated and the plasmid extracted by alkaline lysis as described in section 3.2.2, and re-transformed 
into either the ∆β-gal mutant or DH5α so as to confirm the phenotype.  
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 Sequencing and bioinformatic analysis 
 
In order to de-replicate the multiple positive clones that were found for each library screen, a restriction 
mapping approach was firstly employed, after which a sequencing based approach was used. Several 
restriction enzymes that were mutually compatible in their activity buffers were employed, in various 
combinations. The restriction analysis were done with the restriction map and profile of the pBK-CMV 
vector taken into consideration (Appendix A1 on page 115). Based on the restriction profiles, the clones 
were grouped together in restriction classes. A single plasmid form each class was selected for standard 
Sanger capillary sequencing, using a commercial service (Macrogen, Amsterdam, Netherlands). All 
sequencing reactions were repeated at least three times, so as to reduce the impact of sequencing 
misreads and avoid assembly conflicts. For continued internal sequencing, primers were designed for 
primer walking using the CLC genomic workbench software package (Qiagen, Hilden, Germany). 
Continuous mass assembly analysis after each new round of sequencing revealed whether the different 
clones, from the different restriction classes, belonged in fact to the same contig assembly after which 
and if so, results were pooled and sequencing continued until complete end-to-end sequencing of the 
combined contig was achieved. Following assembly, the multiple ORFs in each assembled contig were 
identified with the CLC genomics workbench software and the deduced nucleotide and translated 
protein sequences were analysed in silico with the BLASTX and BLASTP algorithms respectively, on the 
NCBI webpage [244]. 
 
 Cloning, expression and protein analysis  
 
After in silico identification of putative ORFs and bioinformatic analysis, primers were designed to 
amplify the relevant genes, so as to enable cloning into protein expression vectors. Primers included RE 
sites compatible with that of the MCS of the pRSET-A vector (Thermofisher Scientific) (Appendix A2 on 
page 116), so as to facilitate in frame and directional cloning with the 6x histidine leader sequence. PCR 
products were restriction digested with selected RE’s and cloned into dephosphorylated pRSET-A that 
was also cut with the same REs. In-frame cloning and PCR specificity was confirmed through Sanger 
sequencing. In the case of putative β-galactosidases, the respective protein expression vectors were 
transformed back into the ∆β-gal mutant and expressed overnight in auto-induction medium according 
to the methodology of Studier et al. (2014) [243] (see section 3.2.4). Putative fructosyl transferases were 
transformed into the Bl21 pLysS E.coli protein expression strain and expressed overnight in ZYM-5052 
auto-induction medium (see section 3.2.4). dialysed overnight against 0.1x TE  (1 mM Tris-HCl, 
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0.1 mM EDTA; pH 8.0) with snakeskin dialysis tubing (Thermo Scientific) with a 3.5K molecular weight 
cut off (MWCO).  
The resulting crude protein extract was used for all subsequent experiments in the rudimentary 
characterisation of the respective catalyst and their products. Protein extract from cells transformed 
with empty pRSET-A and pRSET-A containing the E. coli β-galactosidase were used as negative and 
positive controls respectively. Proteins were quantified spectrophotometrically and electrophoretically 
separated by denaturing polyacrylamide gel electrophoresis using the methodology of Bradford et al. 
(1976) and Laemmli et al. (1970) [245, 246]. 
 
 Nitrophenyl based biochemical characterisation of positive clones 
 
A standard linear curve with 4-nitrophenol ranging between 0.0025 µM and 0.04 µM was established 
spectrophotometrically and measured at 405 nm on a VersaMax ELISA microplate reader (Molecular 
Devices). To test for substrate specificity 10 mM of various nitrophenyl based substrates dissolved in 
Z-buffer (20 mM phosphate buffer pH 7.0, 5 mM MgCl2) were incubated with 1 µg total protein of the 
respective cell extracts, and activity was measured continuously at 405 nm for a period of 30 min at 
37oC. All  measurements were done in triplicate. The nitrophenyl based substrates utilized for substrate 
specificity were the following : ONP-α-D-galactopyranoside, ONP-β-D-galactopyranoside, 
ONP-β-D-maltoside, ONP-β-D-xylopyranoside, ONP-β-D-glucoronide, ONP-α-D-glucopyranoside, 
ONP-β-D-glucopyranoside, ONP-β-D-fucopyranoside, ONP-β-L-arabinopyranoside, 
ONP-α-L-rhamnopyranoside, ONP-β-D-cellobioside. All nitrophenyl based substrates were either 
obtained from Sigma-Aldrich (Missouri, USA), or Carbosynth (Berkshire, UK). 
The substrate that showed the highest relative activity for each of the respective protein extracts were 
further utilized in subsequent experiments for the characterisation of the temperature (1oC - 55oC) and 
pH optima (pH 5.2 - pH 10.8). The biological buffers used for the pH characterisation were, acetic acid 
(pH 5.2), sodium phosphate (pH 6.4, pH 7.0, pH 7.6), Bis-Tris-propane (pH 8.2, pH 9.1) and sodium 
carbonate (pH 10.8). For temperature measurements where the continuous spectrophotometric assay 
method could not be employed, the reactions were stopped by heating at 80oC for 10 min followed by 
the addition of an equal volume of 1M Na2CO3, after which an endpoint measurement was taken at 
wavelength 405 nm. 
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 Product characterisation by spectrophotometric analysis of free reducing sugars 
 
After the establishment of substrate specificity together with that off the temperature and pH optima, 
the protein extracts were incubated with either sucrose or lactose as substrate (30%; w/v), under their 
respective optimal conditions overnight in a rotary shaker. The extracts were incubated at a 
concentration of 1 u.mL-1 in a total volume of 10 mL. One unit of activity is defined as the amount of 
total crude protein extract needed to liberate 1 µmole of free reducible glucose from the disaccharidic 
substrate in 1 minute. Following the overnight incubation the samples were twice extracted with an 
equal volume of phenol-chloroform : isoamyl alcohol (25:24:1), and once only with an equal volume of 
chloroform, after which the reducing sugars were assayed. The results were expressed as the ratio 
between the amount of the free reducible monosaccharide constituents of each substrate, i.e. 
glucose : galactose for the lactose substrate, and glucose : fructose for sucrose substrate. This is to give 
a representation of the hydrolytic reaction versus that of the trans-glycosylation reaction of galactose 
and fructose. Free reducing glucose, fructose and galactose were determined using an enzyme linked 
assay based on the reduction of NAD+ to NADH at 340nm on a VersaMax ELISA microplate reader 
(Molecular Devices). Hexokinase/glucose-6-phosphate dehydrogenase (HK-G6DH) was coupled to the 
measurement of free glucose, while fructose was measured with HK-G6DH in conjunction with 
phoshoglucose isomerase (PGI). Galactose-dehydrogenase/mutatarose (GAL-DH/M) coupled with 
HK-G6DH was used for the measurement of free galactose (see Fig 3-7 under results and discussion for 
a visual representation). 
The combined protocol in brief: to each well of a clear-bottom UV transparent microtiter plate, 200 µL 
of either BufferGluc/Fruc (100 mM Tris-HCl pH 7.4; 5 mM MgCl2; 1 mM NAD+; 1 mM ATP), or BufferGluc/Gal 
(100 mM Tris-HCl pH8.5, 1 mM NAD+; 1 mM ATP) was added, taking care not to introduce any air 
bubbles. The respective samples were then added to each well in a total volume of 50 µL, making the 
final volume a combined 250 µL. A continuous assay was then established on the spectrophotometer 
so as to determine when baseline was reached, after which an endpoint background measurement was 
taken of which the value was designated G0. For the measurement of glucose 10 µL of a 40x dilution of 
a HK-G6DH enzyme preparation from Megazyme was added to each well (approx. 1 U hexokinase and 
0.5 U G6-DH per well). Again an continuous assay was established on the spectrophotometer and an 
endpoint measurement taken when baseline was reached when all the free glucose was reduced 
(approx. 20 min). This measurement was designated Ggluc. Depending on which substrate was originally 
assayed, 10 µL of a 50x dilution of either GAL-DH/M (for the measurement of galactose), or PGI (for the 
measurement of fructose) was added to each well (approx. 1 U PGI or GAL-DH per well). A final 
measurement was taken after baseline was established and the final result designated either Ggal or Gfruc 
(approx. 20 min). A standard curve was established for the NADH coupled reduction of free glucose on 
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the spectrophotometer in a range of 0.02 µmole to 0.2 µmole per well (10 µL of 1.7 mM - 20 mM 
glucose stock solution). Because glucose, galactose and fructose all occur at equimolar ratios within the 
lactose and sucrose substrates, the standard curve of glucose can be extrapolated for the measurement 
of free galactose and fructose as well. To calculate free glucose, Ggluc - G0 gives the change in absorbance 
due to the reduction of glucose, whilst Ggal - (Ggluc-G0) and Gfruc - (Gluc-G0) gives the change in absorbance 
due to the reduction of free galactose and fructose respectively. The actual amounts can be deduced 
from the standard curve. 
 
 Product characterisation by thin layer chromatography 
 
For a visual characterisation of the products formed through the enzymatic reactions, when the crude 
extracts were incubated with substrates, thin layer chromatography was employed. The samples were 
prepared the same as described above in section 3.2.8, only the resulting supernatant was diluted 10 
fold with ddH2O. Included in the TLC is the commercially available GOS preparation, Vivinal GOS from 
Friesland Campina (Amersfoort, The Netherlands). Thin layer chromatography was conducted according 
to the protocol of Wang et al. (2014) [247]. Of each sample 0.5 µl was evenly spotted on a pencilled 
horizontal straight line, on aluminium backed silica gel 60 TLC plates (Merck, Germany). The plates were 
briefly dried in an oven, before being run in a sealed glass chamber that was equilibrated for an hour 
with the mobile phase, consisting of butanol/ethanol/water (5:3:2). The plates were run until the mobile 
phase reached ¾ the way up. Again the plates were oven dried before being developed by spray misting 
a solution containing 0.5% (w/v) 3,5-dihydroxytoluene (orcinol) (Sigma-Aldrich, USA) and 20% (v/v) 
sulphuric acid, onto them with the aid of a gravity fed pressurised air micro-spray gun. The silica plates 
were clamped between two glass plates and baked in the oven for a several minutes at 100°C until 
product development could be visualised, after which they were taken out and photographed. 
 
 Results and discussion 
 
 Library construction and screening in the mutant 
 
For the purposes of this study altogether three libraries were constructed and screened. One previously 
constructed library (Hotwood), which was established in our laboratory for the screening of novel 
α-glucosidases, was also utilised in this study and cross-screened for novel β-galactosidases. The three 
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newly constructed libraries were designated ‘MS’ (place of milk-runoff into soil; high lactose 
environment), ‘SASRI’ (South African Sugarcane Research Institute library, from factory runoff at 
sugarcane refinery; high sucrose environment) and ‘Gansbay’ (place of intertidal coastal kelp 
degradation; high galactose polymer environment).  
Primarily the location of the sampling sites were chosen based on the prevalence of galactose or 
fructose containing substrates e.g. lactose, sucrose and galactose rich polysaccharides. Because these 
substrates contain the monosaccharide constituents galactose or fructose, they can be hydrolysed and 
their moieties potentially incorporated into polymers/oligosaccharides through trans-glycosylation. The 
hypothesis is that the occurrence and prevalence of the before mentioned substrates in the sampling 
sites will create a niche environment, that would select for and enhance the probability for the incidence 
of the desired enzymatic biocatalyst, that synthesise galactose or fructose containing 
oligosaccharides/polymers.  
Secondary to the substrate occurrence, other factors were taken into consideration, or at the very least 
noted, that could influence or have bearing on the characteristics of the isolated enzymes. These include 
factors like environmental pH and temperature. The Hotwood library, constructed from wood pulp 
process runoff at a sawmill, represents a thermophilic sampling site rich in glycosidic linkages. No other 
environmental data, other than the fact that the sampling site was hot and humid by nature, were noted 
for the Hotwood library. Figure 3-1 shows the sites that were sampled for the construction of the MS 
(Fig 3-1A) and Gansbay (Fig. 3-1B) libraries. Several sub-sites were sampled at each main-site, so as to 
increase the diversity of the sampled microbiome. Each sub-site was initially sampled individually and 
their pH’s measured so as to make sure they don’t differ significantly, before each main-site’s samples 
were amalgamated and their collective DNA isolated. The sample for the SASRI library was obtained 
from a single bucket, placed under the conveyer belt of the sugarcane refinery. Both the MS and SASRI 
samples were slightly acidic (pH 6.4-6.8), with none of their respective sub-sites differing markedly. This 
is expected due to the presence of lactic acid in milk, which acts as a proton donor, and also due to the 
high probability of anaerobic fermentation of both sucrose and lactose, resulting in an acidic 
environment. The pH for the sampling site at Gansbay was near neutral. The sub-sites at the Gansbay 
sampling site contained sludge from stagnant pools that could potentially differ markedly in 
temperature during day and night. This is due to the sun heating the shallow pools to extreme 
temperatures during the daytime, which then cools rapidly during the night. At the time of the Gansbay 
sampling, the temperature was moderate but at the very least this site is potentially an extreme 
environment due to the occurrence of coastal storms and fluctuating temperatures. No temperature 
was noted for the SASRI sample at collection, but this too is representative of a hot and humid 
environment due to it being in a refinery at a sub-tropical location. 
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Figure 3-1 Visual representation of two of the five library sampling sites i.e. the MS library (A1 and A2) and the Gansbay 
intertidal kelp degradation library (B). Several sub-samples were collected (red arrows) from each sampling site, and were 
eventually amalgamated into one, from which DNA were extracted. This was done so as to achieve broader genetic 
representation. The pH was measured for each individual sub-sample but none differed markedly from each other within each 
sampling zone.   
 
DNA isolated from environmental sources for metagenomic purposes are often degraded and 
contaminated with polyphenolics, polysaccharides and various other contaminants, rendering them 
unusable for downstream application [248, 249]. For this purpose, great care was employed to design 
and optimise the protocol for DNA isolation so as to ensure that highly representative, intact DNA of 
high purity was obtained. The DNA that was isolated from the respective metagenomic sources, by the 
modified and combined protocols of Verma et al. (2011) and Dos Reis Falcão et al. (2008) [237, 238], 
were demonstrated to be of high quality and purity with little degradation and polysaccharide 
contamination as shown by the 260/280 spectrophotometric ratios and separation by agarose gel 
electrophoresis. All the DNA isolated, readily digested with restriction endonucleases and was used 
successfully as template in PCR (results not shown).  
The protocol of Verma et al. (2011) [237] focuses on the removal of charged and small contaminants by 
incubation with PVPP and activated charcoal. This is especially true for polyphenolics and their quinone 
oxidation products, that intercalates with DNA, causing it to break-up with freeze-thaw cycles as well as 
obstructing enzymatic action [250].  
The protocol of Dos Reis Falcão et al. (2008) [238] was originally developed for the extraction of high 
quality RNA from polysaccharide rich brown algae, and focuses on the selective precipitation of high 
molecular weight contaminants (such as polysaccharides) by potassium acetate. The sites sampled all 
had major polysaccharide constituents in their respective environments, whether it be from plant/algae 
breakdown, or visible biofilm formation. Initial attempts failed to isolate adequately pure DNA, and only 
once the potassium acetate selective precipitation step was included, was high purity DNA obtained. 
The guanidinium hydrochloride also included in the protocol, is probably the best known protein 
denaturant and instantly denatures any environmental nucleases present in solution, thereby shielding 
the nucleic acids from proteolytic degradation.  
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The metagenomic libraries were constructed with the Lambda ZAP express pre-digested vector kit 
according to the manufacturer’s recommendations (Agilent Technologies). Fig 3-3A show the results of 
the partial digestion trial, of the MS metagenomic DNA sample that was previously isolated, with the 
Bsp143I (aka Sau3AI) restriction enzyme. This trial was conducted so as to establish the optimal nucleic 
acid and RE concentration for the desired length of incubation time. The fractions visualised in lanes 1 
and 2 contained the majority of their restriction product as fragments larger than 2 kb, and 
subsequently an intermediate RE concentration was chosen for the large scale partial digestion. A total 
of 100 µg of DNA was then digested at a concentration of 0.333 mg.mL-1, with 10 U.mL-1 Bsp143I, for 
30 min. Fig 3-3B shows the CL-2B column fractionation of the partially digested DNA. In order to reduce 
cloning bias towards shorter fragments and interfering nucleotides, only lanes 6 and 7, which showed a 
marked reduction in shorter fragments, were pooled and utilized for the subsequent MS-library 
construction. The same partial digestion trial and column fractionation procedure was repeated for the 
construction of the other two libraries. The fractionated and pooled DNA was ligated into the lambda 
ZAP express bacteriophage vector [236, 239]. The Bsp143I used to partially digest the metagenomic 
DNA recognizes the four base pair (bp) sequence 5'...AT^CGAT...3' and generates compatible ends with 
the BamHI restriction sites of the lambda ZAP express vector.  
 
 
Figure 3-2 The partial digestion and column fractionation of the soil extracted metagenomic DNA that was used for the 
construction of the LacZ library. In Fig A lanes (1-5) is representative of the digestion of 5µg of DNA with successive 2x dilutions 
of 0.2 units Sau3AI per µl in a 15µl reaction volume, in 1x reaction buffer for 30min. An enzyme concentration between lanes 
1 and 2 were chosen for up-scaled digestion. In Fig B lanes (1-22) is representative of the Sepharose cl-2B column fractionation 
of the up-scaled digestion. Lanes 6 and 7 were pooled and used for library construction. 
 
Good titres were obtained for all libraries constructed ranging between 5 x 106 and 1 x 108 pfu/µg 
Lambda DNA, with the exception of the Gansbay library (3 x 104 cfu/µg), which relatively had a lower 
titer than the other libraries (see Table 3-2). The reason for the lower tire could be multifaceted, ranging 
from less pure DNA to faulty ligation, to name but two possible explanations. The construction of 
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lambda phage libraries will always be a hit and miss procedure as a multitude of factors eventually 
influence success, and good titres are never guaranteed. After amplification of the primary libraries, the 
bacteriophage vectors were converted to plasmids by in vivo mass excision according to the 
manufacture’s recommendations and as described previously, yielding usable plasmid libraries that can 
be electroporated into the desired E. coli strain for screening [239]. 
 
Table 3-2 Lists the libraries constructed and carbon source screened on, average insert size determined as per restriction 
digestion a well as the number of putative genes discovered through functional screening and subsequent sequencing. 
  library name  metagenome source carbon source  average insert size library size putative genes  
1 MS soil milk runoff Lactose 4.5 kb 5 x 106 6 
2 SASRI runoff at sugar refinery  lactose and sucrose 3.8 kb 1 x 10
8 6 
3 Gansbay coastal kelp degradation Lactose 4.1 kb 3 x 104 1 
4 Hotwood wood mill high temperature Lactose 3.6 kb unknown 4 
 
 
The Δβ-gal mutant construction was efficacious in that all endogenous β-galactosidase activity was 
abolished. No activity was observed with α-complementation when the empty pBluescript (sk-) plasmid 
was transformed into the Δβ-gal mutant and screened on X-gal, nor could any pcr product be detected 
for primers complementary to the internal β-galactosidase sequence that was homologously removed 
through the ʎ-Red recombineering event. Only when the Δβ-Gal mutant was transformed with the 
pRSET vector containing the complete coding sequence for the E. coli β-galactosidase, was the indigo 
blue phenotype restored when plated out on X-gal containing plates (se Fig 3-3, the K- and K+ controls). 
The in vivo mass excised plasmid libraries were used to screen for β-galactosidase activity in the ∆β-gal 
mutant on MDA-lac minimal media (30% lactose; w/v). All four libraries were screened for the presence 
of novel β-galactosidases but only the SASRI-library was screened for novel fructosyl-transferases on 
MDA-suc minimal media plates (30% sucrose; w/v). This approach was adopted due to the ubiquitous 
nature of the β-galactosidase enzyme. When screening for fructosyl-transferases the normal unmutated 
DH5α strain was used.  
The various libraries were screened for different time intervals and at different temperatures, resulting 
in the cumulative discovery of several hundred positive clones. The Positive clones were identified either 
through presentation of a blue colour when grown on X-Gal  in the case of β-galactosidase screen 
(MDA-lac), or by the visible production of exopolysaccharide for either screen (MDA-lac + MDA-suc). 
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 Sequencing and bioinformatic analysis  
 
The tedious task of de-replicating the positive clones was undertaken firstly, by restriction analysis of 
the alkaline lysis isolated plasmid preparations, and secondly by sequencing the plasmid RE classes. 
RE classification reduced the initial positive clone count from several hundred to just 48. As the 
sequencing progressed, mass sequence analysis and assembly proved that several of the clones that at 
first appeared distinct through the initial restriction analysis, in fact belonged to the same continuous 
contigs, and as a consequence were grouped together and assembled as one from that point forward. 
This reduced the total number of positive contigs to 13 in total, with three originating from the SASRI 
library, five from the Hotwood library, four from the MS library and one from the Gansbay library. Of 
these 13 contigs, 12 were obtained from the screening for novel β-galactosidase activity and identified 
based on the production of a blue phenotype when screened on MDA-lac supplemented with X-gal. One 
contig was from the trans-fructosylation screen and was identified through the visible production of a 
exopolysaccharide.  
The 13 contigs were sequenced end to end and analysed in silico. The ORFs were identified and analysed 
with the BLASTX and BLASTP protocols on the NCBI website which, revealed that several of the contigs 
contained more than one putative gene that could potentially account for the observed phenotype 
(Table 3-3). In all, 17 putative genes were identified, that could potentially either catalyse the 
production of galactose (16 in total) or fructose (1 in total) containing oligosaccharides/polymers 
(Table 3-3; See appendix for sequence information).  
The Carbohydrate-Active Enzymes database (CAZy; http://www.cazy.org) provides a sequence-based 
family classification system, linking the sequence to the specificity of enzymes that synthesise, modify 
or hydrolyse oligo- and/or polysaccharides [113]. The putative genes isolated, and the protein products 
they encode, belong to a range of GH families. β-Glucosidases (EC 3.2.1.21) and β-galactosidases 
(EC 3.2.1.23) catalyse the selective cleavage of glycosidic bonds from the non-reducing ends of their 
substrates and some of them have been shown to have trans-glycosylation activity. Moreover some 
β-glucosidases have been shown to be promiscuous with regards to substrate specificity and not only 
hydrolyse lactose, but also catalyse trans-galactosylation [212]. It is therefore not surprising that a 
number of GH1 family members, which are predominantly β-glucosidases, have been identified through 
functional screen designed primarily to identify β-galactosidase activity.  
For the β-galactosidase screen, the principal GH families isolated belonged to families 2 and 42, families 
which are known to produce GOS [23]. Glycoside hydrolase family 2 comprises enzymes with several 
known activities i.e. β-galactosidase (EC 3.2.1.23); β-mannosidase (EC 3.2.1.25); β-glucuronidase 
(EC 3.2.1.31) [251]. These enzymes contain a conserved glutamic acid residue which has been shown in 
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E. coli β-galactosidase, to be the general acid/base catalyst in the active site of the enzyme [251]. GH42  
are known β-galactosidases (EC 3.2.1.23), however, other commonly found activities are 
α-L-arabinosidase (EC 3.2.1.55) and β-D-fucosidase (EC 3.2.1.38) (see Fig. 3-6; 8A-10A). Three GH53 
β-galatosidases were also isolated, all of which were in combined contigs, but only SAS-βgal3 could be 
associated with the blue phenotype of x-gal hydrolysis. The only known activity of GH53 family proteins 
are β-1,4-galactanase activity and they are usual related to microbial degradation of galactans and 
arabinogalactans in the pectic component of plant cell walls [252].  
 
Table 3-3 The 17 putative genes that were identified and amplified from four metagenomic libraries. The table shows which 
glycosyl hydrolase family each putative gene product belongs to, based on in silico analysis as well as the the nucleotide 
length of the gene and the predicted molecular weight of the protein. It also shows the closest related sequence based on 
BlastP analysis.  
# name family  Xgal  Contig #  size  aa Mw %  similaraity 
1 HW-βgal1 GH 2 yes  HW_C1/C4 3108 bp 117.2 kDa 99% Klebsiella sp. 
2 HW-βgal2 GH 2 yes  HW_C2/C3 3075 bp 116.1 kDa 97% Kosakonia sp. 
3 HW-βgal3 GH 2 yes  HW_C5/C6 3108 bp 118.5 kDa 72% Mangrovibacter sp 
4 HW-βgal2 GH 42 yes  HW_X1 2058 bp 77.3 kDa 94% Klebsiella sp. 
5 HW-βgal3 GH 53 no  HW_X1 1203 bp 44.9 kDa 95% Klebsiella sp. 
6 HW-βgluc1 GH 1 no  HW_X2 1335 bp 41.8 kDa 92% Bacillus 
7 HW-βgluc2 GH 16 no  HW_X2 768 bp 30.6 kDa 65% Caldicellulosiruptor sp. 
8 MS-βgal2  GH 53 no  MS_17A 1203 bp 44.8 kDa 99% Raoultella sp. 
9 MS-βgal3  GH 42 yes  MS_17A 2067 bp 77.6 kDa 99% Enterobacteriaceae sp. 
10 SAS-βgal1 GH 2 yes  SAS_C1/C2/C3 3072 bp 115.8 kDa 97% Enterobacter sp. 
11 SAS-βgal2 GH42 yes  SAS_C4/C5/C6 2108 bp 77.5 kDa 91% Enterobacter sp. 
12 SAS-βgal3 GH 53 yes  SAS_C4/C5/C6 1188 bp 43.9 kDa 99% Enterobacter sp. 
13 GB-βgal1 GH 2 yes  GB_NV5 3120 bp 115.8 kDa 97% Enterobacter sp. 
14 MS-βgal1 GH 2 yes  MS_C32 3396 bp 128.6 kDa 79% Proteiniphilum sp. 
15 MS-βgluc1 GH 1 yes  MS_3L 1314 bp 46.5 kDa 89% Devosia sp. 
16 MS-βgluc2 GH 1 yes  MS_4L 1299 bp 49.3 kDa 51% Candidatus sp. 
17 SAS-LS GH 68 no  SAS_LS 1290 bp 47.1 kDa 77% Komagataeibacter sp. 
 
After sequencing, all of the putative genes were amplified by PCR and ligated in frame to a 6x histidine 
tag in the the pRSET_A vector system, and again sequenced to confirm correct frame and orientation. 
As stated previously, some of the assembled contigs contained more than one putative gene that could 
account for the observed phenotype (HW-βgal2 & 3; HW-βgluc1 & 2; MS-βgal2 & 3 and SAS-Bgal2 & 3). 
In these cases both genes were amplified out and ligated separately into pRSET_A and then 
re-transformed into the mutant to ascertain which genes is responsible for the observed phenotype, 
thus revealing the true positives (Fig 3-3 and Table 3-3) For the GH68 putative levansucrase identified, 
a clear visible exopolysaccharide was observed (Fig 3.4).  
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Figure 3-3 The various putative genes for the β-galactosidase screen, cloned into the pRSET_A vector system and grown on 
MDA-lac plates containing X-gal. The two rows are the same clones photographed on different backgrounds so as to accentuate 
the visual effect. (-K) and (+K) is representative of the Δβ-gal mutant negative and positive controls, containing the empty 
pRSET_A vector and pRSET with the complete E. coli β-galactosidase coding sequence, respectively. (1) HW-βgal1 (2) HW-βgal2 
(3) HW-βgal3 (4) HW-βgal4 (5) MS-βgal3 (6) SASRI-βgal1 (7) SASRI-βgal2 (8) SASRI-βgal3 (9) GB-βgal1 (10) HW-βgal5 (11) 
HW-βgluc1 (12) HW-βgluc2 (13) MS-βgal2 (14) MS-βGluc1 (15) MS-βGluc2. Take note that MS-βgal2 was accidently omitted, 
hence only 15 and not 16 putative genes are represented (refer to table 3-3) 
 
Figure 3-4 Levansucrase gene isolated from the SASRI metagenomic library clearly showing a visible phenotype on a matt of 
plated out E. coli transformants. 
 
 Protein analysis and biochemical characterisation 
 
To ascertain whether the respective protein catalysts have any potential for the production of 
oligosaccharides/polymers, their biochemical characteristics needed to be determined to identify 
optimal production conditions. For the purposes of the rest of this chapter, focus will be given only to 
those positive clones isolated from screening on lactose containing medium, the putative 
β-galactosidases and β-glucosidases. The putative GH68 levansucrase that produced copious amounts 
of exo-polymer (Fig. 3-4) and its sequence will be investigated more thoroughly in chapter 5.All of the 
protein constructs were expressed in the ∆β-gal mutant to remove any background activity resulting 
from the endogenous E. coli β-galactosidase (Fig.3-4). Protein expression in the pRSET vector is driven 
by the T7 promoter and is therefore dependent on the host cell providing the T7 RNA polymerase, 
usually through the induction via the lac promoter [253, 254]. The DH5α host cells that were utilized for 
the creation of the mutant do not contain the DE3 prophage insertion or any other insertions that code 
for the T7 RNA polymerase. Contrary to expectations, more than adequate protein production was 
achieved in the mutant, enabling the characterisation of the proteins. It is hypothesised that other 
polymerases bind to the expression vector for the expression of other vector born genes, and these 
somehow facilitate the expression of the T7 driven genes. It was also observed that expression of any 
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of the putative GH2 β-galactosidases in several different BL21 protein expression strains [BL21(DE3), 
BL21(DE3) pLysS and BL21AI] led to cells that appeared to lyse and flocculate during mid-log phase, and 
no expression could be achieved as the plasmid was dropped mid log phase. Under normal 
circumstances the native GH2 E. coli β-galactosidase is a tetrameric protein and I propose that the 
endogenous β-galactosidase complexes with the newly introduced protein, resulting in disruption of 
cellular integrity and cell lysis. Tangible support for this hypothesis comes from an experiment where 
the GH2 β-galactosidase genes isolated from the various libraries, were expressed in the un-mutated 
DH5α strain. In all the cases, protein expression could not be achieved as was done with the mutant 
strain. It is hypothesised that as was the case in the Bl21 strains, the vector born β-galactosidase 
complexed with the truncated form of the endogenous E. coli β-galactosidase, resulting in the plasmid 
ultimately being dropped due to the stress effected on the cells. This problem was not observed for the 
other β-glucosidases and β-galactosidases from families GH1, GH42 and GH53. The overnight 
incubations of the respective protein expression constructs were extracted through sonication, their 
protein concentrations were quantified through the Bradford method (1976), and then separated on 
SDS denaturing polyacrylamide gel electrophoresis [245, 246]. Only the protein constructs that 
produced a blue phenotype when grown on X-gal were grown overnight for further investigation. The 
protein extracts were grouped according to the three GH families i.e. GH2 (6 in total), GH42 (3 in total) 
and GH1 (3 in total) for the PAGE analysis. This was done for simplicity and visual aid as all the GH2 
proteins were approx. 115 kDa in size, whilst the GH42 and GH1 proteins were approx. 77 kDa and 
50 kDa in size, respectively (see Fig. 3-5 and Table 3-3). Even though it was difficult to discern the 
individual protein bands in some cases, activity was confirmed for all extracts relative to that of the 
controls with the aid of nitrophenyl based substrates (Fig. 3-6)  
 
 
Figure 3-5 The various β-galactosidases and β-glucosidases that were identified through screening of metagenomic libraries on 
minimal media containing lactose and X-gal, all cloned into pRSET and expressed in the ∆β-gal mutant. Proteins are grouped 
according to family, namely (A) GH2 (B) GH42 (C) GH1 respectively. The individual clones are (-K) empty control (+K) positive 
control E. coli β-gal (A1) HW-βgal1 (A2) HW-βgal2 (A3) HW-βgal3 (A4) SASRI-βgal1 (A5) GB-βgal1 (6) MS-βgal1 (B1) HW-βgal4 
(B2) MS-βgal3 (B3) SASRI-βgal2 (C1) HW-βGluc1 (C2) MS-βGluc1 (C3) MS-βGluc2. For the predicted molecular weights of the 
individual proteins refer to table 3-3 on page 54. 
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The overnight protein extracts that were visualised through SDS-PAGE, were used to characterise the 
pH, temperature and substrate specificities of the respective proteins (Fig. 3-6). Because crude extracts 
were utilised and not the purified proteins itself, specific activities of the individual proteins could not 
be determined. Consequently the level of activity would be directly proportional to the level of 
heterologous expression of the individual proteins, which is greatly variable between the different 
constructs. The activities, whether it be for substrate specificity, pH or temperature optima, were all 
expressed as a percentage relative to the maximum activity, which was taken to be 100 (Fig. 3-6). 
Chromogenic nitrophenyl based substrates allows for a relatively easy colorimetric assay to determine 
substrate specificity as well as the pH and temperature optima of the various proteins.  
For an enzyme to be used in the industrial production of GOS and/or polymers it should ideally exhibit 
a broad pH and temperature range to accommodate any robust production needs. Generally there are 
two needs with regards to temperature optima, namely a high activity at low temperatures for the 
production of GOS in milk based products (sub 15oC), or a high level of activity at elevated temperatures 
for GOS production in saturated solutions of whey permeate lactose (above 35oC) [191, 255]. GOS 
production has been shown to have a linear relation with substrate concentration, thus the higher the 
lactose concentration, the higher the rate of GOS production. Lactose itself is not readily soluble at high 
concentrations at temperatures below 30oC, and therefore thermophilic enzymes are often preferred 
when it is used as a substrate [103, 256]  
The characterisation of the crude protein extracts were again grouped together, as was done for the 
SDS PAGE analysis, into the GH2, GH42 and GH1 family groups (Fig. 3-6). All of the GH2 extracts had 
similar pH optima, with the highest activity being observed at slight acidic to near neutral conditions 
(pH 6.8) for all the extracts (Fig. 3-6; 2B-7B). So too were the temperature activity spectrum very much 
the same, with a gradual increase in activity to approx. 40oC, after which a sharp drop in activity was 
observed. The exception to this was GB-βgal1 which showed a maximum activity at 25oC. Interestingly, 
all the GH2 β-galactosidases showed a higher affinity towards 2-β-D-galactosyl nitrophenyl based 
substrates, than for 4-β-D-galactosyl nitrophenyl based substrates. The opposite was observed for GH42 
β-galactosidases and GH1 β-glucosidases. GH42 enzymes have been shown to have high specificity for 
axial C4-OH groups [257]. In addition, all of the GH42 β-galactosidases and GH1 β-glucosidases 
demonstrated significant fucosidase activity, this has previously been shown in the literature and relates 
to glycan degradation of the plant cell walls, often together with that of GH53 proteins, as mentioned 
previously. Moreover they are often found together with cellusomes, which further cements their role 
in glycan degradation [258, 259]. GH42 enzymes are often used in the production of lactose free milk 
[260]. As was the case for the GH2 extracts, the GH42 and GH1 pH optima was near neutral at around 
pH 6.8, except for MS-βgluc2 which had a more acidic optima of pH 6.0, which then suddenly dropped 
with almost no activity at pH 7.0. In general the GH42 extracts had a broader pH spectrum than that of 
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the GH1 extracts, and was more comparable with that of the GH2 extracts. The temperature optima for 
the GH42 and GH1 extracts also gradually increased towards approx. 40oC after which a sudden drop 
was observed. The temperature and pH ranges of the isolated protein extracts correlate with two of the 
most prominent sources of biocatalyst for the production of GOS, namely Kluyveromyces lactis and 
Bacillus circulans, and depending on their product formation capabilities, any one of them could have 
potential industrial relevance [185, 261]. 
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Figure 3-6 The substrate specificity (A), pH optimum (B) and optimum temperature (C) of the various putative genes (2-13) 
with E.coli β-galactosidase (1) as a positive control. The ∆β-gal mutant with empty pRSET vector used as negative control but 
no significant activity could be detected (results not shown). The spectrophotometric hydrolysis was measured at 405 nm  and 
free nitrophenol deduced from a standard linear curve that was established with 4-nitrophenol, ranging between 0.0025 µM 
and 0.04 µM. All activity was expressed as a percentage, relative to the highest amount, which was taken to be 100% 
Temperature and pH was characterised with either 2-β-D-gal-NP or 4-β-D-gal-NP depending on which showed the highest 
activity for the respective constructs. The samples assayed were (2) HW-βgal1; (3) HW-βgal2; (4) HW-βgal3; (5) SASRI-βgal1; 
(6) GB-βgal1; (7) MS-βgal1; (8) HW-βgal4; (9) MS-βgal3; (10) SASRI-βgal2; (11) HW-βGluc1; (12) MS-βGluc1; (13) MS-βGluc2. 
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 Product analysis  
 
The industrial relevance of any potential biocatalyst obtained from the library screens will always be 
underscored by the product formation capabilities and kinetic characteristics of the enzyme. The crude 
characterization of the respective enzymes with nitrophenyl based substrates enabled us to establish 
the optimal conditions for the hydrolytic reaction, but it provides no insight for the trans-glycosylation 
reaction or the products formed. It has always been assumed that the optimal conditions for 
trans-glycosylation is the same as that for the hydrolysis reaction, in seeing that the two reaction are 
interlinked, and all throughout the literature it is treated as such [262-264].  
The product forming capabilities of each of the protein extracts were investigated by overnight 
incubation in a lactose substrate solution (30%; w/v) under their respective optimal conditions, with 
regards to pH and temperature. The extracts were incubated at a concentration of 1 u.mL-1 in a total 
volume of 10 mL. One unit of activity is defined as the amount of total crude protein extract needed to 
liberate 1 µmole of free reducible glucose from the disaccharidic lactose substrate in 1 minute. The 
enzyme linked NADH reduction assay for the measurement of the free reducing sugars glucose, 
galactose and fructose is visually explained in Fig. 3-7 and described in more detail under the material 
and methods section. The standardised overnight reactions will allow for all the reactions to equilibrate 
to endpoint, and enable the final product formations to be visualised through TLC and the ratio of free 
glucose and galactose to be determined. 
The product formation visualised by TLC is shown in Fig. 3-8. Included in the TLC is the commercially 
available GOS preparation, Vivinal GOS, from Friesland Campina (Amersfoort, The Netherlands). It 
should be noted that this industrially produced commercial preparation is a concentrated form that was 
treated by various means so as to rid it of as much free monosaccharide and lactose as possible through 
various fermentation and purification methods. It should be used as a direct comparison of catalytic 
efficiency only in the most extreme case [265]. An ideal enzymes would be one that shows the highest 
propensity for trans-galactosylation over hydrolysis together with a high rate of substrate conversion. 
TLC is a simple and rudimentary chromatography method which gives no insight to linkage type. The 
main three focal points of the TLC in Fig. 3-8 is the final equilibrium amounts of, (i) the free glucose and 
galactose as visualised on top part of the TLC. (ii) The reduction in the substrate lactose in the middle of 
the TLC, indicative of substrate conversion. (iii) The formation of higher DP oligosaccharides towards 
the lower part of the TLC. To further aid in the characterisation of the trans-galactosylation reaction, 
the ratio of free glucose to galactose is shown at the bottom of each TLC sample (Fig 3-8) . From the 
figure below it can be seen that the two enzymatic preparations that appears to produce the largest 
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amount of GOS with the highest equilibrium endpoint towards product formation is (A1) HW-βgal1, and 
(C2) MS-βGluc1. Even though their ratio of free glucose: galactose isn’t the highest, they appear to have 
the highest substrate conversion to GOS, by far. The other protein extract preparations appear to reach 
an endpoint equilibrium where either they continuously hydrolyse and trans-glycosylate the GOS 
already formed, or they produce a disaccharidic product that appear similar to the substrate lactose.  
 
Figure 3-7 The spectrophotometric measurement of free glucose, fructose and galactose is coupled to the reduction of NAD+ 
to NADH which is measurable at 340nm wavelength. For this to be observed glucose first needs to be phosphorylated and 
then reduced to 6-phosphogluconate through the actions of Hexokinase/Glucose-6-phosphate Dehydrogenase (HK-G6DH). 
For the measurement of fructose, it first needs to be phosphorylated to fructose-6-phosphate and then isomerised to 
glucose-6-phosphate through the combined action of Hexokinase/Phosphoglucose-Isomerase (PGI), which in turn can then 
be reduced by HK-G6DH. For the measurement of galactose it needs to be reduced to galactono-1,4-lactone through the 
actions of Galactose Dehydrogenase (GDH). 
 
Figure 3-8 The product formation of the respective enzymes visualised by means of thin layer chromatography. 0.5µl of an 10x 
dilution of a 30% lactose(w/v) solution incubated overnight with 1 U.mL-1 at the optimum temperature and pH for each of the 
respective enzymes. The individual lanes are (Glc) glucose (gal) galactose (lac) lactose (GGL) glucose/galactose/lactose (VGOS) 
Vivinal GOS commercial preparation of GOS (-K) empty control (+K) positive control E. coli β-gal (A1) HW-βgal1 (A2) HW-βgal2 
(A3) HW-βgal3 (A4) SASRI-βgal1 (A5) GB-βgal1 (6) MS-βgal2 (B1) HW-βgal4 (B2) MS-βgal4 (B3) SASRI-βgal2 (C1) HW-βGluc1 
(C2) MS-βGluc1 (C3) MS-βGluc2. The bottom row below the table is the ratio of free glucose to galactose as determined 
spectrophotometrically by NAD+ linked enzyme assay. 
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 Conclusion 
 
The metagenomic DNA isolation was successful and three libraries with decent titters were constructed 
with the lambda ZAP express bacteriophage library system. A β-galactosidase deletion mutant was 
constructed, through ʎ-Red recombineering, to facilitate the screening for novel biocatalyst that 
hydrolyse lactose and x-gal and potentially produce GOS. Altogether five libraries were screened for 
novel enzymes that possesses either trans-galactosylation or trans-fructosylation  activity. Through 
functional screening of the metagenomic libraries, seventeen putative genes were identified that could 
potentially produce prebiotic oligosaccharides/polymers. All were sequenced and in silico analysed. 
They were PCR amplified and cloned into the protein expression vector pRSET_A, and heterologously 
expressed in E. coli. Of these original seventeen, thirteen were again positively associated with the 
phenotype, and further characterised on a rudimentary level. Their substrate specificities, pH and 
temperature optimums were established through the spectrophotometric analysis of their hydrolytic 
action on various nitrophenyl based substrates. Their product forming capabilities were investigated by 
overnight incubation with the substrate lactose, under optimal conditions. The equilibrium end 
reactions were visualised through TLC, and the free reducing sugars assayed through the 
spectrophotometric measurement of the enzyme linked reduction of NADH. Preliminary data of the 
biochemical characteristics and product formation capabilities shows promise but further and more 
detailed analysis is needed of the purified proteins. The putative β-galactosidase HW-βgal1 isolated 
from the Hotwood-library, together with the putative β-glucosidase MS-βGluc1 isolated from the 
MS-library, and the putative levansucrase SASRI-LS2 isolated from the SASRI-library, showed the 
greatest promise with regard to product formation, and were selected for further analysis that will be 
discussed in detail in the next two chapters.  
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 The biochemical characterisation of two novel glycoside hydrolases, a β-galactosidase 
and β-glucosidase, belonging to the Glycoside Hydrolase families 1 & 2 respectively, both with 
high trans-galactosylation activity. 
 
This chapter is partially written in a style aimed at publication. Of the two enzymes characterised here, 
the β-glucosidase is most promising and the article extracted will possibly be submitted to the journal 
‘Applied Microbiology and Biotechnology’ [ISSN: 01075-7598 (pint); 1432-0614 (web)]. So as to avoid 
repletion, some of the ‘Material and Methods’ and ‘Results’ covered in chapter three will be omitted.  
 
 Abstract  
 
Genes encoding two novel glycoside hydrolases named MS-βgluc1 and HW-βgal1, were isolated from 
two separate metagenomic libraries, as described previously in chapter three. The libraries were 
constructed with DNA extracted from soil at either a place where milk runoff occurs at a dairy farm or 
from process runoff collected at a sawmill. In the previous chapter, the crude protein extracts were 
rudimentary biochemically characterized with nitrophenyl based substrates, and  analysed for their 
prebiotic GOS synthesis abilities. In this chapter the proteins were purified and characterised more 
thoroughly with the substrate lactose, and so too their products. Both genes were heterologously 
expressed in E. coli and their respective proteins purified to apparent homogeneity by immobilized 
metal affinity chromatography (IMAC). HW-βgal1, a GH2 type β-galactosidase had a 1035 amino acid 
sequence and a predicted molecular mass of 117 kDa. For the substrate lactose it had a Km of 32 mM, a 
Kcat of 625 s-1 and a catalytic efficiency of 19.5 mM-1.s-1. The optimum pH and temperature for the 
hydrolysis reaction of HW-βgal1 was determined to be pH 7.5 and 35oC respectively. The second 
enzyme, MS-βgluc1, was determined to be a GH1 type β-glucosidase and had a 438 amino acid sequence 
and a predicted molecular mass of 46.5 kDa. For the substrate lactose it had a Km of 41 mM, a Kcat of 
111 s-1 and a catalytic efficiency of 2.7 mM-1.s-1. The optimum pH and temperature for the hydrolysis 
reaction of MS-βgluc1 was determined to be pH 6.0 and 45oC respectively. Both proteins were shown 
to have a high trans-galactosylation activity with HW-βgal1 yielding approximately 43% galacto-
oligosaccharides (GOS), mainly consisting of tri-saccharides of the β-D-1,6-lactose linkage type. MS-
βgluc1 yielded approximately 40% GOS, also consisting mainly of trisaccharides of both the β-D-1,3-
lactose and β-D-1,6-lactose linkage type. The results indicate that both HW-βgal1 and MS-βgluc1 are 
attractive candidates for lactose conversion and galacto-oligosaccharide production based on high 
activity and stability within a broad pH and temperature range. 
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 Introduction 
 
Prebiotics are non-digestible oligosaccharides and polymers that are selectively fermented by the 
commensal microbiota of the human gastro intestinal tract and confer benefits to the hosts, other than 
nutritional value [14, 266, 267]. The benefits conferred are numerous and range from improving mineral 
absorption, inhibiting pathogenic adhesion and prevention of colon cancer, to modulating the hosts 
immune system, regulating metabolism and serum lipid profiles [7, 18, 197, 268]. Prebiotic intake 
through diet is important in the maintenance of a healthy GI microbiota [11, 269]. Perturbations of that 
can be caused by various factors, such as host genetics, antibiotic treatment and infection. Reduced 
microbial diversity and/or the loss of beneficial microbes and pathobiont expansion is referred to as 
dysbiosis [2, 3, 56]. This has been linked to various diseases including metabolic syndrome, dyslipidemia, 
coronary heart disease, inflammatory diseases like coeliac and Crohn’s disease and even diseases of the 
cognitive state like depression, anxiety and dementia [4, 56, 94, 270]. Prebiotics ingestion have been 
proven to be an effective counter for dysbiosis and its resulting effects, by promoting the growth of 
beneficial bacteria [90, 197, 266, 267] 
Galacto-oligosaccharides (GOS) are a form of prebiotic oligosaccharide, derived from lactose and consist 
of galactose monomers often linked to a terminal glucose [271, 272]. GOS can vary in both chain length 
and linkages and normally consist of between three and nine degrees of polymerisation [189, 273]. GOS 
closely resemble human milk oligosaccharides, which are a large constituent of mammalian milk 
specifically aimed at stimulating the growth of beneficial bacteria. This stimulatory growth effect is 
colloquially referred to as the bifidogenic effect, even though they are not exclusively linked to 
Bifidobacterium growth and effect various beneficial commensal bacteria either directly or indirectly 
[174, 266]. For this reason GOS are often added to infant formula [31, 95, 274].  
GOS can be produced from lactose by the enzyme β-galactosidase (EC 3.2.1.23), through its trans-
galactosylation activity [23, 275, 276]. They often catalyse two competing reactions, namely hydrolysis 
and trans-galactosylation. After it has broken the β-1,4-D linkage between the glucose and galactose, 
an enzyme substrate complex is formed between the galactose monomer and the active site. If the 
galactosyl moiety is then transferred to H2O, hydrolysis occurs, but if it’s transferred to another 
carbohydrate, trans-galactosylation results [118, 277]. Eventually a dynamic equilibrium is formed 
between hydrolysis and trans-galactosylation. Enzymes which catalyse a reaction that favours 
trans-galactosylation over hydrolysis will result in higher yields of GOS and are highly sought after by 
industry [128, 191]. Traditionally the main industrial sources of β-galactosidases utilised for the 
production of GOS, has been from the fungal species Kluyveromyces and Aspergillus [118, 190]. 
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However, increasingly the identification of other prokaryotic sources of these enzymes has been sought 
after due to their ease of use in microbial expression system [118, 256, 278]. Some β-glucosidases have 
also been shown to facilitate trans-galactosylation when presented with lactose as a substrate and, as 
they are often smaller in size and more robust than the classical β-galactosidases, they make excellent 
candidates for industrial application [212, 279-281]. 
The combination of metagenomics and functional screening provide a powerful tool for the discovery 
of new catalytic enzymes that can aid in the betterment of industrial processes for the production of 
prebiotic GOS [233, 249]. In this chapter we build upon the work conducted in the previous chapter. 
The heterologous expression of two metagenomic derived genes, encoding a GH1 and GH2 
β-galactosidase and β-glucosidase, referred to as HW-βgal1 and MS-βgluc1 respectively, were 
successfully carried-out. Ultimately their protein products were purified to near homogeneity bye 
means of IMAC. The purified proteins were biochemically characterised. Analysis of their kinetic 
properties and their enzymatic products formed, indicate that both have relatively high 
trans-galactosylation activity.  
 
 Materials and methods 
 
 Strains, plasmids and materials 
 
All chemicals and enzymes were purchased from Sigma (St. Louis, MO, USA) unless stated otherwise. All 
restriction enzymes, T4 DNA ligase, DNA polymerase and corresponding buffers were purchased from 
Thermofisher Scientific (Massachusetts, USA). The enzymes galactose dehydrogenase/mutatarose 
(GAL-DH/M) and hexokinase/glucose-6-phosphate-dehydrogenase (HK-G6DH) were obtained from 
Megazyme (Wicklow, Ireland). The lambda ZAP express vector kit and packaging extract was purchased 
from Agilent technologies (California, USA). The pRSET protein expression vector system was obtained 
from Life technologies (California, United States). The oligosaccharide standards 1,3-galactobiose 
(α-Gal-1,3-Gal); 1,4-galactobiose (β-Gal-1,4-Gal); 1,6-galactobiose (β-Gal-1,6-Gal); galactotriose 
(α-Gal-1,3-β-Gal-1,4-Gal); galactotetraose (α-Gal-1,3-β-Gal-1,4-α-Gal-1,3-Gal); lactose (β-Gal-1,4-Glc); 
allolactose (β-Gal-1,6-Glc); mellibiose (α-Gal-1,6-Glc); lactulose (β-Gal-1,6-Fru); 3' galactosyl-lactose (β-
Gal-1,3-β-Gal-1,4-Glc); 4' galactosyl-lactose (β-Gal-1,4-β-Gal-1,4-Glc); 6' galactosyl-lactose 
(β-Gal-1,6-β-Gal-1,4-Glc); maltobiose (α-Glc-1,4-Glc); maltotriose (α-Glc-(1,4)2-Glc); maltotetraose 
(α-Glc-(1,4)3-Glc); maltopentose (α-Glc-(1,4)4-Glc); maltohexaose (α-Glc-(1,4)5-Glc) and maltoheptahose 
(α-Glc-(1,4)6-Glc), were purchased from either Carbosynth (Compton, United Kingdom) or Dextra 
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laboratories (Reading, United Kingdom). Aluminium backed silica gel 60 thin layer chromatography 
plates were purchased from Merck (Darmstadt, Germany). The ∆β-galactosidase DH5α mutant lacking 
the endogenous β-galactosidase gene in its entirety was created previously through lambda red 
recombineering according to the protocols Datsenko and Wanner (2000), and as described in chapter 
three [241]. 
 
 Library construction and screening, clone selection, sequencing and in silico analysis 
 
The methods of metagenomic DNA isolation, digestion and library construction were conveyed in great 
detail in sections 3.2.1 to 3.2.2 on p34 - p40. The Δβ-gal mutant construction was described in section 
3.2.3 on page 40 - p42, and the screening of the libraries on minimal media plates were covered in 
section 3.2.4 on page 42 - p45. The approach to positive clone selection, de-replication sequencing and 
bioinformatic analysis were covered in section 3.2.5 on page 45.  
 
 Cloning, expression and recombinant protein purification 
 
The complete coding sequence for both the HW-βgal1 and the MS-βgluc1 genes were PCR amplified 
and cloned directionally in-frame into the pRSET_A (Invitrogen) protein expression vector, as described 
in section 3.2.6 on p45. The HW-βgal1 and MS-βgluc1 expression vectors were transformed into the ∆β-
gal mutant and their respective proteins expressed according to the protocols of Studier et al. (2014) 
[282]. In brief: a single colony from a fresh overnight streak was inoculated into 500 mL of ZYM-5052 
auto induction media (1% N-Z-amine, 0.5% yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM 
NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.2x metals, 0.5% glycerol, 0.05% glucose, 0.2% α-lactose) and 
incubated overnight at 37oC in a 2 L baffled flask with vigorous shaking  at approx. ~300 rpm (see section 
3.2.4 for media preparation).  
The cells were spun down at 10,000 xg for 10 min, washed once with 50 mL of ddH2O before being 
pelleted again as before, and reconstituted in 50 ml of protein extraction buffer (50 mM imidazole, 1.5M 
NaCl, 20 mM Tris-HCl pH 7.2). The cell suspension was sonicated five times on ice in 30 second burst 
with 1 minute intervals in-between, with intermittent swirling. The cell debris was pelleted by 
centrifugation at 12,000 xg for 10 min and the supernatant transferred to a new tube. The supernatant 
was force-filtered through a 0.22µm disposable filter connected to a 50 mL syringe, and the sample kept 
on ice till IMAC purification.  
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The recombinant proteins were individually purified, with the aid of a HisTrap HP 5ml column from 
Life Technologies (California, United States) on an ÄKTA FPLC (GE Life Sciences) protein purification 
system, according to the manufacturer’s recommendations. The proteins were eluted in 500 µL 
fractions over an imidazole gradient (50 Mm - 500 mM), and a 50 mL elution volume. The resultant 
fractions were tested for o-Nitrophenyl-β-D-galactopyranoside activity as described below in section 
4.3.4. Fractions demonstrating activity were pooled and dialysed overnight against 0.1x TE (1 mM Tris-
HCL pH 7.0, 0.1 mM EDTA). Protein concentrations were determined according to the method of 
Bradford (1976) using bovine serum albumin as the standard, before being analysed on denaturing SDS 
polyacrylamide gel electrophoresis so as to assess the purity [245].  
 
 Nitrophenyl based assays and enzyme linked assays for enzymatic characterisation. 
 
The nitrophenol based substrate specificity assays conducted in chapter three with the crude protein 
extracts were repeated, but this time only with the purified protein obtained in section 4.3.3. This was 
done in order to ascertain if there was any aberrant effect introduced on the substrate specificity by the 
crude extracts, rather than with the purified proteins.  
The protocol in brief: a standard linear curve with 4-nitrophenol ranging between 0.0025 µM and 0.04 
µM was established spectrophotometrically by measuring at wavelength 405 nm on a VersaMax ELISA 
microplate reader (Molecular Devices). To test for substrate specificity, 10 mM solutions of various 
nitrophenyl based substrates dissolved in Z-buffer (10 mM phosphate buffer pH 7.0, 5 mM MgCl2), were 
incubated with 0.05 µg of the respective purified proteins. The activity was measured continuously at 
405 nm for a period of 30 min at 37oC. If the assayed activity was out of the standard range by either 
being too high or too low, the protein concentration was adjusted accordingly so as to allow adequate 
spectrophotometric analysis of the enzymatic reaction. All  measurements were done in triplicate. The 
nitrophenyl based substrates utilized to assay the substrate specificity of HW-βgal1 and MS-βgluc1 were 
the following: ONP-α-D-galactopyranoside, ONP-β-D-galactopyranoside, ONP-β-D-maltoside, 
ONP-β-D-xylopyranoside, ONP-β-D-glucoronide, ONP-α-D-glucopyranoside, ONP-β-D-glucopyranoside, 
ONP-β-D-fucopyranoside, ONP-β-L-arabinopyranoside, ONP-α-L-rhamnopyranoside, 
ONP-β-D-cellobioside. All nitrophenyl based substrates were either obtained from Sigma-Aldrich 
(Missouri, USA), or Carbosynth (Berkshire, UK). For the nitrophenyl based substrates, one unit of activity 
is defined as the amount of purified enzyme needed to produce 1 μmole of nitrophenol in one minute 
under standard assay conditions. 
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 Biochemical characterization with the substrate lactose, through enzyme linked assay. 
 
In order to appropriately biochemically characterize HW-βgal1 and MS-βgluc1, their kinetics with 
regards to the substrate lactose needs to be quantified. For the enzymatic characterisation using lactose 
as substrate, free reducing glucose and galactose were determined using an enzyme linked assay based 
on the reduction of NAD+ to NADH at 340nm, on a VersaMax ELISA microplate reader (Molecular 
Devices). Hexokinase/glucose-6-phosphate dehydrogenase (HK-G6DH) is coupled to the measurement 
of free reducing glucose. Galactose-dehydrogenase/mutatarose (GAL-DH/M) together with HK-G6DH is 
coupled to the measurement of free reducing galactose.  A standard curve was established for the NADH 
coupled reduction of glucose on the spectrophotometer in a range of 0.02 µmole to 0.2 µmole per well. 
Because glucose and galactose occur at equimolar ratios within the substrate lactose, the standard 
curve of glucose can be extrapolated for the measurement of free galactose also.  
The protocol in brief: to each well of a clear-bottom UV transparent microtiter plate, 200 µL of assay 
buffer (100 mM Tris-HCl pH8.5, 1 mM NAD+; 1 mM ATP) was added. The samples were added to the 
wells in a total volume of 50 µL, making the final volume a combined 250 µL per well. A continuous assay 
was established on the spectrophotometer at 340 nm until baseline was reached, and an endpoint 
background measurement taken. For the measurement of glucose, 10 µL of a 40x dilution of a HK-G6DH 
enzyme preparation from Megazyme was added to each well (approx. 1 U hexokinase and 0.5 U G6-DH 
per well). Again an continuous assay was established and an endpoint measurement taken when 
baseline was reached (approx. 20 min). The change in OD340 from the first measurement, is directly 
proportional to the amount of free glucose in solution, and can be deduced from the standard curve 
previously established. For the measurement of free galactose, 10 µL of a 50x dilution of GAL-DH/M was 
added to the same well (approx. 1 U GAL-DH per well). Again a measurement was taken after baseline 
was reached. The difference in optical density at 340 nm between the last two endpoint measurements 
is directly proportional to the amount of free galactose present in solution, and can be calculated from 
the standard curve. For the substrate lactose, one unit of enzyme activity is defined as the amount of 
protein needed to produce 1 μmole of NADH, through the coupled reduction of glucose, after it was 
liberated from the substrate lactose, per minute, under the standard assay condition.  
Lactose was used as substrate for all enzymatic characterisation, other than the initial substrate 
specificity utilising the nitrophenyl based substrates. The amount of free glucose released by either 
HW-βgal1 or MS-βgluc1 after incubation with lactose was used to characterise the hydrolytic reaction, 
while the the amount of free galactose subtracted from the amount of free glucose was used to 
characterise the trans-galactosylation reaction. For the characterisation of the pH, temperature and 
co-factor optima with lactose as substrate, an endpoint stopped assay was employed. One unit of 
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enzyme activity was incubated in a 500µl lactose solution (20%; w/v) for 20 minutes, after which the 
samples were flash frozen in liquid N2 and subsequently incubated at 90oC for 5 min. Characterisation 
of optimum pH was performed using the following buffers: acetic acid/sodium acetate (pH 5.2; 50mM), 
sodium phosphate Na2HPO4/NaH2PO4 (pH6.4, pH7.0; 50mM), bis-tris propane/citric acid (pH7.6, pH8.2, 
pH9.1; 50mM) and sodium carbonate (pH10.3; 50mM). For the characterisation of the temperature 
optima of HW-βgal1 and MS-βgluc1, temperatures ranging from 10oC to 55oC were evaluated. For the 
co-factors the divalent cations Cu2+, Ca2+, Co2+, Mg2+, Mn2+ as well as NaCl were tested against H2O and 
EDTA in a final concentration of both 1 mM and 5m M. Michaelis–Menten kinetics were assayed in 
lactose concentrations ranging from 8 mM to 1.1 M using the optimum pH, temperature and co-factors 
as determined previously.  
 
 Enzymatic synthesis of GOS 
 
The synthesis of GOS was carried out using lactose monohydrate as the substrate and either HW-βgal1 
or MS-βgluc1 as the catalyst. The reaction was carried out overnight in 10ml final volume lactose 
solution (30%; w/v) containing 10 units of purified enzyme (1 U.mL-1). HW-βgal1 was assayed at pH 8.5 
(20 mM Tris-HCl) and 35oC, whilst MS-βgluc1 was assayed at pH 6.0 (20 mM Tris-HCl) and 43oC, both in 
a thermostatic oscillator. Following the overnight incubation the samples were twice extracted with an 
equal volume of phenol-chloroform : isoamyl alcohol (25:24:1), and once only with an equal volume of 
chloroform. Each time the sample was centrifuged at 12,000 xg for 5 min at 4oC and the supernatant 
transferred to a new tube. The final transfer was diluted with ddH2O to a final concentration of 5% of 
the original substrate concentration and used for further analysis.  
 
 Carbohydrate analysis  
 
The analysis of the final equilibrium reaction of the overnight incubation with the substrate lactose by 
TLC was repeated as in chapter three. This time however the purified enzyme was used as catalyst, 
rather than the crude protein extract. This was done in order to assign the GOS synthesis solely to the 
respective purified proteins, and negate the potential effect to any other enzymatic catalyst in the crude 
extract. Thin layer chromatography was conducted according to the protocol of Wang et al. (2014) 
[247].  
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Of the previously obtained 6x diluted overnight sample described above in section 4.3.6, 0.2 µl was 
spotted next to 0.2 µl of the standards solutions (10% w/v of glucose, galactose and lactose). The 
samples and standards were spotted just above a pencilled horizontal straight line, on aluminium 
backed silica gel 60 TLC plates (Merck, Germany). The plates were briefly dried in an oven, before being 
run in a sealed glass chamber that was equilibrated prior for an hour with the mobile phase, consisting 
of butanol/ethanol/water (5:3:2). The plates were run until the mobile phase reached ¾ of the way up. 
Again the plates were oven dried briefly before being developed by spray misting an orcinol developing 
solution (0.5% 3,5-dihydroxytoluene orcinol, w/v; 20% sulphuric acid, v/v), onto them with the aid of a 
gravity fed pressurised air micro-spray gun. The silica plates were clamped between two glass plates 
and baked in the oven for a several minutes at 100°C, until product development could be visualised, 
and then taken out and photographed.  
However, to fully characterise the end-products of the dynamic equilibrium reaction, a much more 
detailed analysis is needed. This thorough quantitative and qualitative characterisation of the GOS 
products was conducted by means of LC-MS/MS. Oligosaccharide samples were first desalted utilising 
AG 1-X8 formate and AG 50W resin (Bio-Rad, USA) packed spin columns. Columns were packed, washed 
and centrifuged twice, with 2 ml ddH2O at 1,400 xg. The deproteinated, purified and desalted 
carbohydrate samples were then separated on a Waters Acquity UPLC system (Hewlett-Packard, USA), 
coupled to a Waters Synapt G2 QTOF (Hewlett-Packard, USA). Samples (2 µl) were injected and 
separated with a UPLC BEH Amide column (1.7 µm particle size; 2.1 x 150 mm; 35 °C) at a flow rate of 
0.17 ml/minute. Elution was over a gradient utilising ddH2O and acetonitrile as mobile phases, both 
containing NH4OH (0.1%; v/v). The gradient changed from 20 : 80 (water : acetonitrile; v/v) to 50 : 50 
over 22 minutes. The column was then returned to the initial running conditions for 8 minutes so to 
equilibrate, before the next sample was loaded and ran. Electrospray ionization was operated in 
negative mode, under the following MS conditions: nebulizing gas (N2) pressure 260 kPa, cone voltage 
of 40V. The data was analysed in MassLynx version 4.0 software package (Hewlett-Packard, USA). 
For the quantitation of different DP (DP2-7) populations, the following standards were used: lactose 
(DP2), 3'-galactosyl-lactose (DP3), maltotetraose (DP4), maltopentose (DP5), maltohexaose (DP6) and 
maltoheptahose (DP7). Standard curves were established, ranging between 0.086 µg and 1.44 µg total 
carbohydrate injected. The area under the chromatograms were used to extrapolate concentration of 
the samples, and ultimately calculate the actual amount of the different DP populations.  
For qualitative linkage and MS/MS breakdown analyses, the following standards were injected at 
different  amounts (0.5 µg to 2 µg), depending on the highly individualistic MS signal peak strength: 
1,3-galactobiose (α-Gal-1,3-Gal); 1,4-galactobiose (β-Gal-1,4-Gal); 1,6-galactobiose (β-Gal-1,6-Gal); 
galactotriose (α-Gal-1,3-β-Gal-1,4-Gal); galactotetraose (α-Gal-1,3-β-Gal-1,4-α-Gal-1,3-Gal); lactose 
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(β-Gal-1,4-Glc); allolactose (β-Gal-1,6-Glc); mellibiose (α-Gal-1,6-Glc); lactulose (β-Gal-1,6-Fru); 
3'-galactosyl-lactose (β-Gal-1,3-β-Gal-1,4-Glc); 4'-galactosyl-lactose (β-Gal-1,4-β-Gal-1,4-Glc); 
6'-galactosyl-lactose (β-Gal-1,6-β-Gal-1,4-Glc); maltobiose (α-Glc-1,4-Glc); maltotriose 
(α-Glc-(1,4)2-Glc); maltotetraose (α-Glc-(1,4)3-Glc); maltopentose (α-Glc-(1,4)4-Glc); maltohexaose 
(α-Glc-(1,4)5-Glc) and maltoheptahose (α-Glc-(1,4)6-Glc).  
 
 Results and discussion 
 
 Library construction, screening, isolation and preliminary characterisation 
 
The results for the metagenomic DNA isolation, library construction, Δβ-gal mutant generation, library 
screening, positive clone selection, clonal de-replication and sequencing were all presented and 
discussed in sections 3.3.1 to 3.3.2 on p48 - p55, and will not be repeated here again, save to say that 
all efforts led to the identification and cloning of HW-βgal1 and MS-βgluc1 into their respective protein 
expression constructs. 
 
 In silico analysis of HW-βgal1 and MS-βgluc1 
 
Even though a basic in silico analysis for all the positive clones isolated from the various libraries were 
presented in chapter three, a more in-depth analysis is offered here for HW-βgal1 and MS-βgluc1, and 
furthermore explained in context of the libraries from which they were isolated.  
For both libraries, the numerous putative glycoside hydrolase genes isolated from the metagenomes, 
are indicative of their environments. For the HW-library metagenome, the presence of glycoside 
hydrolase activity would facilitate the breakdown and use of plant cell wall components as nutrients 
and contribute towards microbial fitness by providing an energy source. For the MS-library it would 
allow for the breakdown of an abundant energy source, i.e. lactose, conferring to it the competitive 
edge. Initially the HW-library was constructed for the purposes of discovering novel thermophilic 
glucosidases that act upon cellulose, but was screened for β-galactosidase activity also [22, 200]. The 
HW- library yielded altogether five β-galactosidases and only two β-glucosidases, whilst the MS-library 
yielded three β-galactosidases and two β-glucosidases. The expectation was that the HW-library will 
yield more β-glucosidase encoding clones, and the MS-library β-galactosidase encoding ones, however 
the opposite was found. Several factors could account for this. It could relate to the nature of 
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β-galactosidases and β-glucosidases in that their biological function are overlapping with regards to the 
hydrolysing of glycosidic bonds [110, 283]. Further support for this comes from the fact that theses 
enzymatic catalyst often populate the same GH families, e.g. GH1, GH2 and GH42 [283, 284]. Ultimately, 
the probability of recovering a certain gene depends on its abundance in the environmental DNA used 
for library construction. The respective metagenomes could quite possibly have vastly different 
representation of microbial diversity thereby accounting for observed results [285] 
The entire HW-βgal1 reading frame consists of 3108 bp and encodes 1035 amino acid residues with a 
predicted molecular mass off 117.18 kDa and a theoretical pI of 5.53. This enzyme contained 216 
charged amino acid residues (20.9% by frequency) and 542 hydrophobic amino acids (52.3%). The 
estimated α-helix and β-strand contents were 23% and 32%, respectively. The exponential increase in 
the number of available amino acid sequences of glycoside hydrolases (GHs) over the last few decades 
permits the classification of these enzymes based on amino acid sequence similarities. Enzymes with 
β-galactosidase activity are grouped within the GH1, GH2, GH35, and GH42 families, with the majority 
of the commercial enzyme preparations originating from either GH2 or GH42. The GH42 
β-galactosidases of Lactobacilli and Bifidobacteria are frequently inhibited by high glucose 
concentrations, and have a lower preference for trans-galactosylation compared with GH2 
β-galactosidases from the same organisms [208, 286]. Analysis of the primary protein structure of 
HW-βgal1 shows that it belongs to the glycoside hydrolase family 2 and contains the three classical 
conserved domains that characterises this family, namely the TIM-barrel domain stretching between 
amino acid (aa) 343-637, the β-galactosidase small chain domain (aa 760-1033), and the sugar binding 
domain stretching over (aa 55-225) [287]. It also contains the catalytic acid/base region between aa 
455-469 with the catalytic Glu469. When the amino acid sequence was blasted against the 
non-redundant protein sequence database with the BlastP algorithm it showed highest similarity to 
several Klebsiella species (99%); to the best of our knowledge none of these enzymes were 
biochemically characterised. Relative to the better characterised GH2 β-galactosidases, it showed 59% 
similarity to that of E. coli β-galactosidase, and only 32% similarity to that of Kluyveromyces lactis, which 
is one of the dominant commercially utilized GH2 β-galactosidases [288, 289]. SignalP 4.1 server analysis 
furthermore does not predict any signal peptide leading sequences and Prosite analysis predicts a 
cytosolic location. The results presented here, therefore, suggest that the HW-βgal1 enzyme is a 
cytoplasmically localized enzyme of bacterial origin [290-293]. 
Compared to HW-βgal1, the MS-βgluc1 was considerably smaller with a reading frame consisting of 
1314 bp translating to 437 amino acid residues and a predicted molecular mass off 49.3 kDa and a 
theoretical pI of 5.79. This enzyme contained 105 charged amino acid residues (24.0% by frequency) 
and 224 hydrophobic amino acids (51.3%) and an overall aliphatic index of 73.4%. A pfam conserved 
domain analysis showed that MS-βgluc1 belonged to the Glycoside Hydrolase family 1 and was in all 
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probability a β-D-1,4-glucosidase which would account for its high activity on the β-1,4 linked substrate 
lactose [294]. A protein NCBI blastp analysis against the uniprotkb/swiss-prot databases revealed that 
MS-βgluc1 showed highest similarity (48%) to a β-glucosidase (BglA) belonging to Thermotoga maritima, 
a bacteria which was reviewed in an article that investigated the distant relationship between 
β-glucosidases of the GH1 family, and other families of β-1,4-glycoside hydrolases [295].  
 
 Heterologous expression and purification of the HW-βgal1 and MS-βgluc1 proteins 
 
The HW-βgal1 and MS-βgluc1 proteins were cloned in frame into the 6x histidine tagged pRSET protein 
expression vector and heterologously expressed in the ∆β-gal DH5α mutant that contains no coding 
sequence for the endogenous E. coli β-galactosidase polypeptide. This was done for two reasons. Firstly, 
so as to avoid any co-purification of the endogenous E. coli β-galactosidase, thereby skewing results. 
Secondly, all attempts to express HW-βgal1 in strains conventionally used for protein expression, such 
as Bl21 pLysS,  failed. It appears that co-expressing HW-βgal1 with the endogenous β-galactosidase led 
to cellular instability, with the strains ultimately dropping the HW-βgal1 vector before adequate 
heterologous expression could be achieved.  
 
Figure 4-1 SDS-PAGE protein profiles of fractions collected during the HIS-tag IMAC purification of the HW-βgal1 (A) and 
MS-βgluc1 (B) respective recombinant proteins. Lane (M) is protein MW ladder, lane (1) is ∆β-gal mutant negative control 
carrying the empty pRSET A expression vector with no insert , lane (2) is the overnight expression by auto induction of the 
respective expression vector clones and lane (3) is the purified proteins. 
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The MS-βgluc1 glucosidase however had no complications with protein expression in the conventional 
strains but was none the less expressed in the deletion mutant. Both the HW-βgal1 and MS-βgluc1 
proteins were expressed overnight by means of catabolic suppression and auto-induction using lactose 
(which acts as an analogue of IPTG) according to the protocols of Studier et al. (2014) [243]. High levels 
of protein expression were achieved despite the DH5α host strain used not containing the coding 
sequence for the T7 RNA polymerase (Fig 4-1). The proteins were purified by IMAC FPLC and eluted over 
an imidazole gradient. A high purity level was achieved as was visualised by SDS PAGE analysis (Fig 4-1). 
The collected fractions were dialysed overnight against 0.1xTE buffer (10 mM Tris-HCL pH 8.0, 1 mM 
EDTA) to rid the protein solution of imidazole. The samples were stored on ice until characterisation. 
 
 Substrate specificity of HW-βgal1 and MS-βgluc1  
 
GH1 and GH2 family proteins are diverse and have numerous overlapping activities including 
β-galactosidase (EC 3.2.1.23); β-mannosidase (EC 3.2.1.25); β-glucuronidase (EC 3.2.1.31) and 
α-L-arabinofuranosidase (EC 3.2.1.55) [107]. It was decided to repeat the enzymatic specificity towards 
the chromogenic nitrophenyl based substrates that was first assayed with the crude protein extracts. 
This was done in order to eliminate the possibility of other endogenous E. coli proteins possibly 
accounting for the observed activities, as well as for the purposes of publication. Again, as was the case 
with the crude extracts, HW-βgal1 showed highest activity towards p-nitrophenyl-β-D-
galactopyranoside and o-nitrophenyl-β-D-galactopyranoside with fewer activity towards p-nitrophenyl-
β-D-fucosidase (Fig 4-2). MS-βgluc1 showed highest activity towards 4-β-D-glucopyranoside, but also 
demonstrated significant activity using 4-β-D-galactopyranoside , 4-β-D-fucopyranoside 4-β-D-
cellobiose and 2-β-D-galactopyranoside. Neither HW-βgal1 and MS-βgluc1 showed activity towards the 
nitrophenyl based substrates of α-D-galactopyranoside, β-D-maltoside, β-D-xylopyranoside, β-D-
glucoronide, α-D-glucopyranoside, β-L-arabinopyranoside, α-L-rhamnopyranoside. These results were 
the same as for the crude protein extracts as discussed in chapter three, and is further confirmation for 
the successful creation of the Δβ-gal deletion mutant. The β-glucosidases are grouped in the GH1 and 
GH3 families, whilst β-galactosidases are grouped in the GH1, GH2, GH35 and GH42 families [103]. 
Although β-galactosidase activity has frequently been reported for GH1 glucosidases, no β-glucosidase 
activity has ever been reported for GH2 galactosidases, as is observed for HW-βgal1 which showed no 
statistically significant activity towards either ONP-4-β-D-glucopyranoside or ONP-4-β-D-cellobiose 
(Fig 4-2) [190, 286, 287]. 
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Figure 4-2 Substrate specificity for the purified HW-βgal1 and MS-βgluc1 expressed relative (%) to the highest activity which 
was taken to be 100. No activity was detected for ONP-α-D-galactopyranoside, ONP-β-D-maltoside, ONP-β-D-xylopyranoside, 
ONP-β-D-glucoronide, ONP-α-D-glucopyranoside, ONP-β-D-glucopyranoside, ONP-β-L-arabinopyranoside, 
ONP-α-L-rhamnopyranoside, ONP-β-D-cellobioside for either HW-βgal1 and MS-βgluc1. 
 
 The effects of temperature and pH on HW-βgal1 and MS-βgluc1 activity 
 
In order to determine the optimal conditions for both the hydrolytic and trans-galactosylation reactions 
of HW-βgal1 and MS-βgluc1 with lactose as substrate, the release of free glucose and galactose were 
quantified over a broad pH and temperature range. Because there is 1:1 stoichiometric relationship 
between glucose and galactose within lactose, the hydrolytic reaction can be characterised by the 
release of free glucose, and the trans-galactosylation can be characterised by the subtracting the free 
galactose from that of the glucose assayed. Few reports exist that characterise both the hydrolytic and 
trans-galactosylation simultaneously and, to our knowledge, this is the first quantitative distinction 
between free glucose and galactose with regard to these two reactions. Previous studies characterising 
reaction parameters and kinetics were often performed with the aid of either the chromogenic 
substrate o-nitrophenyl-β-D-galactopyranoside (which serves only to characterise the hydrolytic 
reaction), or by determining release of reducing sugars by 3,5-dinitrosalicylic acid (DNSA), which is 
unable to distinguish between galactose and glucose. Other methodologies, such as HPLC are also 
unable to differentiate between the individual monosaccharide contributions of glucose and galactose 
and any quantitative analysis by means of peak integration merely group them together. It is often not 
clear therefore, what the relative velocities of the hydrolysis and trans-galactosylation reactions are. 
For both enzymes in this study the hydrolysis reaction was about 5 fold greater, at the optimal pH and 
temperatures, than the trans-galactosylation reaction. One mistaken assumption is that the reaction 
parameters for both reactions are identical. This is often thoughtlessly taken as true in the literature, 
with no real attempt, up to date, to distinguish between the two reaction. It is evident from the data in 
this study, that this is not necessarily the case. The temperature optimum for MS-βgluc1 differs between 
the hydrolytic (35°C) and trans-galactosylation (45°C) reactions (Fig 4-3). In addition the pH optima is 
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pH7.5 for hydrolysis and 8.5 for trans-galactosylation. The higher rate of trans-galactosylation at the 
respective pH and temperature optima is most likely the result of three dimensional conformational 
changes in the active site which reduce the water potential and favour an increase in the rate of 
trans-galactosylation [103, 105]. The optimum temperature and pH reactions catalysed by HW-βgal1 
are however the same for both reactions, at 45oC and pH6.0. Both HW-βgal1 and MS-βgluc1 can be 
characterised as mesophilic with a broad range of discernible activity ranging from 10oC to 55oC. MS-
βgluc1 however, demonstrates activity over a broader pH range (pH5.5-10) than HW-β-Gal1 (pH5-8). 
 
 
Figure 4-3 The effect of temperature and pH on both the hydrolytic and trans-galactosylation reaction of HW-βgal1 (A) and 
MS-βgluc1 (B). The effect is expressed as a percentage relative to that of the maximal activity. Generally the trans-
galactosylation reaction occurs at a slightly higher temperature and pH, than that of the maximal hydrolytic activity. 
 
 The effects of co-factors on HW-βgal1 and MS-βgluc1 activity 
 
Previous reports examining the effects of divalent cations and salts on glycoside hydrolases have 
indicated that they can influence enzyme activity differentially, either to the positive, negative or both 
depending on their actual concentration [103, 296, 297]. For this reason the co-factors were tested at 
final concentrations of both 1 mM and 5 mM. Several divalent cations and salts were tested for their 
efficacy in either promoting or decreasing the rate of lactose hydrolysis and trans-galactosylation for 
both the HW-βgal1 and MS-βgluc1 enzymes. There was however no differential effect of the co-factors 
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on hydrolysis and trans-galactosylation for either enzyme, and only the results for the hydrolytic 
reaction are henceforth shown. All co-factors were measured relative to the controls of either ddH2O 
with no additives, or 5 mM EDTA. The activity of lactose hydrolysis in H2O was taken as the standard 
against which all other reactions were expressed against. GH2 enzymes often contain several metal 
binding sites and between 1-10 mM of Mn2+ or Mg2+ are usually required for optimal activity [286, 297]. 
This is evident in Fig 4-4 that shows that the presence of Co2+, Mg2+ or Mn2+ led to a nearly twofold 
increase in activity. Several compounds reduced activity significantly including EDTA ( ̃80%), Cu2+ ( ̃80%) 
and Ca2+ ( ̃40%), all in line with previous reports [264, 288, 298, 299]. For MS-βgluc1 no stimulatory 
effect was observed for any of the cations or salts indicating that no co-factor is required. Cu2+ was 
however a strong inhibitor of the reaction. Only three previous publications have reported an inhibitory 
effect of Cu2+ for β-glucosidase, one of which also reported trans-glycosylation activity. It should be 
noted though that none of these reports used lactose as a substrate [300-302]. No additive effect was 
observed for either the stimulatory divalent cations or the inhibitors when combined, for either enzyme 
(data not shown). 
 
Figure 4-4. The effects of the various co-factors on the hydrolytic reaction of HW-βgal1 (A) and MS-βgluc1 (B). The influence of 
activity is expressed as a percentage relative to the activity in ddH2O with no added metals or salts, which was taken as a 100%. 
The influence of the co-factors on the trans-galactosylation reaction is statistically the same as that of the hydrolytic reaction 
(data not shown). 
 
 Reaction kinetics for HW-βgal1 and MS-βgluc1 
 
Both GH2 β-glycosidases and GH1 β-glucosidases are retaining enzymes and follow a classical Koshland 
double-displacement mechanism as was first evidenced in 1951 by Wallenfels, who reported the 
trans-galactosylation of lactose by means of an implicated glycosyl-enzyme intermediate [303]. 
Michaelis-Menten kinetics were determined for both the hydrolytic and trans-galactosylation reactions 
of HW-βgal1 and MS-βgluc1.  
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The trans-galactosylation reaction of both catalysts demonstrated a linear and non Michaelis-Menten 
correlation between substrate concentration and activity. This is indicative of the relationship between 
acceptor concentration, other than H2O, and trans-galactosylation. Previous studies showed an 
increased trans-galactosylation reaction at higher substrate concentrations due to the excess substrate 
reducing the water potential, thereby increasing the chance of the galactosyl moiety being transferred 
to another carbohydrate rather than H2O [117, 192, 278].  
The reaction kinetics for the hydrolytic reaction of HW-βgal1 showed that it had a Km of 32 mM and a 
Kcat of 625 s-1 and a catalytic efficiency (Km/Kcat) 19.5 mM-1.s-1. MS-βgluc1 had a Km of 41 mM and a 
Kcat of 111 s-1 and a catalytic efficiency (Km/Kcat) 2.7 mM-1.s-1. The kinetic parameters of some of the 
other characterized microbial β-galactosidases with trans-galactosylation activities are summarized in 
in Table 4-1. HW-βgal1 has an especially high catalytic turnover of 625 s-1 compared to the other 
characterised βgalactosidases (Table 4-1). Even though the enzyme’s affinity for its substrate is lower 
than some of the other, GOS is usually industrially synthesised under high lactose concentrations so as 
to reduce the water potential and favour the trans-galactosylation reaction. This observation, alongside 
the low Km and the high Kcat indicates that HW-βgal1 has a very high catalytic efficiency making it 
suitable for industrial application. MS-βgluc1 too is favourable for industrial application with regards to 
hydrolysis but ultimately it is the product synthesis capabilities of the trans-galactosylation reaction that 
has the most industrial relevance. 
 
Table 4-1 Summary of some of the more well known microbial β-galactosidases and their kinetic parameters, compared to that 
of HW-βgal1. 
Enzyme source substrate  Km (mM) kcat (s-1) kcat/Km (s-1mM-1) Reference 
 
β-glucosidases       
MS-βgluc1 lactose 41 111 2.7 This study  
Halothermothrix orenii lactose 154 231 1.5 Hassan et al. 2014 [280] 
Talaromyces thermophiles lactose 18 79 4.4 Nakkharat et al. 2006 [281] 
       
β-galactosidases       
HW-βgal1 lactose 32 625 19.5 This study  
Arthrobacter psychrolactophilus lactose 42 3 0.1 Nakagawa et al. 2007 [281] 
Caldicellulosiruptor saccharolyticus lactose 30 42 1.4 Park and Oh 2009 [304] 
Lactobacillus acidophilus lactose 4 50 12.5 Nguyen et al. 2007 [223] 
Lactobacillus reuteri lactose 31 58 1.9 Nguyen et al. 2006 [305] 
Saccharopolyspora rectivirgula lactose 0.7 63 84.0 Nakao et al. 1994 [201] 
Sulfolobus solfataricus lactose 13 1.9 0.1 Pisani et al. 1990 [306] 
Lactobacillus delbrueckii lactose 1.05 45.7 46 Rhimi et al. 2009 [307] 
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Figure 4-5. The Michaelis Menten kinetic representation of the hydrolytic and trans-galactosylation reactions of HW-βgal1 and 
MS-βgluc1 in µmole.mg-1.min-1 against the substrate concentration of lactose (M) 
 
 Product characterisation  
 
The GOS yield, lactose conversion rate and composition of produced GOS vary depending on the enzyme 
used. It is difficult to analyse the lactose conversion and GOS production due to the inability to easily 
distinguish disaccharidic GOS from lactose in normal HPLC analysis, unless mass spectrometry is 
employed. Even with GOS of a higher DP the variety of linkages leads to different elution patterns off 
the column resulting in either co-elution or fractioned elution patterns. Furthermore, with MS analysis 
one has to be mindful of formate adduct formation and breakdown products if one is to thoroughly 
analyse GOS formation [308, 309]. The GOS produced by HW-βgal1 and MS-βgluc1 were characterised 
by hydrophobic liquid interaction (HILIC) LC-MS/MS according to the protocols of Hernandez et al.  
(2012). The quantitative standards lactose, 3'-galactosyl-lactose, maltotetraose and maltoheptahose 
were used to set up calibration curves for the quantitative analysis of synthesized GOS [310]. 
 
 
Figure 4-6 Thin layer chromatographic analysis of the overnight incubation of purified HW-βgal1 with a 30% lactose solution in 
20 mM Tris-HCl pH 8.3 at 37oC. lane (1) is glucose, (2) is galactose, (3) is lactose, (4) is all three standards combined, and lane 
(5) is the overnight incubation product with GOS visible. 
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To date, the highest lactose conversation to GOS (63%) is achieved by a thermostable enzyme from 
Bifidobacterium infantis, whilst the highest production (0.318 g.L-1) is achieved by Sulfolobus solfataricus 
(Table 4-2). Their thermostabilty allowed high solubility of lactose and, consequently, a higher reaction 
velocity [208]. Both HW-βgal1 and MS-βgluc1 and are mesophilic enzymes that operates optimally at a 
lower temperature, but still managed to demonstrate an approximate 43% and 45% GOS yield 
respectively, with an initial lactose substrate concentration of 30% (w/v) (Table 4-2). As can also be seen 
from thin layer chromatography of the overnight incubation conducted with the purified protein, there 
appears to be a high conversion of lactose with limited hydrolysis of the GOS product. (Fig 4-6). 
Table 4-2 Summary of some of the GOS forming enzymatic sources, reaction conditions, initial lactose concentration and GOS 
formed expressed as a percentage (%) of the initial lactose substrate concentration. 
 
 
Figure 4-7 The relative % of GOS populations according to degrees of polymerisation as determined by the quantitative analysis 
of the overnight product by LC-MS. The majority of the GOS were tri-saccharides (60%) for both HW-βgal1 and MS-βgluc1, 
whilst approximately 30% and 20% were disaccharides respectively for HW-βgal1 and MS-βgluc1. Fewer than 10% were higher 
DP GOS for HW-βgal1 and approximately 20% for MS-βgluc1. 
 
GOS structures can differ in terms of their saccharide composition, regio-chemistry of the glycosidic 
linkages and the degree of polymerisation. In vitro evidence suggests that prebiotic microbes grow 
differently on oligosaccharides with different structures [16]. LC-MS/MS analysis demonstrated the 
synthesis of 11 different di- and tri-saccharides by HW-βgal1 and 10 by MS-βgluc1 (Fig 4-8). Although it 
Enzyme source Temp oC pH lactose g.L-1 GOS  % GOS g.L-1  Refrence 
HW-βgal1 37 8.3 300 43 129  This study 
MS-βgluc1 40 8.5 300 45 135  This study 
Bifidobacterium infantis 60 7.5 300 63 189 Hung et al. 2009 [208] 
Pyrococcus furiosus 80 5 270 22 59.4 Bruins et al. 2003 [311] 
Sulfolobus solfataricus 80 6 600 53 318 Park et al. 2008 [312] 
Geobacillus stearothermophilus 73 6.5 180 23 41.4 Placier et al. 2009 [221] 
Kluyveromyces lactis 40 7 400 25 100 Chockwasdee et al. 2004 [261] 
Bacillus circulans 40 6 460 40 184 Bakken et al. 1992  [185] 
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is difficult to assign identities to all peaks, with regards to linkage analysis, the major populations of di 
and tri-saccharides could be identified. Quantitative analysis showed that the biggest population of GOS 
product for HW-βgal1 were tri-saccharides making up almost 60% of the GOS whilst approximately 30% 
were di-saccharides and all the other higher DP population composed fewer than 10% (Fig. 4-7). 
MS/MS data reveal that the majority of the linkages formed were β-1,6 and that the major tri-saccharide 
present was β-D-galactose-1,6-lactose. MS-βgluc1 synthesised an equal amount of disaccharides and 
higher DP GOS (combined, 20% of the total), and approximately 60% of the total GOS were made up of 
tri-saccharides of which there was an equal distribution between β-D-galactose-1,3-lactose and 
β-D-galactose-1,6-lactose. 
 
Figure 4-8 The HILIC LC-MS/MS Chromatogram of the final overnight equilibration reaction of the purified protein with lactose. 
Here the MS-βgluc1 reaction is shown as example. The statistical representation for both reactions is shown in Fig. 4-7. (A) is 
representative of the total chromatogram of the overnight incubation whilst (B) is the mass extracted chromatogram for the 
di-saccharides and (C) is mass extracted chromatograms for the tri-saccharides. 
 
 Conclusion 
 
The GH2 HW-βgal1 and GH1 MS-βgluc1 genes isolated from metagenomic libraries were heterologously 
expressed and their protein products purified by IMAC. The recombinant proteins were biochemically 
characterised with the substrate lactose. Their kinetic properties demonstrated that the enzymes had a 
high catalytic efficiency. LC-MS/MS analysis of the overnight reaction demonstrated that both catalyst 
produced a mixed population of GOS and had a high yield. The HW-βgal1 and MS-βgluc1 proteins have 
the potential for industrial application. Contextualised relevance of the data obtained, as well as future 
research will be discussed in the final chapter six.  
Stellenbosch University  https://scholar.sun.ac.za
 83 
 
 Production of a β-2,6 extracellular fructan by a novel metagenome derived levansucrase 
 
This chapter is partially written in a style aimed at publication. The enzyme characterised here has 
industrial relevance and the article extracted will be submitted to the journal ‘Bioscience, Biotechnology, 
and Biochemistry’ [ISSN: 0916-8451 (print); 1347-6947 (web)]. So as to avoid repletion, some of the 
‘Material and Methods’ and ‘Results’ covered in chapter three will be omitted 
 
 Abstract 
 
A novel metagenome derived levansucrase gene was cloned and heterologously expressed in E. coli. 
The resultant recombinant protein, SAS-Ls, was purified to apparent homogeneity and biochemically 
characterised for both its hydrolytic and trans-fructosylation reaction. The two reactions, were found 
to have the highest Kcat’s, 7682 s-1 and 5587 s-1 respectively, ever reported for a levansucrase. The 
enzyme had an Km of 61 mM for the substrate sucrose and pH and temperature optima of pH 4.5 – 5.0 
and 25oC - 35oC respectively. The fructo-oligosaccharides produced by the enzyme were identified by 
NMR as a levan type with β-2,6 linkages. These data indicate that SAS-LS could be a candidate for 
industrial application, most notably in the prebiotic market.  
 
 Introduction  
 
Fructans are homopolymeric oligo-and polysaccharides comprised of fructose. They differ from each 
other, not only in chain length, but also in their structural isomerism linkage types [140]. The best 
characterised fructan is inulin, which consists of a terminal glucose and a series of β-2,1 linked fructosyl 
units [148]. It is a plant derived fructan, extracted mainly from chicory root, and is employed 
predominantly as a prebiotic fibre [91, 157]. Prebiotics are non-digestible oligosaccharides and polymers 
that are selectively fermented by the commensal microbiota of the human gastro intestinal (GI) tract 
and confer benefits to the hosts, other than nutritional value [14, 266, 267]. The benefits conferred are 
numerous and range from improving mineral absorption, inhibiting pathogenic adhesion and 
prevention of colon cancer, to modulating the hosts immune system, regulating metabolism and serum 
lipid profiles [7, 18, 197, 268].  
Recently levan, a bacterial β-2,6 linked fructan, has garnered much scientific attention due to its 
numerous uses and prospective application. Whereas in plants the functional role of fructans relates to 
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bridging the temporal gap between resource availability and energy demands, in microorganisms their 
evolutionary role relates to exopolysaccharide production for microbial biofilm formation in response 
to environmental and competitive stressors [152]. It is therefore not surprising that levan has favourable 
rheological properties, such as being soluble in both water and oil, having a high tensile strength (990 
psi) and low intrinsic viscosity (ɳ =o.18 dl.g-1). It is also compatible with most salts, surfactants, acids and 
bases, has high water and chemical retention and film forming capacity (for review see [313]). These 
biological properties of levan lends it to be utilized as stabilising or encapsulating agents, emulsifiers, 
osmoregulators and cryoprotectants [314]. Apart from its industrial application levan also has numerous 
biomedical properties. These include acting as anti-inflammatory, anti-viral, anti-carcinogenic, 
fibrinolytic, hypolipidemic, immunostimulatory and anti-oxidant agents as well as being a 
hyperglycaemic inhibitor [159-164]. It is also being explored for application in nanotechnology based 
drug delivery systems and wound dressings [155]. Levan type FOS are also sold as a health beneficial 
artificial sweetener [165] and levan has recently been advanced as a potential prebiotic fibre, much like 
inulin [144, 169-173]. The prebiotic potential of any complex carbohydrate is dependent on numerous 
factors including, but not limited to, its degree of polymerization, monomeric composition, linkage type, 
crystallinity, solubility and its relationship with other substrates [174]. Several studies have concluded 
that FOS with β-2,6 linkage type selectively enhance Bifidobacteria and Lactobacilli numbers in the 
human GI tract, presumably by providing a good growth substrate that consequently lead to the 
production of lactic and acetic acid (For review see [144]). In addition, certain Bacteroides species has 
been shown to possess extra-cellular endo-levanase activity capable of degrading the longer chain levan 
into oligosaccharides which are more readily fermented [178]. All the above mentioned literature 
indicates that levan is an excellent candidate for a prebiotic fibre and research is ongoing [157]. 
Numerous levansucrases (EC: 2.4.1.10) that produce either levan or levan type FOS have been identified 
from a wide range of microorganisms including Zymomonas, Streptococcus, Bacillus, Pseudomonas, 
Erwina, Acetobacter and Leuconostoc [155, 313-316]. Despite all the previously described functional 
applications and potential uses of microbial levan, its actual usage remains limited due to its high 
production cost and low yield [160, 317, 318]. There is, therefore, a need for the discovery of a novel 
catalyst that will enhance their industrial production [160]. In this chapter we describe the isolation, 
identification, cloning and heterologous expression of a novel metagenome derived Glycoside 
Hydrolase Family 68 levansucrase, henceforth referred to as SAS-Ls. Analysis of its kinetic properties 
indicate that SAS-Ls demonstrates relatively high trans-fructosylation activity and has potential for the 
industrial production of microbial levan.  
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 Materials and methods 
 
 Strains, plasmids and materials 
 
All chemicals and enzymes were purchased from Sigma (St. Louis, MO, USA) unless stated otherwise. All 
restriction enzymes, T4 DNA ligase, DNA polymerase and corresponding buffers were purchased from 
Thermofisher Scientific (Massachusetts, USA). The enzymes hexokinase/glucose-6-phosphate-
dehydrogenase (HK-G6DH) and phoshoglucose isomerase (PGI) were obtained from Megazyme 
(Wicklow, Ireland). The lambda ZAP express vector kit and packaging extract was purchased from Agilent 
technologies (California, USA). The pRSET protein expression vector system was obtained from Life 
technologies (California, United States). 
 
 Library construction and screening, clone selection, sequencing and in silico analysis 
 
The methods of metagenomic DNA isolation, digestion and library construction were conveyed in great 
detail in sections 3.2.1 to 3.2.2 on p34 - p40. The methodologies for the screening of the library on 
minimal media plates were covered in section 3.2.4 on page 42 - p45. The approach to positive clone 
selection, dereplication, sequencing and bioinformatic analysis were described in section 3.2.5 on page 
45. 
 
 Recombinant protein production and purification 
 
The complete coding sequence for the SAS-Ls gene was PCR amplified and directionally cloned in-frame 
into the pRSET_A (Invitrogen) protein expression vector, as described in section 3.2.6 on p45. The SAS-Ls 
expression vector was transformed into the Bl21(pLysS) E. coli expression strain and heterologously 
expressed according to the protocols of Studier et al. (2014) [282]. His protocols are an ingenious system 
that utilises defined and/or complex media (see section 3.2.4 for media preparation) allowing for the 
maintenance of inducible cells until a metabolic switch triggers auto-induction during the late log phase, 
thereby producing fully induced high density cultures at saturation. Cultures can be inoculated directly 
from a frozen glycerol stock, rather than a ‘fresh streak’ for overnight expression, and routinely yields 
higher protein production than the tedious IPTG cell monitoring density dependent inducer method 
[282]. The system is briefly described below. 
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The inducible heterologous production of proteins by cloned genes utilising the T7 expression system in 
E. coli is a common laboratory practise. However, more often than not, premature unintended induction 
inadvertently give rise to cultures that produce either poor or variable results. The gene for the T7 RNA 
polymerase is located on the chromosome of the E. coli expression strains, and is under the control of 
the lacUV5 promotor. Even the slightest basal induction of lacUV5 can result in the unwarranted 
expression of the T7 RNA polymerase, which in turn drives the heterologous protein expression of the 
cloned gene on the plasmid, via the T7 promoter. This process could redirect the majority of the cellular 
resources towards heterologous protein production. It could place the cells under untimely  stress, 
ultimately resulting in the plasmid being ‘dropped’, long before saturation is reached.  
The discovery by Grossman et al. (1998) that growth in most complex media resulted in a  high level of 
auto-induction as the cell culture approached saturation, defined the problem and allowed for a 
targeted approach [319]. Several attempts have been made to counter this ‘leaky’ expression. Firstly, 
reduction in basal expression can be achieved by introducing small amounts of lysozyme, which inhibit 
the transcription of the T7 RNA polymerase [320]. Secondly, transcription of the target gene can be 
reduced by placing a binding site for the lac repressor immediately after the T7 promoter (referred to 
as a T7lac promoter) [321]. And thirdly, a more recent strategy was to place the gene for the expression 
of the T7 polymerase under the control of the pBAD promoter, rather than lacUV5, which is induced by 
arabinose and is thought to have lower basal expression (Bl21-AI from life Technologies). All three 
methods have been employed with varying success. However it was the investigations by Studier et al. 
(1991-2005) in how the composition of complex media influenced growth, cell density at saturation and 
heterologous protein expression that finally produced an explanation for the inadvertent induction, and 
laid the foundation for the development of defined non-inducing media as well as high density 
auto-inducing media that allows for the successful and reproducible high-level production of 
heterologous proteins in E. coli utilising the T7 expression system [243, 282, 320, 322].  
Amino acids and small residual peptides provide the primary energy source in complex media such as 
LB and SOC broth. It is derived from the enzymatic digest of the milk protein casein (e.g. Tryptone or 
NZ-amine), as well as the yeast extract in the broth. Since milk is rich in lactose (an inducer of the T7 
expression), variable amounts can be present in the digest depending on the specific batch. The residual 
amounts of lactose is however not enough to promote appreciable expression during early log-phase 
growth, but is more than adequate to drive expression as the cell density approaches saturation, 
particularly at lower rates of aeration [282]. The presence of glucose prevents such induction, but it also 
causes the solution to acidify when culture saturation is approached [282]. Recent work also found that 
small amounts of galactose present in the media, also caused unintended induction in Bl21(DE3) [323]. 
This probably occurs because Bl21 strains cannot metabolise galactose due to a lack of galacto-kinase, 
causing galactose (also a weak T7 inducer) to build up intracellularly to a high enough level were it 
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induces T7 expression [322]. However, the presence of glucose in the solution also prevents induction 
by galactose as was the case for lactose. This prevention of induction by both lactose and galactose, is 
based on the premise that as long as glucose is present it remains the preferred carbon source for 
metabolism. This causes only glucose transporters to be expressed and concomitantly strongly 
supresses the expression of operons for the metabolism of  lactose, galactose and arabinose, thereby 
preventing them from entering the cell and inducing T7 expression [324].  
This catabolic suppression remains true for as long as there is glucose present in the solution, and as 
long as the medium doesn’t acidify [324]. Glucose is highly effective at preventing induction and even 
strains that express highly toxic target proteins grow well and maintain a high fraction of inducible cells 
before induction begins. To grow cultures to high densities (OD600 ~10) and cell concentrations greater 
than 1010.mL-1 , glucose concentrations must be finely adjusted so as to prevent the pH of the culture 
falling below pH6. This metabolic balancing of pH requires that the culture be well aerated. A glucose 
concentration is also required that is just depleted and causes auto-induction during the mid to late log 
phase, as aeration is falling and induction of target protein is robust. A reliable carbon source in addition 
to amino acids is required to maintain metabolic activities when glucose becomes depleted during auto-
induction. For this purpose glycerol is provided as a good carbon source that does not prevent glucose 
depletion during growth, glucose exclusion of inducing sugars, or the uptake of inducing sugars upon 
glucose depletion [243]. Non-inducing and auto-inducing media make production of proteins from 
cloned genes in E. coli reliable and convenient, and are adaptable for applications from small-scale 
laboratory testing to large-scale screening and protein production. 
The protocol in brief: a stab from a SAS-Ls glycerol stock was inoculated into 500 mL of ZYM-5052 auto 
induction media (1% N-Z-amine, 0.5% yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 
mM Na2SO4, 2 mM MgSO4, 0.2x metals, 0.5% glycerol, 0.05% glucose, 0.2% α-lactose) and incubated 
overnight at 37oC in a 2 L baffled flask with vigorous shaking  at approx. ~300 rpm (see section 3.2.4 for 
media preparation).  
The cells were spun down at 10,000 xg for 10 min, washed once with 50 mL of ddH2O before being 
pelleted again as before, and reconstituted in 50 ml of protein extraction buffer (50 mM imidazole, 
1.5 M NaCl, 20 mM Tris-HCl pH 7.2). The cell suspension was sonicated five times on ice in 30 second 
burst with 1 minute intervals in-between, with intermittent swirling. The cell debris was pelleted by 
centrifugation at 12,000 xg for 10 min and the supernatant transferred to a new tube. The supernatant 
was force-filtered through a 0.22µm disposable filter connected to a 50 mL syringe, and the sample kept 
on ice till IMAC purification. The recombinant protein was purified with the aid of a HisTrap HP 5ml 
column from Life Technologies (California, United States) on an ÄKTA FPLC (GE Life Sciences) protein 
purification system, according to the manufacturer’s recommendations. The proteins were eluted in 
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500 µL fractions over an imidazole gradient (50 mM - 500 mM), and a 50 mL elution volume. The 
resultant fractions were tested for the release of glucose when incubated with the substrate sucrose, 
by means of the enzyme linked reduction of NADH, as described below in section 5.3.4. Fractions 
demonstrating activity were pooled and dialysed overnight against 0.1x TE (1 mM Tris-HCL pH 7.0; 
0.1 mM EDTA). Protein concentrations were determined according to the method of Bradford (1976) 
using bovine serum albumin as the standard, before being analysed on denaturing SDS polyacrylamide 
gel electrophoresis so as to visually assess the purity [245].  
 
 Biochemical characterisation of SAS-Ls 
 
Sucrose was used as substrate for all enzymatic characterisation. For the characterisation of the pH, 
temperature and co-factor optimums, a stopped assay was used. Zero point one units of SAS-Ls enzyme 
was incubated in a 500µl final volume of sucrose solution (10%; w/v) for 30 minutes, after which the 
samples were flash frozen in liquid N2 before being incubated at 90oC for 5 min to dead-stop the 
reaction. For the substrate sucrose, one unit of enzyme activity is defined as the amount of protein 
needed to produce 1 μmole of NADH, through the coupled reduction of glucose, after it was liberated 
from the substrate sucrose, per minute, under the standard assay condition.  
Characterisation of optimum pH was performed using acetic acid/sodium acetate (pH 3.5, pH 4.0, pH 
4.5, pH 5.0, 50 mM) and sodium phosphate Na2HPO4/NaH2PO4 (pH 5.5, pH 6.0, pH 6.5, pH 7.0, pH7.5, 
50 mM). For the characterisation of temperature optimum of SAS-Ls, temperatures ranging from 5oC to 
55oC were assessed. For co-factors the divalent cations Cu2+, Ca2+, Co2+, Mg2+, Mn2+ as well as NaCl were 
tested against H2O and EDTA in a final concentration of both 1 mM and 5 mM. Michaelis–Menten 
kinetics were assayed in sucrose concentrations ranging from 8 mM to 300 mM using the optimum pH, 
temperature and co-factors as determined above, by a continuous assay on a VersaMax ELISA 
microplate reader (Molecular Devices).  
The amount of free glucose released by SAS-Ls after incubation with sucrose was used to characterise 
the hydrolytic reaction, while the the amount of free fructose subtracted from the amount of free 
glucose was used to characterise the trans-fructosylation reaction. The liberation of glucose and 
fructose from sucrose were measured spectrophotometrically in stopped assays by the enzyme linked 
reduction of NAD+ to NADH at 340nm utilising hexokinase/glucose-6-phosphate-dehydrogenase 
(HK-G6DH) and phoshoglucose isomerase (PGI). A standard curve was established for the NADH linked 
reduction of glucose on the spectrophotometer in a range of 0.02 µmole to 0.2 µmole per well. Because 
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glucose and fructose occur at equimolar ratios within the substrate sucrose, the standard curve of 
glucose can be extrapolated for the measurement of free fructose also. 
The protocol in brief: to each well of a clear-bottom UV transparent microtiter plate, 200 µL of assay 
buffer (100 mM Tris-HCl pH 7.4; 5 mM MgCl2; 1 mM NAD+; 1 mM ATP) was added. The samples were 
added to the wells in a total volume of 50 µL, making the final volume a combined 250 µL per well. A 
continuous assay was established on the spectrophotometer at 340 nm until baseline was reached, and 
an endpoint background measurement taken. For the measurement of glucose, 10 µL of a 40x dilution 
of a HK-G6DH enzyme preparation from Megazyme was added to each well (approx. 1 U hexokinase 
and 0.5 U G6-DH per well). Again an continuous assay was established and an endpoint measurement 
taken when baseline was reached (approx. 20 min). The change in OD340 from the first measurement, is 
directly proportional to the amount of free glucose in solution, and can be deduced from the standard 
curve previously established. For the measurement of free fructose, 10 µL of a 50x dilution of PGI was 
added to the same well (approx. 1 U PGI per well). Again a measurement was taken after baseline was 
reached. The difference in optical density at 340 nm between the last two endpoint measurements is 
directly proportional to the amount of free fructose present in solution, and can be calculated from the 
standard curve.  
 
 Enzymatic synthesis of levan and carbohydrate analysis 
 
Levan was produced by incubating SAS-Ls (0.2 U.ml−1) in a 10 ml sucrose solution (0.3 M sucrose, 50 mM 
sodium acetate buffer pH 4.6) at 30oC overnight in an incubator oscillator. The next day the levan was 
recovered by precipitation with an equal volume of ethanol before being freeze dried. Acid hydrolyses 
were performed on 5 mg of levan in a 500 µl 1 M triflouroacetic acid solution (TFA) (Merck) at 100°C for 
2 hours, after which the liquid was evaporated and washed twice with high grade methanol to remove 
residual TFA. The final hydrolysis product was suspended in 100 µl ddH2O and the free glucose and 
fructose ratio determined as described in section 5.3.4. Levan glycosidic linkages were examined by 
NMR analysis. The sample was suspended in D2O (2 mg.ml-1) and the spectra were obtained on a Varian 
VNMRS-500 operating at 100.5 MHz for 13C and 499.9 MHz for 1H. The13C spectrum is the accumulation 
of 448 transients with a 45° pulse width, acquisition time of 1.3 s and a recycle delay of 1 s. Lorentzian 
broadening of 1.0 Hz was applied before Fourier transformation. The 1H spectrum is the accumulation 
of four transients with a 45° pulse width, acquisition time of 2.0s and a recycle delay of 1s.  
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 Results and discussion 
 
 Library construction, screening and isolation of SAS-Ls 
 
The results for the metagenomic DNA isolation and SASRI library construction were all discussed in 
section 3.3.1 on p48 to p53. In chapter 3 however the majority of the focus was on the screening for 
putative β-galactosidases, and the analysis and screening of the SASRI library weren’t discussed in great 
detail at all, and will consequently be conveyed here briefly.  
For the SASRI library a high titre of approx. 8 x 107 pfu/μg lambda DNA was obtained with an average 
insert size of approximately 3.8 kb. After in vivo mass excision the converted plasmid library was 
transformed into the DH5α and screened on minimal MDA-suc  media containing 20% sucrose (w/v) as 
the sole carbon source. Two hundred and fifteen positive clones, that grew vigorously and produced 
copious amounts of a clear, sweet smelling and sticky viscous exopolysaccharide were isolated. After 
plasmid isolation, preliminary restriction fingerprinting and first round sequencing was conducted so as 
to de-replicate the positive clones. All of the 215 positive clones proved to be related to the same library 
insert. A representative clone that presumably contained the full insert, was chosen and sequenced in 
full from both ends. The insert was analysed for the complete open reading frames (ORFs) and 
preliminary analysed utilising BLASTX so as to assign possible function [244]. A putative Glycoside 
Hydrolase 68 gene was amplified by PCR with primers containing the necessary restriction sites and 
directionally cloned into the pRSET_A protein expression vector. The exopolysaccharide phenotype was 
reconfirmed by transforming the SAS-Ls pRSET construct back into DH5α and plating out on media 
containing sucrose. 
 
 In silico analysis of SAS-Ls 
 
In chapter 3 a rudimentary in silico analysis of SAS-Ls was presented whilst a more in-depth review is 
offered here. The entire SAS-Ls reading frame consists of 1290 bp and encoded for 429 amino acid 
residues with a predicted molecular mass off 47.15 kDa and a theoretical pI of 4.98. This enzyme 
contained 81 charged amino acid residues (18.8% by frequency), 227 hydrophobic amino acids (52.9%) 
and 113 (26.3%) hydrophilic amino acids. The exponential increase in the number of available amino 
acid sequences of glycoside hydrolases (GHs) over the last few decades permits the classification of 
these enzymes based on amino acid sequence similarities [113, 325]. BlastP analysis using the 
non-redundant Genbank peptide database showed highest similarity (77%) to a hypothetical 
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levansucrase from Komagataeibacter xylinus, and when blasted against the UniprotKB/Swiss-Prot 
SAS-Ls showed only a 58% similarity to that of the already characterised and well known levansucrase 
from Zymomonas mobilis [244, 326]. A Pfam domain analysis revealed that SAS-Ls belongs to the 
Glycoside Hydrolase Family 68 family of the hydrolase/transferase class of enzymes which contains the 
frucosyltransferases of levansucrase (EC 2.4.1.10), beta-fructofuranosidase (EC 3.2.1.26) and 
inulosucrase (EC 2.4.1.9), all of which use sucrose as donor substrate [327].  
 
Table 5-1 Conserved motifs among bacterial fructosyl transferases. Table adapted from Meng and Fütter [328] 
Motif number Motif designation 
Consensus 
sequence Position* Function† 
I QWDTG (V/L)WD(T/S)(W/M) 41-45 Catalytic nucleophile, conserved in GH68 family 
II EWSGG (E/Q)W(A/S)G(T/S) 117-121 Sucrose box I, conserved in GH68 family 
III DG DG 165-166 Involved in acceptor recognition 
IV MFYTS L(F/Y)T(D/C) 134-138 Sucrose box II and acceptor recognition 
V RDP RDP 193-195 Catalytic centre, stabilises transition state 
VI YCLFE Y(M/L)VFE 207-211 Sucrose hydrolysis and trans-fructosylation 
VII PLV PL(V/I) 270-272 Conserved among fructosyl transferase, unknown function 
VIII DQTER D(Q/E)(T/I)ER 279-283 Catalytic centre, acid base catalyst, conserved in GH68 family 
IX YLFT YLF(T/S) 294-297 Conserved among fructosyl transferase, unknown function 
X YRPLN YXP(L/M)N 327-331 Conserved among fructosyl transferase, unknown function 
XI TYS TYS 347-349 Orientates nucleophilic residue for trans-fructosylation 
*Motif designation and amino acid positions are relative to the SAS-Ls levansucrase 
† Meng and Fütterer 2003 [328], Martínez-Fleites et al. (2005) [329], Van Hijum et al. (2006) [330] 
 
Algorithms within the SignalP 4.1 prediction program indicated the probable presence of a signal 
peptide on the N-terminus of SAS-Ls [293]. This prediction is supported by the observed 
exopolysaccharide produced by SAS-Ls in E. coli and the fact that many bacteria, both Gram positive and 
negative, secrete levansucrases [331-334]. Tajima et al. (2000) reported a conserved signal peptide 
motif in the N-terminal domain of Gram negative levansucrases, WT(R/I)ADA(L/M,) which is located 
between amino acids 8–14 of SAS-Ls (WTIADAL), indicating that SAS-Ls could originate from a Gram 
negative bacterium [335]. The catalytic domains of microbial levansucrases have 11 conserved sequence 
motifs that are shown in Table 5-1 [328]. Although there are some differences, most notably in the first 
and last amino acid of the catalytic nucleophile domain (QWDTG) and also the last amino acid of the 
sugar box I, SAS-Ls conforms to the spatial arrangements and motifs of the catalytic domains of the eight 
other best characterised and industrially relevant levansucrases (Figure 5-1) [329, 330]. A phylogenetic 
tree analysis was performed for these eight levansucrases together with that of SAS-Ls, by the 
neighbour-joining method using the Jukes-Cantor protein distance measure demonstrating that SAS-Ls 
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is furthest removed from Gram positive bacteria (e.g. B. subtilis and G. diazotrophicus) and its closest 
relative is the Gram negative bacterial levansucrase of Z. mobilis (Figure 5-1). Few crystallography 
studies has been conducted on levansucrases, therefore further studies into SAS-Ls, its catalytic 
nucleophile and its crystal structure could be a significant contribution to the field [329, 336]. 
 
Figure 5-1 Phylogenetic tree of microbial levansucrases. Analysis was performed by the neighbour-joining method using the 
Jukes-Cantor protein distance measure. The number at the nodes indicates confidence bootstrap percentages of 500 repeats. 
Sequences are represented by the names of the organisms they derive from except for SAS-Ls. All sequences were obtained 
from the UniprotKB/Swiss-Prot. database and were validated. The accession numbers are as follow Bacillus subtilis (P05655), 
Gluconacetobacter diazotrophicus (Q43998), Pseudomonas syringae (Q88BN6), Rahnella aquatilis (O54435), Leuconostoc 
mesenteroides (Q5IS34), Lactobacillus reuteri (Q8GGV4), Lactobacillus sanfranciscensis (Q70XJ9), Zymomonas mobilis 
(Q60114). 
 
 Heterologous expression and purification of SAS-Ls 
 
 
Figure 5-2 SDS-PAGE protein profiles of fractions collected during the HIS-tag IMAC purification of the SAS-Ls protein. Lane (M) 
is protein MW ladder, lane (1) is Bl21 pLysS with the empty pRSET_A vector, lane (2) is the overnight expression by auto 
induction of the Hiss-SAS-Ls in Bl21-pLysS, and lane (3) is the purified proteins. 
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The SAS-Ls gene was heterologously expressed in Bl21(pLysS) according to the methods of Studier et al. 
(2014), as described in section 5.3.3 on p85 [243]. Copious amounts of protein was obtained, after 
inoculation from a frozen glycerol stock and overnight incubation, by means of catabolic suppression 
and auto-induction using lactose (which acts as an analogue of IPTG). The signal peptide was not 
removed but this showed no notable effect on cytosolic accumulation of recombinant protein as seen 
from the SDS-PAGE analysis (Figure 5-2). The histidine tagged polypeptide was purified by IMAC FPLC 
and eluted over an imidazole gradient. Fractions were tested for levansucrase activity by measuring the 
hydrolytic release of glucose from sucrose. A high purity level was achieved as was visualised by SDS 
PAGE analysis (Fig 5-2). The collected fractions were dialysed overnight in 0.1xTE buffer (10 mM Tris-
HCL pH 8.0, 1 mM EDTA) to rid the protein solution of imidazole. The protein was stored on ice at 4oC 
for further analysis and showed no loss of activity over a 14 day period on ice in the 4oC walk in room. 
 
 The effects of temperature and pH on SAS-Ls activity 
 
Levansucrase can catalyse two distinct reactions depending on the fructosyl acceptor, namely (i) 
hydrolysis when H2O is the acceptor and (ii), trans-fructosylation/polymerisation when any other 
reducing molecule, including fructose acts as an acceptor [155]. Levansucrase generally shows different 
temperature optima for the hydrolysis and trans-fructosylation reactions. For example, the protein from 
Pseudomonas syringae pv. phasiolicola demonstrates marked optima difference of 18oC and 60oC for 
hydrolysis and polymerization respectively [337]. On the other hand the levansucrase for Zymomonas 
mobilis, showed maximal polymerization at 30oC whilst the highest rate of hydrolysis was at 45-50oC 
[338]. In general, microbial levansucrases seems to exhibit optimum levan formation activity at lower 
temperatures, usually below 50oC (for review see [155]). This is also true for SAS-Ls where the rates of 
hydrolysis and trans-fructosylation are similar at temperatures lower than 20°C, being nearly identical 
at 10oC (Fig 5-3). Maximum hydrolytic activity for SAS-Ls was at 35oC after which a sharp decline in 
activity for both the hydrolytic and trans-fructosylation reactions was observed. Overall SAS-Ls activity 
exhibited a broad temperature range of 12-37oC where activity was above 50% of the maximum activity 
for both reactions, a property that would render it suitable for industrial applications (Table 5-2) [155]. 
With regards to pH, SAS-Ls also shows a broad reaction viability ranging from pH 3.7-6.0 where activity 
is above 50% of maximal for both the hydrolytic and trans-fructosylation reaction. This is similar for 
previously reported levansucrase whom all tend to be more active under acidic conditions than alkaline 
(Table 5-2). The hydrolytic reaction was greater than the trans-fructosylation one at all temperatures 
and pH’s. 
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Figure 5-3 The effect of temperature and pH on both the hydrolytic and trans-fructosylation reaction of SAS-Ls. The effect is 
expressed as a percentage relative to that of the maximal activity which was taken to be 100. 
 
 The effects of co-factors on SAS-Ls activity 
 
All co-factors were measured in conjunction with the controls of pure ddH2O or 10 mM EDTA solution. 
The effect of various co-factors were tested at final concentrations of 1 mM and 5 mM, for both the 
hydrolysis and trans-fructosylation reaction. The only metal ion to have an effect was Cu2+, which 
inhibited both reactions by more than 50% at a 1 mM concentration and more than 90% at a 5 mM 
concentration (Figure 5-4). A similar effect has also been reported for the levansucrases from 
Zymomonas mobilis and Bacillus subtilis [339, 340].  
Szwengiel et al. (2007) reported that the presence of Mn2+ increased the transferase activity of 
Bacillus subtilus levansucrase by 100% whilst lowering the hydrolytic reaction by 80% [163, 341]. Other 
compounds have also been shown to have a stimulatory effect on the activities of various levansucrases. 
Fe2+ had an 4 fold increase in both reactions on the thermostable Bacillus sp. TH4-2 [342], Co2+ has been 
shown to have a slight enhancing effect on the levansucrase of Gluconacetobacter diazotrophicus for 
both reactions [343]. Ca2+ has also been shown to play an important structural role in the levansucrases 
of both Lactobacillus reuteri and Bacillus subtilis [344, 345]. None however had any effect on SAS-Ls 
activity (Figure 5-4), which makes SAS-Ls rather unique in its co-factor independence. 
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Figure 5-4 The effects of the various co-factors on the hydrolytic and trans-fructosylation reaction of SAS-Ls. The influence of 
activity is expressed as a percentage relative to the activity in ddH2O with no added metals or salts, which was taken as a 100%. 
The influence of the co-factors on the trans-fructosylation reaction is statistically the same as that of the hydrolytic reaction 
(data not shown). 
 
 
 Reaction kinetics of SAS-Ls 
 
The initial reaction rates of both the hydrolytic and trans-fructosylation reactions were determined at 
35oC over a sucrose concentration range of 0−300 mM, where the enzyme behaviour adhered to 
Michaelis−Menten kinetics, as indicated by the linearity of the corresponding Lineweaver−Burk double 
reciprocal plots (Figure 5-5). The values of Km, Kcat, and the catalytic efficiency (Kcat/Km) were 
determined by linear regression of the Lineweaver-Burk plot as well as integrated non-linear regression 
using the GraphPad Prism software (Figure 5-5). The Km value for hydrolysis and trans-fructosylation 
were calculated as 61.07 ± 3.59 mM and 61.03 ± 4.49 mM, the Kcat’s were 7682 ± 190.2s-1 and 5587 ± 
173.1 s-1, and the catalytic efficiencies were 7.55 x106 M-1min-1 and 5.49 x106 mM-1min-1, respectively. 
Table 5-2 compares the catalytic characteristics of the other microbial levansucrases that have been 
characterised with that of SAS-Ls. Although SAS-Ls exhibits a relatively high Km compared with the other 
characterised levansucrases, it has an extremely high catalytic turnover which at 7682 s-1 is a 3.38 fold 
increase over that of the enzyme from Bacillus megatarum. In fact the catalytic efficiency of SAS-Ls 
(Kcat/Km) at 7.55 x106 M-1min-1, is only exceeded by that of Bacillus megatarum (5.93x107 M-1min-1) due 
to the lower Km of the B. megatarum levansucrase (2.3 mM compared to 61 mM of SAS-Ls). This, 
however is of little consequence as industrial application of levansucrases rarely occurs at such low 
concentrations [346].  
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Figure 5-5 The Michaelis Menten kinetic representation of the hydrolytic and trans-fructosylation reactions of SAS-Ls in 
µmole.mg-1.min-1 against the substrate concentration of sucrose (mM), together with the Lineweaver-Burk double reciprocal 
plot. 
 
Table 5-2 Summary of some of the more well known microbial levansucrases and their kinetic parameters, compared to that 
of SAS-Ls. 
Organism/source Accession number Km (mM) Kcat (s
-1) cat efficiency (Kcat/Km) M-1min-1 Vmax pH  Temp  Reference 
SAS-Ls NA 61.07 7682 7.55x106 151.3 4.5-6 25-35 This study 
Bacillus 
amyloliquefaciens NA 47.81 NA NA 10.8 6-6.2 25 [334, 347] 
Bacillus megatarum NA 2.3 2272 5.93x107 NA 6-7 45 [346] 
Bacillus subtilis  P05655 40 164.6 2.47x105 203 5.2-6 30 [161] 
G. diazotrophicus  Q43998 11.4 1 5.26x103 NA 5 30-40 [348] 
Lactobacillus panis NA 22.5 NA NA NA 4-4.6 45-50 [349] 
Leuconostoc 
mesenteroides Q5IS34 26.6 NA NA 126.6 6.2 28-30 [350] 
Pantoea agglomerans NA 28 NA NA NA 6 NA [351] 
Pseudomonas. 
savastanoi NA 160 NA NA 298 6.5 37-60 [337] 
Rahnella aquatilis  O54435 50 NA NA 731 4-6 55-60 [352] 
Zymomonas mobilis Q60114 40 461 6.92x105 NA 4-6 37-50 [353, 354]  
 
 
 NMR analysis and product characterisation 
 
To characterise the structure of the polymer/oligosaccharide, the 1H and 13C NMR spectrums were 
determined for the product of the overnight incubation of SAS-Ls with sucrose. As a positive control the 
commercially available levan from Z. mobilis was used (Fig 5-6). Table 5-3 summarises the main 
resonances of carbon signals (in ppm) and is compared to that of other previously characterised levans 
[160, 355-357]. The resonances for C1 (60.5), C2 (104.8), C3 (76.9), C4 (75.8), C5 (80.9) and C6 (64.04) 
(Fig 5-3) aligns with that of the levan of Z. mobilis as originally characterised and assigned by Han and 
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Clarke (1990) [358]. The large C2 resonance is indicative of a β-fructofuranose, and overall, the data 
strongly indicates that the SAS-Ls product is a levan with a [→6-β-D-Fruc-2→]n structure. The nearly 
identical peak pattern of the 1H spectra’s further acts as confirmation. 
 
Table 5-3 Chemical 13NMR shifts of microbial levans from various sources compared to the levan of SAS-Ls 
Carbon 
atom Chemical shifts of Levan 13C NMR ppm 
SAS-Ls P. Fluoresces [357] Z. Mobilis [357]  L. Reuteri [356] B. Subtilis [355] B. Polymyxa [355] 
C-1 60.54 60.428 60.761 61.4 60.1 60.7 
C-2 104.84 104.696 104.641 105.6 104.4 104.2 
C-3 76.92 76.77 77.683 77.8 76.5 77 
C-4 75.83 75.783 75.754 76.7 75.4 75.7 
C-5 80.93 80.88 80.783 81.7 80.5 80.5 
C-6 64.04 63.987 63.957 64.8 63.6 63.6 
 
 
Figure 5-6 The 13C and 1H spectra of the levan produced by SAS-Ls compared to that of the commercially available Zymomonas 
mobilis levan. As can be seen both spectra are nearly identical for both 13C and 1H. 
 
To estimate the average approximate chain length of the levan produced by SAS-Ls a reducing sugar 
assay was conducted on both hydrolysed and un-hydrolysed levan. This led to an estimation of the 
average chain length being 13.2 ± 3.2 which indicates that SAS-Ls produces fructo-oligosaccharides 
rather than longer chain polymers. This is in line with previous research which found that levans 
produced by enzymatic systems generally consists of 10-12 residues as compared to a whole cell system 
where the polymer can be comprised of several million residues [160, 359]. Furthermore Gram negative 
bacterial levansucrases have been associated with the production of levan type fructo-oligosaccharides 
Stellenbosch University  https://scholar.sun.ac.za
 98 
 
as compared to the Gram positive levansucrases which are more often found to synthesise higher DP 
levan [360]. Although both levan polymer and levan FOS demonstrate interesting properties, levan FOS 
are often preferred over a levan polymer, especially in regards to prebiotic dietary supplementation 
[157]. This has led to the design of bi-enzymatic systems which have both a levansucrase, and an endo-
levanase/inulase which generates FOS from the longer chain levan [169, 361]. A levansucrase from 
Zymomonas mobilis has been demonstrated to produce either levan polymer of FOS, depending on 
reaction conditions and, due to the similarity of that protein with SAS-Ls, it certainly warrants further 
investigation to see if the same is true for SAS-Ls [314] 
 
 Conclusion 
 
In this study a novel metagenome derived levansucrase (SAS-Ls) was successfully isolated, cloned, 
heterologously expressed and biochemically characterised. SAS-Ls has a high and desirable catalytic 
turnover making is an excellent candidate for industrial application. SAS-Ls was further shown to 
produce levan type fructo-oligosaccharides rather than longer chain levan polymer. Because of the low 
extraction yield of levan and FOS from natural sources, biocatalytic approaches based on 
trans-fructosylation is an attractive alternative for its synthesis. The SAS-Ls levansucrase could certainly 
aid in this regard. Future research and alternative applications of SAS-Ls and its enzymatic products will 
be further discussed in the final chapter.
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 General discussion and future prospects  
 
 The metagenomic approach 
 
 Origins and context of metagenomic analysis for novel product discovery 
 
It is perhaps prudent to give a brief contextualised review on the origins and evolution of the 
metagenomic concept, up until its application in functional screening, so as to aid in the discussion. 
Metagenomics has its roots in bacterial classification and description, and to a considerable extent this 
still contributes to the field of study today. For nearly 300 years the study of microorganisms were based 
primarily on morphological features as well as selective growth [362]. Woese et al. (1977) was the first 
to propose the use of ribosomal RNA gene sequences as a universal molecular marker for life’s 
classification [363]. In the very same year Sanger et al. (1977) first published his automated sequencing 
method. These two procedures, together with the development and controversial patenting of the PCR 
procedure by Kary Mullis in 1983, revolutionised the classification of microbial life in the coming years 
[364, 365]. All of this phylogenetic analysis were however conducted on a single species cultivation 
basis, making it difficult to study collective communities. In fact, based on real time microscopic cell 
counts in conjunction with 16s rRNA phylogenetic profiling, it was established that approx. 1% or less of 
all the microbial organisms can be recovered from soil samples through standard laboratory cultivation 
[366, 367]. Especially certain conglomerates of microbes such as those present in soil, have been shown 
to contain a collective gene pool of several thousand different microbial genomes per gram of soil [366, 
368, 369]. This represents a treasure trove of genetic material and logic dictates that scientist would 
haste in their endeavour to investigate such environments and the genetic data it contained, but for the 
pre-metagenomic era, this large gene pool was mostly inaccessible.  
In the quest to overcome this impediment, phylogenetic classification was the initial driving force, and 
in 1990 Giovannoni et al. described the first microbial community study by 16S rRNA analysis [370]. For 
about a decade though, albeit due to technical limitations, focus was lost on the rest of the metagenome 
as researchers zoomed in on phylogenetic markers and specific conserved genes of interest. Gradually, 
with the advances in molecular techniques especially with regards to cloning and heterologous gene 
expression, a window of opportunity was presented, for the attention to shift from the phylogenetic 
complexity to that of the functional complexity of the metagenome. By transposing these new 
techniques onto the microbial diversity interpretation, access was granted to this new ‘uncultured 
world’. This resulted in the emphasis shifting from classification to that of discovery, and in 1998 
Stellenbosch University  https://scholar.sun.ac.za
 100 
 
Handelsman et al. coined the term ‘metagenomic analysis’ describing it as the study of the collection of 
all the genomes of a microbial community from a specific environment, with the the focus on a new 
frontier for natural product discovery [371]. Products such as ‘terragines’ discovered from Streptomyces 
lividians in 2000, and other broad-spectrum antibiotics were all cloned from soil-DNA libraries, heralding 
in this new era of biotechnology [372, 373]. Since the early 2000s functional metagenomics progressed 
to its prominent role, all while co-evolving with other technological advances such as the sequencing 
revolution. These all present their own unique set of challenges, technical limitations and inherent 
biases necessitating the need for a tailored metagenomic approach for each individual case. It is in this 
context that the the novel products discovered through a functional metagenomic approach, as 
presented earlier in this dissertation, will be discussed. In general however, the metagenomic approach 
can be broken down into several strategic stages that is best summarised in Figure 6-1, and the 
construction and screening of the libraries generated in this dissertation will briefly be discussed as such. 
 
 
Figure 6-1 The five primary steps involved in the general metagenomic approach is presented in the grey central boxes. The 
blue peripheral call-out boxes represent key issues and decisions relevant to each of the central steps. Figure adapted from 
Kowalchuk et al. (2007) [374]. 
 
 Environmental sampling and diversity assessment 
 
With the environmental sampling, a multitude of factors will influence the eventual site chosen, all 
relating to the effect the environment exerts on the microbial community. The vast majority of our 
biosphere’s genetic and metabolic miscellany are contained within the microbial communities of the 
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world. These microbial groups colonise habitats that can be complex in nature (e.g. soils and 
sediments’ dregs), and also extreme in both location (e.g. deep see marine sulphur hot vents, arctic 
tundra, cavernous subterranean) and environmental parameters (e.g. temperature, pH, salinity, 
nutritional limitation, meteorological pressure). The physiological and genetic properties of the 
microorganisms that reside in these and other environments are habitually adapted to them. Complex 
and extreme environments often yield diverse and/or extreme enzymes [375, 376].  
It therefore makes sense, that in consideration of the appropriate sampling site, these environmental 
parameters be of paramount importance to the decision making, as it can be crucial to the success when 
conducting the metagenomic screening for specific enzymes (Figure 6-1) [377]. To this extent the 
Hotwood, SASRI and Gansbay represents environments that at least temporarily are exposed to high 
temperatures. The interest in high temperature tolerant biocatalyst relates to the linear relationship 
between substrate concentration and enzymatic competence for oligosaccharide and/or polymer 
formation, and the fact that the substrates (i.e. lactose and sucrose) have higher saturation levels at 
higher temperatures. None of the enzymes isolated and characterised were however thermophilic in 
nature, but had high activity in the upper mesophilic range. 
The foremost selection parameter in choosing the sampling sites were however that of substrate 
availability. Genomic diverse environments such as soil and sediment, owe their microbial diversity to 
the heterogenous nature of the biotic and abiotic factors. Samples for metagenomic environments are 
often collected from natural environments as was the case for the Gansbay library, and to a certain 
extent the milk-soil library (MS) as well. Often environments are pre-treated prior to sampling, but this 
can have a significant outcome on the metagenomic DNA isolated. Spiking with certain substrates can 
confer growth benefits to certain microbial species which share certain physiological traits. Care should 
be taken though as this can severely reduce the microbial diversity in this quid pro quo approach. This 
is also the case for where natural enrichment (high galactose content of degrading kelp) of the 
environmental sample might have occurred, or where anthropogenic factors (milk leakage) influenced 
microbial diversity as was the case for Gansbay and MS libraries respectively [378, 379]. Both the 
Hotwood (saw mill run-off) and SASRI libraries (sugarcane refinery run-off) represents artificial 
environments that were enriched to the extreme for their respective substrates.  
None of the libraries were analysed for their microbial diversity, to a certain extent this was due to to 
time and cost constraints, but also by reason of the fact that the microbial diversity is more or less 
expected to be restricted as a consequence of the enriched environments as discussed above. This hold 
true to a lesser extent for the Gansbay and MS libraries. Non the less, a reduced microbial diversity 
could not be interpreted as a qualitative qualifier for the constructed libraries. Microbial 16S rRNA 
diversity analysis would however have been insightful from a phylogenetic perspective so as to 
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recognize the dominant species, as this might be relevant to the search for the novel catalyst but this 
information can be ascertained to a limited, albeit skewed, extent from the in silico analysis of the 
isolated positive clones itself.  
Instead of targeting certain specialised and enriched environments, enzyme activities may also be found 
in atypical environments. Against expectancy, enzymes don’t necessarily share similar physiological 
properties with the habitat from which they originate from. One example is the interesting discovery of 
two novel amylases from a acid mine drainage site, which shared no homology to any of the known 
sequences on public databases [375]. It is for this very reason that the libraries were cross screened on 
the different media containing either lactose or sucrose, and indeed β-galactosidases were isolated 
from the SASRI library but this in all probability relates to the ubiquitous nature of the β-galactosidase 
gene.  
 
 Metagenomic DNA isolation and preparation 
 
The outcome of any metagenomic library is first and foremost dependent on the quality of the nucleic 
acids isolated. The nucleic acids should be suitable for downstream molecular procedures and 
applications including enzymatic action, cloning, transformation, hybridisation and direct sequencing. 
Nucleic acids purified are qualified on three basic characteristics namely, (i) purity and the absence of 
sample site contaminants, (ii) fragment size and degree of shearing, and (iii) and concentration. 
Particularly DNA isolated from soil are known to be severely contaminated by humic impurities that 
harshly impede molecular biological applications [380]. 
Numerous protocols exist for the extraction of metagenomic DNA, and various commercial products are 
available. The nature of the sample can however differ greatly and no one solution will fit all. Water 
samples can be filtered through various membranes so as to concentrate the sample before nucleic acid 
extraction. Generally two approaches are taken with regard to solid samples namely, (i) direct lysis, or 
(ii) the preceding separation of matrix adherent cells. Separation of the cells from the matrix is achieved 
through either mechanical or chemical treatment, thereby releasing the microbial cells from the 
particles before being concentrated by various means. Direct lysis extract all the nucleic acid from all 
the biological material within the sample, whereas separation techniques only lyse cells that were 
separated and concentrated [381, 382]. Comparatively and generally, direct lysis yields between 10-100 
times more nucleic acid, but the co-extraction of extra-cellular DNA as well as DNA from degrading plant 
material and such, probably contribute to this significantly. On a diversity level no real differences were 
observed between the two general approaches [383, 384].  
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The actual lysis of the cells can be accomplished through mechanical shearing, chemical disruption or 
enzymatic release. In this dissertation the protocol developed simultaneously took care of ridding the 
extracted DNA of high molecular weight polysaccharide contaminants, as well as preventing any 
enzymatic degradation. The protocol is based on the direct lysis method and contains the chaotropic 
salt guanidinium hydrochloride, as well as various other chemical agents that bind and inhibit 
contaminants and nucleases [237, 238]. The protocol proved to be universal for all three environmental 
samples from which metagenomic DNA was extracted and copious amounts of clean, intact and high 
quality DNA were obtained for all sites sampled. 
 
 The construction of the metagenomic libraries 
 
Depending on the fragmentation size of the isolated metagenomic DNA, it can be cloned into either 
plasmid based vectors (< 15 kb), fosmids (up to 50 kb), or bacterial artificial chromosomes (BACs; up to 
200 kb). If smaller fragments are desired, various means exist to reduce them to size such as ultrasonic 
fragmentation, Hamilton syringe treatment, or enzymatic digestion which can yield compatible ends for 
cloning, as was done in this dissertation. The latter has the added advantage that it negates the potential 
need for blunting and adaptor ligation, thereby avoiding further induced biases through additional 
ligation and cloning.  
The various insert-size libraries each have their own advantages and limitations. Generally though, 
smaller size plasmid based libraries focuses on the expression of single genes in a size range of 
1 kb - 3 kb. Plasmid based libraries have the added advantage of being high-copy number and usually 
contain strong promoters (e.g. T7), thereby making the detection of under-active enzymes more likely. 
In contrast, large-inset libraries usually rely on the expression of many genes and operons that are 
driven by their own native promoters located on the library insert itself. Often these insert derived 
promoters aren’t active with the cloning host’s transcriptional machinery. The F’ based E. coli origin of 
replication employed in many of these large insert vectors maintains a single copy thereby making the 
detection of toxic genes more achievable [385-387]. It also makes the upkeep of such a large DNA insert 
within the host cell more probable. Mechanisms to selectively Induce multi-copy numbers (approx. 100 
copies per cell) through the employ of the OriV multiple origins, by TrfA (trans-replication protein) 
induction, are employed by several library systems [388]. This enables higher DNA recovery yields for 
downstream purposes, as well as enhance detection of the positive phenotype once stable growth of 
the host cells is achieved [377].  
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Several of the library systems, whether it be small or large insert based, contain cos-sites for the 
packaging of the ligated DNA into ʎ-bacteriophage heads. These phage based vectors can enter the host 
cell much more readily than naked DNA, particularly the larger vectors. There are several advantages to 
employing phage based libraries. For the smaller insert size M13 bacteriophage based libraries, storage 
and handling are considerably improved, as the packaged DNA can be maintained almost indefinitely in 
its protective capsids and the initial amplified library often yields adequate amounts of library phage 
making sharing amongst scientist more feasible. Moreover, most small insert size M13 based library 
systems like the ʎ-ZAP library system employed in this study, enables the easy conversion from the 
phage vector to that of a plasmid (pBK-CMV) through in vivo excision, thereby providing it all the 
benefits of plasmid based screening as discussed above. Furthermore, ʎ-based vectors enables the use 
of other molecular techniques, like single strand DNA recovery and hybridisation studies, more 
practical [236].  
The main objective of this project was to discover novel enzymatic biocatalyst that could have 
application in the industrial production of prebiotic oligosaccharides and polymers through a 
metagenomic approach. It therefore makes sense that these biocatalyst should have a reduced 
transcriptional footprint so as to incur a minimalist burden on the host cell for its heterologous 
production. This can be achieved through having a higher catalytic efficiency, increased durability, being 
smaller in size, or a combination of all. More often than not, the more robust and stable industrial 
biocatalyst are also smaller in size [389]. In this regard, the smaller insert size M13 based ʎ-ZAP library 
construction mechanism is the perfect choice to achieve the main objective. 
 
 Approaches toward metagenomic bioprospecting 
 
By far the most frequent application of metagenomics is the quest for novel biocatalyst. This can be 
accomplished through either function-based and/or sequence-based screening techniques. Both 
approaches have their advantages, as well as shortcomings. In general, functional screening has the 
potential to identify novel enzymes based on functionality that share no homology to already known 
and characterised protein sequences that are available on the public databases. In contrast to the before 
mentioned, sequence based screening generates huge amounts of data through next generation 
sequencing platforms, and find potential positives based primarily on the homology to conserved 
sequences and domains. It therefore identifies new variants of already known enzyme families, but 
often fails to identify really novel gene sequences as they aren’t related to known sequences, as is the 
case for functional screening [390, 391]. A prudent and recent example of functional vs. sequence based 
screening, was the discovery and biochemical characterisation of three novel β-galactosidases by 
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Cheng et al. (2017) from a soil metagenomic library. Although two of the sequences contained 
conserved domains, none showed any homology to the known glycoside hydrolase families and their 
ORFs and functional assignment could not be identified through standard bioinformatic analysis [392].  
Never the less, sequence based screening has the potential to overcome many of the inherent biases 
related to library construction as well as the problems associated with heterologous gene expression, 
all of which are preconditions for functional screening of metagenomic libraries [233]. A sequenced 
based approach to metagenomic screening can also be advantageous in that the phylogenetic data will 
be readily available for profiling of the microbial community, should such a need exist. Furthermore the 
time consuming procedures of DNA manipulation, cloning, transformation and library maintenance can 
be circumvented. However, for the functional genes to be identified the de novo sequence data firsts 
needs to be assembled, and for huge data sets to be adequately assembled sufficient coverage needs 
to be achieved. To this extent the processing and meaningful interpretation of the metagenomic 
sequence data obtained, still remains the biggest challenge and bottleneck in a sequence based 
screening approach. In general two self-explanatory types of assembly methods are employed, namely 
reference based assembly and de novo assembly [393]. In seeing the high diversity often associated with 
microbial communities such as soil, the latter is most often employed in metagenomic analysis. After 
the initial assembly, downstream in silico analysis involves ORF prediction and functional assignment. 
To assign the most probable functions, expert-curated databases like SWISS-PROT, Pfam, TIGRFAMs, as 
well as integrated databases like the non-redundant NCBI, UniProt and InterPro are accessible [294, 
394-398]. Other databases are based on the phylogenetic classification of proteins by Clusters of 
Orthologous Groups (COG), or by Gene Ontology (GO), or by mapping enzymatic function to biochemical 
pathways using the Kyoto Encyclopaedia of Genes and Genomes (KEGG) [399-401]. Furthermore 
comprehensive databases with detailed information regarding the different enzymes and their 
respective families, like BRENDA and CAZy are also available [325, 402].  
In contrast to sequence based screening, functional metagenomic screening relies on the successful 
heterologous expression of the gene products in the host organism, which is usually E.coli. Three broad 
differential functional screens can be distinguished namely, (i) phenotypic detection which is based on 
the actual enzyme activities that are detected by indicator agents, (ii) modulated detection which 
involves heterologous complementation that allows the metagenomic clones to grow under selective 
conditions, e.g. defined selective media. And lastly (iii), induced gene expression detection which 
involved substrate or product induction of reporter genes within the expression host. The functional 
screening approach employed in this dissertation was a combination of the first two, i.e. phenotypic 
and modulated detection. For the screening of β-galactosidase and thus potentially 
trans-galactosylation activity, the relative cheap and convenient indicator substrate 5-bromo-4-chloro-
3-indolyl-β-D-galactopyranoside (x-gal) was used. This screening method could only be employed once 
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all of the endogenous β-galactosidase background activity was removed from the screening host 
through recombineering. By further employing a combinational screen through an added modulated 
approach, i.e. screening on minimal media with distinctive carbon sources, a very selective and effective 
screening system was developed. The effectiveness of a functional screen lies predominately in its 
design and is extensively reviewed in the Taupp et al. article titled ‘The art and design of functional 
metagenomic screens’ [377]. Because of the effectiveness of the screen design, and the data analysis 
challenges associated with a purely sequence based screening approach, it was decided to employ a 
functional screen for the experimental section of this dissertation. However, due to the ever 
advancement of data analysis platforms and methodologies, and the still falling cost of next generation 
sequencing, for future purposes a dual approach might very well be employed.  
 
 Enzymatic production of prebiotic galacto-and fructo-oligosaccharides  
 
 The bifidogenic effect and prebiotic relevance of enzymatically produced oligosaccharides 
 
To a large extent, there is still a dominant belief that even though dietary intake my modulate certain 
metabolic activities associated with the intestinal microbiota, changing one’s diet has little effect on the 
overall composition of the microbial community of the GI tract [403]. Over the last decade however 
compelling research has begun to dispel this inexactness to the contrary. Increasingly it is being 
recognised that even small changes to the diet can have a significant influence on the relative species 
composition and physiological traits of the GI microbiota, and thereby greatly effect the health of the 
human host [21]. The impact of dysbiosis of the GI tract, as well as its remediation through pre-, pro-, 
and synbiotics were extensively reviewed in chapter 2 section 2.4 -2.5 on pages 10 - 17.  
Also in chapter 2, the prebiotic effect was defined as the particular stimulation of growth and/or 
activities of a selective number of microbial species of the gut microbiota that confer a health benefit 
to the host other than nutritional value [266]. The three key characteristics of a good prebiotic are: (i) 
that it is non-digestible by the human host, (ii) that it is selectively fermented by a key set of resident 
species of the GI microbiota, and (iii) that this consequently results in the targeted increase of the 
specific bacteria, which then subsequently through various means effect a health benefit on the 
host [21]. Its is in the beforementioned context that the the novel biocatalyst and their respective 
oligosaccharide products, described in this dissertation in chapters 4 and 5, must be interpreted. 
Prebiotics are dietary derived carbohydrates and the two major carbohydrate groups that satisfy the 
criteria described in the preceding paragraph, are fructans and galactans e.g. FOS and GOS 
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(for review see chapter 2). Inulin type fructans with β-2,1 linkages and a terminal α-linked glucose are 
either extracted from plants or synthesised enzymatically from sucrose, and have been shown in 
numerous studies to promote the prebiotic ‘bifidogenic’ effect (for review see Shoaib et al. 2016) [148]. 
Increasingly β-2,6 levan type FOS are being touted as an proper prebiotic source. This is apart from all 
its other biomedical, pharmaceutical and food science related applications [157]. Several studies have 
shown that levan and levan type FOS, selectively and more specifically stimulate bifidobacteria growth 
than even inulin on occasion, and thus rightfully act as a prebiotic substrate on its own [144, 157, 404]. 
Contrary to FOS, prebiotic GOS are galactose containing oligosaccharides with a terminal β-linked 
glucose monomer. The disaccharide lactose occurs almost exclusively in the milk of Mammals [182, 
405]. Commercial lactose derivatives include GOS, lactitol, lactulose and lactosucrose [138, 297]. The 
GOS that are commercially derived from lactose by the enzymatic action of glycoside hydrolases, are 
colloquially revered to as β-GOS. These β-GOS differ their stereo- and regio-chemistry from the plant 
derived galacto-oligosaccharides/polymers, most commonly found in beans and pulses and which 
contain α-linked galactose and glucose moieties and can furthermore be terminally β-linked to a 
fructose monomer (e.g. raffinose, stachyose and verbascose) [406]. Due to this diversity in linkage of 
the plant derived GOS, they can be fermented by any bacteria that contain the enzymatic machinery for 
these bonds, thus explaining the reported observation that plant GOS is less selective in its 
bifidobacteria growth stimulation than lactose derived β-GOS [407]. Prebiotic GOS research therefore 
increasingly focuses, much like that of FOS, on the enzymatic production rather than extraction from 
natural sources, due to its specificity in the promotion of bifidobacteria and other key probiotic bacterial 
growth [406].  
The developmentary origins for commercially derived β-GOS was modelled on human milk 
oligosaccharides (HMO). Breastfed infants have been shown to have an intestinal microbiota that is 
dominated by bifidobacteria, whereas non-breastfed infants contains less bifidobacteria and greater 
numbers of potentially harmful bacteria like clostridia and enterococci [408, 409]. Infants who are fed 
powdered milk, have also been shown to display elevated levels of detrimental constituents like 
ammonia, amines and phenols. [410]. Based on the analysis of human milk and its high concentration 
of galactose, Boehm et al. (2002) developed a prebiotic mixture to be added to cows milk, consisting of 
10% FOS and 90% GOS, so as to simulate human milk for the use in infant formula. When this formula 
was fed to term and pre-term infants, it ultimately led to an increase in intestinal bifidobacteria and 
lactobacilli which more resembled the composition of microbiota in breastfed infants  [411, 412]. HMOs 
contain lactose at their reducing end, much like many of the enzymatically derived β-GOS. Furthermore, 
HMOs can also be fucosylated and/or sialylated with α-linkages [413]. Ultimately, when taking into 
consideration monomer composition, linkage types and degree of polymerisation, more than 1000 
structures for HMOs exist, this however varies among individuals and is related to the maternal Lewis 
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blood type [413]. The quest to imitate HMO is a considerable driving force for the enzymatic production 
of GOS and novel oligosaccharides, creating a demand for an increased repertoire of regio and stereo 
specific linkages. This has led to the discovery of various catalytic sources for the production of different 
types of GOS, as well as different types hetero-oligosaccharides produced by glycosides hydrolases 
utilising lactose and other compounds as either glycosyl substrate or donor, as is discussed in sections 
6.2.2 and 6.2.3 below. 
In infants HMOs are specifically metabolised by Bifidobacterium longum ssp. infantis, however their 
benefit to health is not limited to the bifidogenic effect and include numerous other effects (for 
extensive review see Chapter 2), including the prevention of pathogen adhesion. So too does β-GOS 
resemble cell surface glycoconjugate receptor structures used by pathogens for adherence in GI 
tract [414]. The bifidogenic effect in itself is also not restricted to infants, as evidence suggest that 
Bifidobacterium adolescentis and Bifidobacterium longum predominate in most adults, whereas 
Bifidobacterium  breve and Bifidobacterium infantis are the main species colonising the infant GI tract. 
[415]. There is also an age related observational decline in the bifidobacteria and lactobacilli content of 
the GI tract in the elderly [416] There are numerous feeding studies that show that bifidobacteria, as 
well as lactobacilli numbers can be increased by FOS and GOS supplementation [151, 417-419]. It is 
bifidobacteria and lactobacilli that play an important role in the eco-physiology of the GI microbiota and 
it is these bacteria specifically that has been associated with a healthy microbiota and the prevention of 
dysbiosis. Some bifidobacteria and many lactobacilli manifest strong anti-mutagenic and anti-tumour 
properties, and at least in animal models have prophylactic and therapeutic benefits [420]. Some strain 
of bifidobacteria also produce large amounts of folate, nicotinic acid, thiamine, pyridoxine and 
vitamin B12 [90]. 
But why the metabolic propensity of bifidobacteria and lactobacilli towards GOS and FOS? Due to their 
β-glycosidic bonds, GOS and FOS are neither hydrolysed nor absorbed in the acidic upper GI tract, and 
thus travel to the large intestine where they ca be fermented [117]. Bacteria have different specificity 
for the prebiotics they can utilise. Gene clusters within their genomes dictate which saccharolytic 
machinery they posses and ultimately which prebiotic metabolites they can metabolise and to which 
extent. Genetic mechanisms for β-GOS specificity have been identified within bifidobacteria. They 
express higher activity for β-galactosidase and they often contain multiple isoforms of the enzyme, all 
of which explain why they show such a preference for β-GOS [421]. A study by Vulevic et al. (2009) 
which assayed 1% (w/v) culture additions of various prebiotic substrates, showed that enzymatically 
derived β-GOS in specific, increased the growth rates of Bifidobacterium spp but not other bacteria 
[407]. An additional possible explanation for this could be that some bifidobacteria at least, including 
Bifidobacterium adolescentis, have no transmembrane domains on some of their β-galactosidases and 
evidence suggest that they internalise oligosaccharides prior to digestion, thereby preventing the 
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scavenging of GOS by other bacteria. Furthermore, in vitro studies suggests that certain bifidobacteria 
preferentially utilise oligosaccharides and disaccharides before glucose in mixed cultures [422]. A 
randomised cross-over controlled study in 59 healthy volunteers showed that either one of two 
different types of enzymatically derived β-GOS preparations, had a significant bifidogenic effect at seven 
gram a day supplementation [423]. So too did a recent study by Hamdy et al. (2017) show that the levan 
produced by levansucrases from bacteria isolated from honey and bee gut, to possess a significant 
prebiotic effect and in specific promoted the growth of Lactobacillus casei and Lactobacillus reuteri 
[424]. Regardless of the exact mechanisms, it is these bacterial populations of bifidobacteria, lactobacilli 
and a few other species, that benefit most from GOS and FOS supplementation and ultimately account 
for this prebiotic aka ‘bifidogenic’ effect. Due to these properties of GOS and FOS as active ingredients 
in functional foods and as HMOS substitutes, the prebiotic market is rapidly expanding. In view of the 
above mentioned, in conjunction with the reasons provided  in the review chapter 2, the isolation and 
characterisation of the MS-βgluc1,  HW-βgal1, and SAS-Ls genes and their translational protein products 
as well as their respective GOS and β-2,6 type FOS preparations, have the potential to significantly 
contribute towards the field of enzymatic production of prebiotic fibres.  
 
 Composition of the GOS synthesised by β-galactosidases and β-glucosidases 
 
Commercial preparations of GOS utilises the β-galactosidases from Kluyveromyces lactis, Bacillus 
circulans (Vivinal GOS), Bifidobacterium bifidum (Bimuno), Aspergillus oryzae and Streptococcus 
thermophilus (oligomate55) [117]. These preparations differ in their substrate specificities and the 
range of compositional GOS they produce. In all of these commercial preparations, the residual lactose 
together with the GOS that range in DP2 to DP4, constitute approx. 90% of the total solids [273]. The 
glycosyl hydrolase family 2 type β-galactosidases produce mainly β-1,6 linked GOS with 
6’-galactosyl-lactose being the major trisaccharide produced. This is exactly as was established for the 
major GOS constituent of the preparation by the GH2 HW-βgal1 characterised in this dissertation, and 
is in line with current research for other characterised β-galactosidases most notably that of Aspergillus 
oryzae, Aspergillus aculeatus, Kluyveromyces lactis, Bifidobacterium breve, Lactobacillus sakei, 
Lactobacillus reuteri and Lactobacillus plantarum [425]. Even though these β-galactosidases have been 
shown to synthesise β-1,4 and β-1,3 linkages, this is to a much lesser degree and only A. oryzae really 
does so to any real significant extent (approx. 5% total) [190]. Originally the bifidogenic effect was 
attributed to mostly β-1,6 linkage type and more specifically the trisaccharide 6’-galactosyl-lactose 
[118]. However the bifidogenic effect for β-1,3 linkage type has also been proven since, but few true 
sources exist for it in view of the dominance of the β-1,6 and to a much lesser extent the β-1,4 linkage 
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types most commonly produced by GH2 β-galactosidases [120, 223, 230]. It is here that the GOS 
synthesised by β-glucosidases rather than β-galactosidases can contribute significantly in that they 
appear to favour the formation of GOS with linkages other than the predominant β-1,6. In a study by 
Hassan et al. (2015) a thermostable β-glucosidase from Halothermothrix orenii produced a similar GOS 
profile in its equal distribution of 6’-galactosyl-lactose and 3’-galactosyl-lactose as did MS-βgluc1 
described in Chapter 4 [280]. In fact the recent literature shows that more and more research is being 
focussed on GOS production by means of β-glucosidases [426-428]. Several reasons for this abide but 
most notable is that unlike GH2 β-galactosidases, β-glucosidases which are predominantly from the GH1 
family are much smaller (avg. 50 kDa) in size and monomeric in nature. Furthermore, the stable 
(α/β)8-barrel which accounts for the functional catalytic site of β-glucosidases is located to a single 
polypeptide chain, as apposed to the complex tetrameric active site associated with GH2 
β-galactosidases. This simplicity of β-glucosidases makes their protein production easier and less costly. 
It also lends them to mutational improvement and has provided much insight in to the catalytic 
mechanisms of trans-galactosylation. Recently, Yang et al. (2017) created seven mutant variant of the 
Thermotoga naphthophila β-glucosidase resulting in a 350 fold decrease in the hydrolytic reaction in 
the F414S variant which ultimately increased the GOS yield by 50% [428]. Also recently, another 
β-glucosidase was isolated and characterised from T. naphthophila. What is remarkable from this 
catalyst is that it exclusively synthesise a yet uncharacterised trisaccharide GOS [427]. This β-glucosidase 
has a deep catalytic pocket that prevents simultaneous access of both lactose and another trisaccharide 
to the catalytic site, accounting for its distinct catalytic specificity. Thus far all reported GOS preparations 
are mixed populations of different DPs and linkages, and this is the first time that such specificity has 
been shown. The production of homogenous oligosaccharide preparations have the potential to 
significantly reduce downstream purification cost and also provide insight into the the finer details of 
GOS synthesis. In all, future production of GOS might be more inclined to the exploitation of 
β-glucosidases, rather than the classical β-galactosidase models and further study of the MS-βgluc1 
characterised in this dissertation, including it’s potential mutational analysis, could significantly 
contribute to this field.  
 
 Hetero-oligosaccharides synthesised by glycoside hydrolases 
 
As stated above, the initial drive to imitate HMOs led to innovative means in the production of various 
hetero-oligosaccharides. Two distinct types of hetero-oligosaccharides can be produced utilising lactose 
and other substrates; namely the ones synthesised by β-Gals and β-Glucs with lactose as galactosyl 
donor, and the ones synthesised with the aid of various glycoside hydrolases where lactose act as an 
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acceptor. In general the specificity of β-galactosidases and indeed some fructosyl-transferases like 
levansucrase are low with respect to the acceptor molecule. Therefore, various sugars can 
interchangeably act as acceptor to the trans-glycosylation reaction, enabling the synthesis of unique 
hetero-oligosaccharides [155, 275, 297]. It is also not only carbohydrates that can act as acceptor, but 
other hydroxyl containing compounds like alcohols as well [429]. This opens up many possibilities for 
the production of various compounds and in this regards MS-βgluc1, HW-βgal1 and SAS-Ls should be 
targeted in future research for possible application. When these type of reactions occur with sucrose 
and lactose in the reaction medium, and depending on the glycoside hydrolase/s present, the reaction 
medium will contain a combination of the the hydrolytic products (i.e. glucose, galactose, fructose), 
GOS/FOS, as well as these other compounds of interest. Thus far, three valuable hetero-oligosaccharide 
compounds have been obtained by utilising this enzymatic strategy namely, lactulose, lactosucrose and 
lactitol. 
Lactulose (Gal-β-1,4-Fruc), can be produced either enzymatically, or through chemical isomerisation. Its 
main application is the treatment of hepatic encephalopathy, and also as a prebiotic source [24]. 
Lactulose actively reduces the ammonia levels in the blood resulting from decreased liver function by 
being a preferred fermentation substrate over that of proteins, resulting in less ammonia being 
produced by the GI microbiota which can ultimately ‘fog’ cognitive function [430]. In the process of 
lactulose synthesis the trans-galactosylation of residual glucose produced by the hydrolysis of lactose 
also occurs, thereby co-generating allolactose (Gal-β-1,6-Glc) in the reaction medium [431]. The yield of 
the lactulose is ultimately dependant on the ratio of lactose : fructose [432]. Both lactulose and 
allolactose can also act as galactosyl acceptor thereby yielding fructosyl-GOS, most commonly 
β-Gal-1,6-lactulose/allolactose or β-Gal-1,4-lactulose/allolactose [275]. The trans-glycosylation reaction 
of the hetero-oligosaccharides are still related to the original enzymatic source, and in this regard the 
investigation into whether the β-glucosidase MS-βgluc1 could potentially produce Gal-β-1,3 linkage 
types for hetero-oligosaccharides as it did for its initial GOS production, could be of significance in the 
production of rare β-1,3 compounds. Currently lactulose is produced exclusively through chemical 
catalysis, due to the fact that its enzymatic production yields heterologous mixtures of different 
oligosaccharides that is difficult to purify. The enzymatic route is however a good green chemistry 
option that is increasingly gaining favour. Furthermore,  through mutational engineering the possibility 
exist for creating catalyst that is specific in their substrate formation e.g. lactulose, as was described for 
the β-glucosidase from T. naphthophila in section 6.2.2 which would then ultimately simplify 
purification. 
Lactosucrose (β-Gal-1,4-sucrose) is a very rare trisaccharide that scarcely exist in nature and is difficult 
to chemically synthesize. It has been shown to possess a significant bifidogenic effect and also inhibit 
Clostridium difficile growth [124]. Furthermore, it is exceptionally good at promoting mineral absorption 
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and the administration of lactosucrose has been shown to have the long term effect of enhancing 
intestinal calcium retention and absorption and reducing bone resorption in healthy young women 
[433]. There are reports of it having the beneficial effect of inhibiting fat accumulation and thereby 
preventing obesity, and in mice it has been shown to reduce serum cholesterol levels [47, 197]. In 
addition, lactosucrose is an outstanding excipient for spray dried powders and shows promising results 
in the protein stabilisation of IgG and could therefore potentially be utilised as an amorphous powder 
for inhalation drug delivery [434]. Lactosucrose can be produced either through the trans-fructosylation 
of lactose by β-fructofuranosidase and levansucrase, or through the trans-galactosylation of sucrose by 
β-galactosidase and β-glucosidase. All of MS-βgluc1, HW-βgal1 and SAS-Ls could potentially contribute 
in the synthesis of lactosucrose and further research in this regard is warranted.  
Klewicki et al. studied the the trans-galactosylation of several polyhydroxy-alcohols most notably 
sorbitol, xylitol, lactitol and erythritol [435]. During these enzymatic processes GOS were co-synthesised 
and the production of galactosyl-sorbitol was of special interest because it is an epimer of lactitol 
(4-O-α-D-galactopyranosyl-D-sorbitol) [436]. Lactitol is an artificial synthetic sugar produced from 
lactose by the catalytic hydrogenation of the glucose moiety in the disaccharide [437]. Lactitol has been 
reported to have excellent prebiotic properties. Furthermore, it is purported to have special synbiotic 
efficacy by increasing the viability of several probiotic strains [438]. It is also a low calorific sweetener 
with use as a substitute for sucrose in the food industry [272]. 
Galactosidases, sialidases, glucansucrases, fructansucrases, α-fucosidases and N-acetyl-
glucosaminidases are all retaining glycoside hydrolases with trans-glycosylation activity. They all have 
the ability to transfer their corresponding sugar moieties to acceptor sugars such as lactose and sucrose, 
to generate a multitude of hetero-oligosaccharides, which ultimately include several fundamental 
structures of human milk oligosaccharides. Here special reference was given to the 
hetero-oligosaccharide production by β-glucosidases, β-galactosidases and levansucrases, in seeing 
their relevance in this dissertation. The high added value products that can potentially be obtained by 
the application of MS-βgluc1, HW-βgal1 and SAS-Ls, other than the obvious GOS and FOS production, 
adds even more worth to these enzymatic catalyst. It is a great incentive for continual research into 
these three  specific enzymes.  
 
 Summary and concluding remarks 
 
It is well known that the disaccharides lactose (O-β-D-galactopyranosyl-1,4-D-glucopyranose) and 
sucrose (O-α-D-glucopyranosyl-1,2-β-D-fructofuranoside) are two of the most common and cheapest 
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substrates available. Several million tons of whey derived lactose are produced annually as a by product 
in the cheese manufacturing industry. The disposal of industrial whey is a never-ending environmental 
problem with no real green solution in sight. Sucrose is an ubiquitous sweetener in the food industry 
and has a multi-billion dollar footprint. It is produced globally in the tropical and subtropical regions; 
areas which are often associated with poverty and being heavy reliant on the sugarcane industry. 
Increasingly though the excess consumption of sucrose, especially its high fructose corn syrup 
derivative, are being linked with a multitude of negative health associated risk including the current 
obesity epidemic and type II diabetes. This has led to a gradual global decline in the sugar industry, and 
alternate uses are actively being sought. To the contrary and ironically, the prebiotic oligosaccharides 
GOS and FOS which are enzymatically derived from lactose and sucrose, are associated with a multitude 
of health related benefits and are actively being promoted as functional food ingredients in an attempt 
to address these very concerns currently facing the global population. The utilisation of both lactose 
and sucrose to produce functional derivatives especially GOS and FOS, therefore presents not only an 
economical viable model but also addresses the environmental aspects and the quest for alternate uses 
of these substrates. 
In CHAPTER 3:  the construction and functional screening of several metagenomic libraries were 
presented. A collection of these libraries were screened on minimal media containing lactose in a 
specially constructed β-galactosidase deletion mutant, for the presence of lactose hydrolysing and 
trans-galactosylation enzymatic catalyst. A library was also constructed from runoff collected at a 
sugarcane refinery, and screened for the presence of trans-fructosylation enzymatic catalyst, on 
minimal media plates containing sucrose as the sole carbon source. In all, 17 putative glycoside 
hydrolase genes, from various families, were isolated, in silico characterised, and preliminarily analysed 
for their oligosaccharide/polymer producing capabilities (Table 3-3, section 3.3.2). Eventually three 
candidates genes were selected for further and more detailed analysis, which were then researched in 
the following two chapters.  
In CHAPTER 4: the two genes encoding for the novel glycoside hydrolases named MS-βgluc1 and 
HW-βgal1, belonging to Glycoside Hydrolases family 1 and 2 respectively, were cloned, heterologously 
expressed and biochemically characterised together with their respective end products. MS-βgluc1 had 
a Km of 41 mM, a Kcat turnover of 111 s-1 and a catalytic efficiency of 2.7 mM-1.s-1 for the substrate 
lactose at its optimum pH 6 and temperature of 45oC. The second enzyme, HW-βgal1 had a Km of 32 mM, 
a Kcat turnover of 625 s-1 and a catalytic efficiency of 19.5 mM-1.s-1 for the substrate lactose at its optimal 
pH 7.5 and temperature of 35oC. Both proteins were shown to have high trans-galactosylation activity 
with HW-βgal1 yielding approximately 43% galacto-oligosaccharides (GOS), mainly consisting of 
tri-saccharides of the β-1,6-galactosyl-lactose type. MS-βgluc1 yielded approximately 40% GOS, 
consisting of a combination of the trisaccharides β-1,3-galactosyl-lactose and β-1,6-galactosyl-lactose. 
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Both enzymatic catalyst have industrial relevance and especially the β-glucosidase has the potential for 
the synthesis of more novel and rare β-1,3 linked GOS and other hetero-oligosaccharides. 
In CHAPTER 5:, a novel gene encoding for a Glycoside Hydrolase Family 68 levansucrase, SAS-Ls, was 
cloned, heterologously expressed and biochemically characterised together with its reaction 
end-product. SAS-Ls had a Km of 61 mM for the substrate sucrose and displayed its optimum reaction 
conditions at pH 4.5 – 5.0 and a temperature of 35oC. Furthermore, SAS-Ls had an extremely high Kcat 
turnover of 7682s-1 and 5587s-1 for the hydrolytic and trans-fructosylation reaction respectively, which 
makes it one of the highest reported yet. The fructo-oligosaccharides produced by SAS-Ls was identified 
as a levan type with β-2,6 linkage by NMR and hydrolysis analysis. β-2,6 linked FOS together with GOS 
are proven prebiotic sources and SAS-Ls could significantly contribute to the production of prebiotic 
FOS. Leven type oligosaccharides and polymers also have a multitude of other potential applications in 
the food, cosmetic and medical industries, in all of which SAS-Ls could potentially find relevance. Like 
the galactosidase activity of MS-βgluc1 and HW-βgal1, SAS-Ls could furthermore possibly contribute to 
the production of novel and rare hetero-oligosaccharides through its trans-glycosylation activity, and 
this needs to be explored in future research.  
In CHAPTER 2: the various characteristics and health promoting effects of prebiotics were extensively 
reviewed, together with its influence on the GI microbiota and ultimately its human, host both in a 
diseased and healthy state. Additionally to the before mentioned, was an examination of its enzymatic 
production, and also a review of the unique biocatalyst that facilitate this. In CHAPTER 6: the enzymatic 
catalyst isolated and characterised in the three experimental chapters were thoroughly discussed, not 
only in the prebiotic context, but also in their potential application in the synthesis of other 
hetero-oligosaccharides derived from lactose and/or sucrose. All three biocatalyst have potential to be 
employed on an industrial level and their discovery and characterisation adds to the ever expanding 
field of prebiotic enzymatic synthesis. Numerous avenues exist for further research to be conducted, so 
as to broaden their application and relevance.  
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APPENDIX 
A1 pBK-CMV vector map 
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A2 pRSET A, B and C vector map. 
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A3 GB-BGal1 sequence 
LOCUS GB_Bgal1_GH2 1024 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..1023 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 47..216 
/Domain bit score=174.9 
/Domain bias=0.0 
/Accession=PF02837.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_N 
Region 219..330 
/Domain bit score=56.6 
/Domain bias=0.0 
/Accession=PF00703.16 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2 
Region 333..626 
/Domain bit score=394.1 
/Domain bias=0.0 
/Accession=PF02836.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_C 
Region 749..1021 
/Domain bit score=277.4 
/Domain bias=0.0 
/Accession=PF02929.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Bgal_small_N 
ORIGIN 
1 MPSTLASLLS RRDWENPVVT QWHRLAAHAP MRSWRDETAA RDEADSAAHH SLNGIWQFSF 
61 FASPEAVPEQ WLEQDCADAV AMPVPSNWQM QGFDTPIYTN VTYPIPVNPP FVPQQNPTGC 
121 YSLTFNVDAE AIAEGQTRIV FDGVNSAFHL WCNGQWVGYS QDSRLPAEFD LSAVLRAGEN 
181 RLAVMVLRWC DGSYLEDQDM WRMSGIFRDV SLQHKPALHI ADYHYTTALN AEFTRASVQV 
241 TVELAGEFAG SRVTAVLWRN GEKIASGEQT PGSAVVDERG NWAERLSLTL PVESPLLWSA 
301 ETPNLYRLTL TLYDAQGSCV EAEACDVGFR HVEIHQGLLK LNGQPLLIRG VNRHEHHPEH 
361 GQAVDEATMW RDIELMKQHN FNAVRCSHYP NHPLWYRLCD RYGLYVVDEA NIETHGMVPM 
421 SRLADDPRWL PAMSERVTRM VQRDRNHPSI IIWSLGNESG HGANQDALYR WLKSTDPTRP 
481 VQYEGGGANT AATDIICPMY SRVDQDQPFP AVPKWSIKKW IGMPNETRPL ILCEYAHAMG 
541 NSFGGFAKYW QAFRAAPRLQ GGFVWDWVDQ ALTKTGADGE LFWAYGGDFG DTPNDRQFCM 
601 NGLVFPDRTP HPALFEAQRA QQFFQFSLLS ASPLTIEVTS EYLFRTSDNE VLRWRVERDG 
661 EVLAQGETAL VIAPQGKVQI ALDLPELAAA PGEVWLNAEV YQREATAWSA AGHRCAWDQW 
721 RLPAPLWVAV PDKQGEQPTL EVNDETYTVK QGNQRWAFCR QRGNLVQWWR DGQETLLTPV 
781 TDCFTRAPLD NDIGVSEVTR IDPNAWMERW KAAGMYDLHA ELLSFEVQES AQEVTLRTVH 
841 RWIGAGKSAF ISEKTWRIDR TGGLQADIEV VVANDIPPPA RIGLVCQLAE RPAEVSWLGL 
901 GPHENYPDRK LAACQGRWTQ PLAALHTPYI FPGENGLRCD TRLLQCGAHQ LEGRFHFSLG 
961 CYSDTQLRET THHHLLREEA GCWLHLDAFH MGVGGDDSWS PSVSPEFILQ QERVRYRLRW 
1021 QQA* 
//   
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A4 HW-Bgal1 sequence 
 
LOCUS HW_Bgal1_GH2 1036 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..1035 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 56..225 
/Domain bit score=160.7 
/Domain bias=0.0 
/Accession=PF02837.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_N 
Region 228..341 
/Domain bit score=37.5 
/Domain bias=0.0 
/Accession=PF00703.16 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2 
Region 344..637 
/Domain bit score=401.4 
/Domain bias=0.0 
/Accession=PF02836.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_C 
Region 761..1033 
/Domain bit score=295.3 
/Domain bias=0.0 
/Accession=PF02929.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Bgal_small_N 
ORIGIN 
1 MPISDTSRRH APDFHAVLAR EDWQNQTITH LNRLPAHPAF ASWRDELAAR DNRPSPRRRQ 
61 LDGEWQFAYA RSPFAVDAQW LTQDLPGSRG TPVPSNWQME GYDAPIYTNV RYPIDTIPPR 
121 VPEDNPTGCY SLHVAIDDAW HTDGQTQIIF DGVNSAFHLW CNGAWVGYSQ DSRLPAAFDL 
181 SPFLRPGDNR LCVMVMRWSA GSWLEDQDMW RMSGIFRSVW LLNKPHQRLC DVQLTPTLDA 
241 LCRDGALQVQ ATVEATEAAL AGLCVGVSLW RGEQPVAAHR QPLGSPAVDE RGHYAERVDF 
301 SLAVAAPAHW SAETPNCYRA VVTLWRGDEL LEAEAWDIGF RRIEIADGLL RLNGKPLLIR 
361 GVNRHEHHHL RGQVVSEADM VQDILLMKQN NFNAVRCSHY PNAPRWYELC NRYGLYVVDE 
421 ANIETHGMVP MNRLSDDPAW LPAFSARVTR MVQSNRNHPC IIIWSLGNES GGGGNHEALY 
481 HWLKRNDPSR PVQYEGGGAD TTATDIICPM YARVERDQPI PAVPKWGIKK WISLPGEQRP 
541 LILCEYAHAM GNSLGNFADY WQAFREYPRL QGGFIWDWAD QAICKTFDDG SVGWAYGGDF 
601 GDKPNDRQFC MNGLVFPDRT PHPSLIEAKH AQQYFQFALL STSPLRVRIA SEYLFRQSDN 
661 EALRWQVQAA GETLYHGNLT LALPPEGSDE ITLLDDLILP PGARAVWLTL EVVQPRATDW 
721 SPADHRVAWQ QFPLPAPLAL PAPTVPAGAP DLVVSEEAWQ IRAGTQCWTV DRRTGLLSGW 
781 SLAGQEQLLT PLQDQFIRAP LDNDIGVSEV ERIDPNAWVE RWKSAGLFDL EACCVQCDAQ 
841 RLANETLVDS RWHYLRGDEV VIVSHWRMRF TADGTVRLTV DGERAETLPP LPRVGLHFQV 
901 AEQQAPVSWL GLGPHENYPD RRSSACFARW EQPLAAMSTP YIFPTENGLR CDTQALDWGR 
961 WHVSGHFHFS VQPWSTRQLM ETDHWHKIQA KDGVWITLDG LHMGVGGDDS WTPSVLPQWL 
1021 LTQTRWQYEV SLRCL*  
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A5 HW-Bgal2 sequence 
LOCUS HW_Bgal2_GH2 1025 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..1024 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 48..217 
/Domain bit score=167.1 
/Domain bias=0.0 
/Accession=PF02837.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_N 
Region 220..331 
/Domain bit score=54.7 
/Domain bias=0.0 
/Accession=PF00703.16 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2 
Region 334..627 
/Domain bit score=396.9 
/Domain bias=0.0 
/Accession=PF02836.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_C 
Region 750..1022 
/Domain bit score=255.9 
/Domain bias=0.0 
/Accession=PF02929.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Bgal_small_N 
ORIGIN 
1 MSATALSSLV SRRDWENPVI THWHRLPAHA PLRSWRDENA ARDDAASPAR RLLNGEWRFS 
61 LFGSPEAVPE RWITEDCADA VAMPVPSNWQ MQGFDTPIYT NVTYPIPVTP PFVPQQNPTG 
121 CYSLTFLMEE EALAQGQTRI VFDGVNAAFY LWCNGQWIGY SQDSRLPAEF DLSQALHPGE 
181 NRLAVMVLRW CDGSYLEDQD MWRMSGIFRD VSLQHKPQTH IADFHYVSEL NAELTHAQLQ 
241 VNVQLAGAFA ECRVAVALWH DGKNIAAAQQ SPGSAVVDER GAWAERLCVT LPVAAPVLWS 
301 AETPNLYRLT LTLLDAQGNV LEAEACDVGF RKVEICNGLL LLNGKPLLIR GVNRHEHHPE 
361 NGQAIDEATM RRDIELMKQH NFNAVRCSHY PNHPLWYRLC DRYGLYVVDE ANIETHGMVP 
421 MSRLADDPGW LPAMSERVTR MVQRDRNHPS IIIWSLGNES GHGANHDALY RWLKTTDPTR 
481 PVQYEGGGAN TAATDIVCPM YARVDQDQPF PAVPKWSIKK WIGLPGENRP LILCEYAHAM 
541 GNSFGGFAKY WEAFRAFPRL QGGFVWDWVD QALTKTGDDG QPFWAYGGDF GDTPNDRQFC 
601 MNGLVFPDRT PHPALYEAQR AQQFFQFSLL STTPLVLEVE SEYLFRATDN EYLRWSVARD 
661 GDVLAQGEIT LDIAPQGKQR IELNIPALVA APGEVWLNVD VFQRAATRWS AADHRCAWDQ 
721 WRLPAPLYIA PRVVQNSRPT LQASEQEFVI THQSQRWHFC RRSGNLQQWW RDEQPTLLAP 
781 LSDCFSRAPL DNDIGISEVT RIDPNAWVER WKAAGMYDLS AELLYCDVEE RSTGIVVNTG 
841 QRWLGAGKTA FLSHKCWRID GDGALHGDVT VQVARDIPPP ARVGLVCQLA ERHPQVSWLG 
901 LGPHENYPDR QLAARQGRWT QPLSALHTPY IFPGENGLRC NTRAVWYGAH QWQGDFHFSL 
961 GCYSDKQLRE TTHHHLLREE AGCWLHLDAF HMGVGGDDSW SPSVSPEFIL QDETVRYAFC 
1021 WWQN* 
//  
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A6 HW-Bgal3 sequence 
LOCUS HW_Bgal3_GH2 1036 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..1035 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 55..224 
/Domain bit score=173.6 
/Domain bias=0.0 
/Accession=PF02837.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_N 
Region 227..339 
/Domain bit score=39.6 
/Domain bias=0.0 
/Accession=PF00703.16 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2 
Region 342..635 
/Domain bit score=391.6 
/Domain bias=0.0 
/Accession=PF02836.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_C 
Region 759..1031 
/Domain bit score=270.1 
/Domain bias=0.0 
/Accession=PF02929.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Bgal_small_N 
ORIGIN 
1 MSKPISSASL TGLATLLARR DWENPVVTHW HRLACHAPLA SWRTEQEARG GAPSAQRYSL 
61 NGQWAFCLYP SPESVPESWL QADEPQSVAT PVPGNWQMAG FDTPVYTNVN YPIVATPPCV 
121 PVENPTGCYS RRFSVEPDWL MSGQTRIIFD GVNAAFYLWC NGHWVGYSQD SRLPAEFDLT 
181 PYLTAGENRL AVMVLRWCDG TWLEDQDMWR MSGIFRDVTL LHKPACRIAD YHHQVCFNSD 
241 YSRASLTLTL ETEGEQPQAC QAEVSLWRDG QCIVRQTKPL GSQVIDERGN YPERVTLTLD 
301 IENPLLWSAE TPHRYRLVMV LQDKQGQCLD AEACWTGLRE IVIQNGLLKL NGKPLLIRGV 
361 NRHEHHPEHG QVMDEATMRQ DILLMKQHNF NAVRCSHYPN HPLWYQLCDE YGLYVVDEAN 
421 IETHGMQPMS RLADDPRWFG AMSERVTRMI QRDRNHACII IWSLGNESGH GANHDALWRW 
481 VKTTDPSRPV QYEGGGANTA ATDIVCPMYA RVDEDQPFEQ VPKWSIKKWV GMPDEHRPLI 
541 LCEYAHAMGN SLGGFYRYWQ AFRQYPRLQG GFVWDWVDQA LTRHTEQGED WWAYGGDFGD 
601 KPNDRQFCLN GLVFPDRTPH PALFEAQHAQ QFFRFDLVDA HPLTVRITSE YLFRDTDNER 
661 LCWAVMQDGE PVLEGHRVLN LAPEAEVTIV LGDVPVQTRP GQRWLTLWVE YAADTLWARA 
721 GQACAWGEWQ LPARLFSLPE AEPMGDLPQL TTTETEYVVC HGNKQWVFDR AQGTLAQCRV 
781 DGAAQLYSPV VDQFVRAPLD NDIGTSEAAR IDPLAWVERW KAAGMYQLTP QVVLCEAGTV 
841 FGDVVIRTRH AWYAQQQCCF ISEKQWRIDR LGILHIDVDV HIAGDIPPPA RIGLCCQLAI 
901 VAPRVEWLGR GPHENYPDRK LSALQGRWRL PLEEMHTPYI FPSENGLRCD TRKLCYGHHQ 
961 WQGEFHFGLG RYSLQQLMDV SHRHLLTEEP GTWLNLDAFH MGIGGDDSWS PSVHRENILT 
1021 KTHVHYQLRW SLDAM* 
//  
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A7 HW-Bgal4 sequence 
LOCUS HW_Bgal4_GH42 686 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..685 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 20..393 
/Domain bit score=514.6 
/Domain bias=3.2 
/Accession=PF02449.10 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_42 
Region 404..616 
/Domain bit score=242.3 
/Domain bias=0.0 
/Accession=PF08532.5 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_42M 
Region 627..683 
/Domain bit score=42.1 
/Domain bias=0.0 
/Accession=PF08533.5 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_42C 
ORIGIN 
1 MNKFAPLHPK VNTLLHGADY NPEQWENDPD IIDKDIAMMQ QAKCNVMSVG IFSWAKLEPR 
61 EGVFDFAWLD TILDKLYAAG IHVFLATPSG ARPAWMSQRY PQVLRVGRDR VPALHGGRHN 
121 HCMSSPIYRE KTLKINSLLA ERYAAHPAVL GWHISNEYGG ECHCDLCQAR FRGWLKARYQ 
181 TLENLNQAWW STFWSHTYSD WSQIESPAPQ GETSIHGLNL DWHRFNTAQV TDFCRHEIAP 
241 LKAANAALPV TTNFMEYFYD YDYWQLAEVL DFISWDSYPM WHRDKDETAL ACYTAMYHDM 
301 MRSLKGGQPF VLMESTPGAT NWQPTSKLKK PGMHILSSLQ AVAHGADSVQ YFQWRKSRGS 
361 VEKFHGAVVD HVGHIDTRIG REVSKLGEIL SKLPEVRGCR TEAKVAIIFD QQNRWALDDA 
421 QGPRNLGMEY EKTVNEHYRP FWEQGIAVDV IDADADLTPY RLVIAPMLYM VRDGFAARAE 
481 AFVASGGHLV TTYWTGIVNE SDLCYLGGFP GPLRNLLGIW AEEIDCLNDG EFNLVQGLAG 
541 NQCGLQGPYQ VRHLCELIHT ESAQTLATYR DDFYAGRPAV TVNGFGKGKA WHVASRNDLA 
601 FQRDFFAALS KELALPRAIA ADLPPGVVAT ARTDGESTFV FLQNYSAQSH TLSLPSGYRD 
661 CLTDAAVSDP LTLSAWDCRI LRRHA* 
//  
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A8 HW-Bgal5 sequence 
LOCUS HW_Bgal5_GH53 401 aa linear UNA 
FEATURES Location/Qualifiers 
sig_peptide 1..23 
/note="Cleavage site: 23^24: SLA-AD" 
/note="D-score: 0.696" 
/note="D-cutoff: 0.45" 
/note="Max C-score: 0.448" 
/note="Max S-score: 0.922" 
/note="Max Y-score: 0.603" 
/note="S-mean: 0.842" 
/note="Networks: SignalP-TM" 
sig_peptide 1..23 
/note="Cleavage site: 23^24: SLA-AD" 
/note="D-score: 0.927" 
/note="D-cutoff: 0.57" 
/note="Max C-score: 0.853" 
/note="Max S-score: 0.975" 
/note="Max Y-score: 0.905" 
/note="S-mean: 0.953" 
/note="Networks: SignalP-noTM" 
Region 1..400 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 41..399 
/Domain bit score=403.2 
/Domain bias=0.8 
/Accession=PF07745.8 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_53 
ORIGIN 
1 MKRFTPAWLA VCLACSFSLP SLAADALETR AFQGMPADFI KGADISTLLD AEKHGAIFYD 
61 QNNQRKDPIA ILKENGVNYV RLRLWVDPQS ASGEGYGGGN NDLATTLALA KRAKAQGMKL 
121 LLDFHYSDFW TDPGKQFKPK AWEKMDYPQL KTAIHDYTRD TIARFKQAGV LPDMVQIGNE 
181 INGGMLWPEG KSWGQGGGEF DRLAGLLNAA IDGLKANLRN GEQVKIMLHL AEGTKNDTFR 
241 WWFDEIEKRH VPYDVIGLSM YTYWNGPISA LKANMDDISK RYNKDVIVVE AAYAYTLANC 
301 DNAENSFQAK EEKDGGYPAT VQGQYRYIHD LMQAVIDVPD QRGKGIFYWE PTWIAVPGNT 
361 WATPAGMKYI HDEWKEGNAR ENQALFDCQG KVLPSVKVFN * 
//  
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A9 HW-Bgluc1 sequence 
LOCUS HW_Gluc1_GH1 445 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..444 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 2..444 
/Domain bit score=542.5 
/Domain bias=6.9 
/Accession=PF00232.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_1 
ORIGIN 
1 MNKFSKDFIF GTATSSYQIE GAYQEDGRTP SIWDTFSRTP GKVFNMDNGD IACDHYHLYE 
61 KDIEILKTLG VDSYRFSIAW PRIFPKQGKY NEAGMDFYKR LITRLIENGI KPAVTLYHWD 
121 LPMWAHEKGG WTNRESVNWF LEYAEKCFEE LDEHVEMWST HNEPWCAGFL GYHQGVHAPG 
181 HTNMEEAVKA VHHMLLSHGE AVSLLKGKFV SETPIGITLN LSPMYPASNS ANDQLAANNA 
241 DGYTNRWFLD PVLKGSYPAD MMNLFSKYVH SFDFIQEGDL EKISVECDFF GINYYNRSLV 
301 EFNSASDFLF KSAYSDYPKS GMGWDISPAE FKELIHRLRK EYTNLPIYIT ENGSAFDDHV 
361 SEDHRVHDSD RQDYVEKHIT AVAELNDEGM NVAGYYLWSL LDNFEWAFGY DKRFGITYVD 
421 FETQERILKD SGYRYAEIIR NRSI* 
//  
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A10 HW-Bgluc2 sequence 
LOCUS HW_Gluc_GH16 256 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..255 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 41..249 
/Domain bit score=136.2 
/Domain bias=0.8 
/Accession=PF00722.16 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_16 
ORIGIN 
1 MMTLSKTEAE WSLVWEENFD LPDIDESKWN FVEAGTGFGN EESQFYTRRK ENARIENGML 
61 VLEARNEEYN GMDYTSAKLT TRGKAAWTYG RFSIRAKLPE GQGIWPAIWM MPEDMELYTG 
121 WPACGEIDIM ELIGHQPGTV YGTLHYGMPH TYTGENYTLP DGKKFSEDFH VFTLDWKPGE 
181 FRWYVDDVPY ARQTEWFSQS PESAEKQAGF APFDRDFYLQ LNLAVGGKWP GYPDEKTQFP 
241 QQMTVDYIKV YKKEK* 
//  
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A11 MS-Bgal1 sequence 
LOCUS MS_Bgal1_GH2_(32) 1132 aa linear UNA 
FEATURES Location/Qualifiers 
sig_peptide 1..22 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 72..252 
/Domain bit score=166.5 
/Domain bias=0.4 
/Accession=PF02837.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_N 
Region 255..365 
/Domain bit score=62.0 
/Domain bias=0.0 
/Accession=PF00703.16 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2 
Region 377..661 
/Domain bit score=279.1 
/Domain bias=2.9 
/Accession=PF02836.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_C 
Region 787..905 
/Domain bit score=55.2 
/Domain bias=0.1 
/Accession=PF02929.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Bgal_small_N 
Region 1057..1115 
/Domain bit score=26.4 
/Domain bias=0.0 
/Accession=PF02929.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Bgal_small_N 
ORIGIN 
1 MKFKFLSLVL TVGLSTIVTL HAQESRMISS QRKTPYWQDV NVVQVNKEYP RTQFMTFDNK 
61 PEAMNSRFEE SKYYISLNGT WKFYFVEGYK QLPENVTDSV VSLSGWKEIK VPGNWELQGF 
121 GTPIYVNHPY EFVERDPKTR FPKFAPPYLP EKNPVGVYRR EIDIPQDWKD REIFLSIDGA 
181 KSGVYVYING KEVGYSEDSK TSAEFRISKY VKPGKNSLVL KIFRWSTGSY LECQDFWRIS 
241 GIERDVFLWS QPKTSLRDFR VKSTLDDSYQ NGIFELETTV SNYSPGVSYA EVFYELLDAA 
301 GKTAASGSQA VSVQGQGENT VKFEAQLPNV ATWTSEHPNL YKLLISVRKE GEKSGEVVPY 
361 SVGFRRFEIK AVKTGERIDR LFLVNGQPIK LKGVNIHETN PKTGHYVPEE LMRKDFELMK 
421 QNNINTVRLS HYPQARRFYE LCSEFGLYVY DEANIESHGM YYGQESLAKH PEWEQAHRDR 
481 TVNMFERNKN HPSVAIWSLG NEAGNGINFF HTYKYLKDQE RNFMNRPVNY ERGLWEYNTD 
541 MYVPQYPSAA WLEEVGKKGS DRPVVPSEYS HAMGNSSGNL DLQWQAIYKY PNLQGAYIWD 
601 WVDQGMEAVD ENGRVYYTYG GDYGTDMPSD GNFLCNGIVN PDRTPHPAMA EVKYTHQNFA 
661 VEAVDLTKGI FNIINRQYFS NTDNYTFKYN ITENGKQISE GVLPVTLAPQ QAAHATVPVG 
721 QIKARPGMEY FLNFEVVQKT ATQLIPANHI VAVEQFKLPI TLPKQAFTDK SQKPELNITS 
781 SGKSIVVKSP TVNFVFDKKS GTVTSYKVTG QEYFDKGFGI QPNFWRAPND NDFGNGNPHR 
841 LQVWKQSSRH FNVTDVKGYA QGNNAVVETT YLLAAGNLYT IKYTVHPSGV VKVDVEFHST 
901 DMQAAQLEAS EATLMATASP EATAARKASS ELVVPRIGVR FRLPASMNAV EYFGRGPGEN 
961 YIDRASGSKV GLYKTTADEM YFPYVRPQEN GHRTDTRWVA LKGAGNGLMV VADETIGFNS 
1021 LKNSVEDFDS EEATRRPYQW NNFSSEEIAG RDDADAKNKR PRHTHINDIT PRNFVEVCVD 
1081 MKQQGVAGYN SWGARPLPEY SIPANQNYKW GFTLVPFGNA GDIQIKSVLK Y* 
//  
Stellenbosch University  https://scholar.sun.ac.za
 126 
 
A12 MS-Bgal2 sequence 
LOCUS MS_Bgal2_GH42_(17A) 689 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..688 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 23..396 
/Domain bit score=515.3 
/Domain bias=4.7 
/Accession=PF02449.10 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_42 
Region 407..619 
/Domain bit score=239.1 
/Domain bias=0.0 
/Accession=PF08532.5 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_42M 
Region 630..686 
/Domain bit score=36.3 
/Domain bias=0.0 
/Accession=PF08533.5 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_42C 
ORIGIN 
1 MFIMNKFAPL SPKVNALLHG ADYNPEQWEN YPGIIDQDIA MMQQAKCNVM SVGIFSWAKL 
61 EPQEGVFEFG WLDSILDKLY AAGIHVFLAT PSGARPAWMS QAYPQVLRVG RDRVPALHGG 
121 RHNHCMTSPV YREKIFKINS LLAERYAQHP AVLGWHISNE YGGDCHCERC QARFRDWLKA 
181 RYQTLDNLNH AWWSTFWSHT YSDWSQIESP APQGEVSIHG LNLDWRRFNT AQVTDFCRHE 
241 IAPLKAANAD LPVTTNFMEY FYDYDYWQLA QALDFISWDS YPMWHRDKDE TTLACYTAMY 
301 HDMMRSLKGG KPFVLMESTP SATNWQPTSK LKKPGMHILS SMQAVAHGAD SVQYFQWRKS 
361 RGSVEKFHGA VIDHVGHLDT RVGREVSRLG DMLSRLPGVV GCRTDAKVAI IFDQQNRWAL 
421 DDAQGPRNLG MEYENTVNEH YRPFWEQGIA VDIIDADGDL SAYQLVIAPM LYMVRDGFAA 
481 RAEAFVADGG HLVTTYWTGI VNESDLCHLG GFPGPLRNLL GIWAEEIDCL NDGERNLVQG 
541 LAGNEGGLQG PYQVRHLCEL IHAESARPLA TYRDDFYAGR PAVTVNHFGK GKAWHVASRN 
601 DLAFQRDFFA VISRELALPR AIESELPPGV VATARTDGET TYVFLQNYSA QQHSVSLPQG 
661 YQDSLSGAAI SAPLTLTAWD CRILSRKA* 
//  
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A13 MS-Bgal3 sequence 
LOCUS MS_Bgal3_GH53 401 aa linear UNA 
FEATURES Location/Qualifiers 
sig_peptide 1..23 
/note="Cleavage site: 23^24: ALA-AE" 
/note="D-score: 0.813" 
/note="D-cutoff: 0.45" 
/note="Max C-score: 0.604" 
/note="Max S-score: 0.967" 
/note="Max Y-score: 0.745" 
/note="S-mean: 0.92" 
/note="Networks: SignalP-TM" 
Region 1..400 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 41..399 
/Domain bit score=403.5 
/Domain bias=2.0 
/Accession=PF07745.8 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_53 
ORIGIN 
1 MKRLTPALLA VCLACSFSPA ALAAEALQTR AFRALPADFI KGADISTLLD AEKHGAKFYN 
61 HNNQQQDPIA ILKADGVNYV RLRLWVDPKD AQGQGYGGGD NDLAATLALA KRAKAQGMKL 
121 LLDFHYSDFW TDPGKQFKPK AWEKMDYPQL KTTIHDYTRD TIARFKQEGV LPDMVQIGNE 
181 INGGMLWPEG KSWGQGGGEF DRLAGLLNAA IDGLKENLQN GEQVKIMLHL AEGTKNDTFR 
241 WWFDEISKRN VPYDIIGLSM YTYWNGPISA LKANMDDISR RYNKDVIVVE AAYAYTLENC 
301 DNAENSFQAK EEKEGGYPAT VQGQYNYIHD LMQAVADVPD QRGKGIFYWE PTWIAVPGNT 
361 WATPAGMKYI HDEWKQGNAR ENQALFDCQG KVLPSAKVFN * 
//  
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A14 MS-Gluc1 sequence 
LOCUS MS_Gluc1_GH1_(3L) 438 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..437 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 6..437 
/Domain bit score=498.7 
/Domain bias=0.1 
/Accession=PF00232.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_1 
ORIGIN 
1 MFSFDRRDFG SNFTFGVATA AYQIEGGQGD GRGQSIWDTF SATPGNVHNG DTGRDACNHY 
61 ELWAQDLDLI RDGGFDAYRF SFAWPRLIPE GTGAINQAGV DFYDRLIDGM LERGIKPYAT 
121 LYHWDLPSAL QDRGGWMNRD IANWFADYAS LIAEKYGDRL AATATINEPW CVAFLSHFLG 
181 VHAPGYRDLR AAARAMHHVL YAHGTAIDAL RAGGAKNLGI VLNLEKSEPA TESDEDKAAC 
241 NFGDALFNRW YLGGVFKGQY PKELTEWLAP YLPANYQADM DVVSRPLDWL GINYYTRSLY 
301 KASQMPGRPV DQVKGPLEKT DIGWEIYPKG LSDLLVRVSN EYTKLPIFVT ENGMAEVEGD 
361 NDPRRVKYYE DHLKAVLAAK KDGADVRGYF AWSLLDNYEW AEGYNKRFGL VHVDYETQKR 
421 TPKASFRSFQ GLLHNTR* 
//  
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A15 MS-Gluc2 sequence 
LOCUS MS_Gluc2_GH1_(4L) 433 aa linear UNA 
FEATURES Location/Qualifiers 
sig_peptide 1..23 
/note="Cleavage site: 23^24: AAA-AT" 
/note="D-score: 0.738" 
/note="D-cutoff: 0.45" 
/note="Max C-score: 0.647" 
/note="Max S-score: 0.886" 
/note="Max Y-score: 0.705" 
/note="S-mean: 0.79" 
/note="Networks: SignalP-TM" 
Region 1..432 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 28..289 
/Domain bit score=134.6 
/Domain bias=0.0 
/Accession=PF00232.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_1 
Region 269..431 
/Domain bit score=89.3 
/Domain bias=0.0 
/Accession=PF00232.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_1 
ORIGIN 
1 MNRRTVIGMI GASAAASAFP AAAATGKPRR TPAGFLWGTA GAAYQVEGGN VASDLWVVEQ 
61 LNTPLFAEPS GDACDVYHRY EDDLELVARL GFNCHRLGIE WSRIEPERGQ ISEAELAYYR 
121 RVLQACVRNG LKPVITFSHF TVPRWVAASG GFKDPANIEA FAAHCARLTR TMGDLIHLAA 
181 TFNEPNLSTV VRWTGLGDKI RPLIESVQRA AGASQNAPKW SSPMLGGETQ FEGIIAAHTR 
241 AIDAIRQAGG RFPIGLTLAL PADTAAGGDD GPLKRKQAEM MDRWIAAPGD FIGVQTYTST 
301 PVGPDGDLPP APGTELTQMG YPFTPSAVEG AVRMVAARTS KPIYITENGV ATEDDSRRIA 
361 YIDGAIAGVQ RLLADGIDLR GYIHWSLLDN WEWMHGYKPK FGLVAVDRKT FKRTPKPSAS 
421 HLGAIARRGG LA* 
//  
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A16 SAS-Bgal1 sequence 
LOCUS SAS_Bgal1_GH2 1024 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..1023 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 47..216 
/Domain bit score=174.9 
/Domain bias=0.0 
/Accession=PF02837.13 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_N 
Region 219..330 
/Domain bit score=56.6 
/Domain bias=0.0 
/Accession=PF00703.16 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2 
Region 333..626 
/Domain bit score=394.1 
/Domain bias=0.0 
/Accession=PF02836.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_2_C 
Region 749..1021 
/Domain bit score=277.4 
/Domain bias=0.0 
/Accession=PF02929.12 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Bgal_small_N 
ORIGIN 
1 MPSTLASLLS RRDWENPVVT QWHRLAAHAP MRSWRDETAA RDEADSAAHH SLNGIWQFSF 
61 FASPEAVPEQ WLEQDCADAV AMPVPSNWQM QGFDTPIYTN VTYPIPVNPP FVPQQNPTGC 
121 YSLTFNVDAE AIAEGQTRIV FDGVNSAFHL WCNGQWVGYS QDSRLPAEFD LSAVLRAGEN 
181 RLAVMVLRWC DGSYLEDQDM WRMSGIFRDV SLQHKPALHI ADYHYTTALN AEFTRASVQV 
241 TVELAGEFAG SRVTAVLWRN GEKIASGEQT PGSAVVDERG NWAERLSLTL PVESPLLWSA 
301 ETPNLYRLTL TLYDAQGSCV EAEACDVGFR HVEIHQGLLK LNGQPLLIRG VNRHEHHPEH 
361 GQAVDEATMW RDIELMKQHN FNAVRCSHYP NHPLWYRLCD RYGLYVVDEA NIETHGMVPM 
421 SRLADDPRWL PAMSERVTRM VQRDRNHPSI IIWSLGNESG HGANQDALYR WLKSTDPTRP 
481 VQYEGGGANT AATDIICPMY SRVDQDQPFP AVPKWSIKKW IGMPNETRPL ILCEYAHAMG 
541 NSFGGFAKYW QAFRAAPRLQ GGFVWDWVDQ ALTKTGADGE LFWAYGGDFG DTPNDRQFCM 
601 NGLVFPDRTP HPALFEAQRA QQFFQFSLLS ASPLTIEVTS EYLFRTSDNE VLRWRVERDG 
661 EVLAQGETAL VIAPQGKVQI ALDLPELAAA PGEVWLNAEV YQREATAWSA AGHRCAWDQW 
721 RLPAPLWVAV PDKQGEQPTL EVNDETYTVK QGNQRWAFCR QRGNLVQWWR DGQETLLTPV 
781 TDCFTRAPLD NDIGVSEVTR IDPNAWMERW KAAGMYDLHA ELLSFEVQES AQEVTLRTVH 
841 RWIGAGKSAF ISEKTWRIDR TGGLQADIEV VVANDIPPPA RIGLVCQLAE RPAEVSWLGL 
901 GPHENYPDRK LAACQGRWTQ PLAALHTPYI FPGENGLRCD TRLLQCGAHQ LEGRFHFSLG 
961 CYSDTQLRET THHHLLREEA GCWLHLDAFH MGVGGDDSWS PSVSPEFILQ QERVRYRLRW 
1021 QQA* 
//  
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A17 SAS-BGal2 sequence 
LOCUS SAS_Bgal2__GH42 686 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..685 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 20..393 
/Domain bit score=516.5 
/Domain bias=5.4 
/Accession=PF02449.10 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_42 
Region 404..616 
/Domain bit score=240.9 
/Domain bias=0.0 
/Accession=PF08532.5 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_42M 
Region 627..683 
/Domain bit score=40.2 
/Domain bias=0.0 
/Accession=PF08533.5 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_42C 
ORIGIN 
1 MNKFAPLSPK VVSLLHGADY NPEQWENYPG IIDKDIAMMQ QAKCNVMSVG IFSWSKLEPQ 
61 EGVFNFAWLD EVIEKLYAAG IHIFLATPSG ARPAWMSQKY PQVLRVGRDR VPALHGGRHN 
121 HCMTSPVYRE KTLKINTLLA ERYGQHPAVL GWHISNEYGG ECHCDLCQQK FRDWLKARYQ 
181 TLEALNHAWW SDFWSHTYSD WSQIESPAPQ GEVSIHGLNL DWRRFNTAQV TDFCRHEVAP 
241 LKAANAALPV TTNFMEYFYD YDYWQLAEAI DFISWDSYPM WHRDKDETQL ACYTAMYHDM 
301 MRTLKGGKPF VLMESTPSVT NWQPTSKLKK PGMHILSSLQ AVAHGADSVQ YFQWRKSRGS 
361 VEKFHGAVID HVGHLDTRVG REVSALGEML SKLTPVMGCR TEARVAIIFD QQNRWALDDA 
421 QGPRNKGMEY EKTVNEHYRP FWEKGVAVDV INADADLGRY HLVIAPMLYM VRDGFAERAE 
481 SFVASGGHLV TSYWSGVVNE SDLCHLGGFP GPLRNLLGIW AEEIDCLDDH ERNLVQGLAG 
541 NEAGLQGPYQ VRHLCELIQL EGAQPLATYR DDFYAGRPAV TVNAFGKGKA WHVASRNDLA 
601 FQRDFFANLI DTLSLPRALN VELSPGVVAT AREDGEQAFV FIQNFTAQQQ SITLPPGYHD 
661 CLSEAAVSGA LALKPWDCRV VRRDA* 
//  
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A18 SAS-BGal3 sequence 
LOCUS SAS_Bgal3__GH53 396 aa linear UNA 
FEATURES Location/Qualifiers 
sig_peptide 1..21 
/note="Cleavage site: 21^22: ASA-VT" 
/note="D-score: 0.639" 
/note="D-cutoff: 0.45" 
/note="Max C-score: 0.223" 
/note="Max S-score: 0.973" 
/note="Max Y-score: 0.454" 
/note="S-mean: 0.928" 
/note="Networks: SignalP-TM" 
sig_peptide 1..21 
/note="Cleavage site: 21^22: ASA-VT" 
/note="D-score: 0.892" 
/note="D-cutoff: 0.57" 
/note="Max C-score: 0.718" 
/note="Max S-score: 0.978" 
/note="Max Y-score: 0.832" 
/note="S-mean: 0.959" 
/note="Networks: SignalP-noTM" 
Region 1..395 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 36..394 
/Domain bit score=398.2 
/Domain bias=1.9 
/Accession=PF07745.8 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_53 
ORIGIN 
1 MKRLTPALLA VCLAASFSAS AVTTRPFTQM PADFIKGADI STLLDAEKHG ATFYNDKNQP 
61 QDALAILKAN GVNYVRLRLW VDPKDAQGNA YGGGDNDLAT TLALAKRAKA QGMKLLLDLH 
121 YSDFWTDPGK QFKPKAWEKL DYPQLKSRVH DYTRDTIAQF KQAGVLPDMV QIGNEINGGM 
181 LWPEGKSWGQ GGGEFDRLAG LLTAGIDGVK ENLNNGEQVK IMLHLAEGTK NDTFRWWFDE 
241 ITKRNVPFDV IGLSMYTYWN GPISALQANM DDISKRYNKD VIVVEAAYAY TLANCDNAEN 
301 SFQAKEEKAG GYPATVQGQY DYVHDLMQSV INVQGQRGKG IFYWEPTWIA VPGNGWATPA 
361 GMKYINDHWK EGNARENQAL FDCQGKVLPS VKVFN* 
//  
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A19 SAS-LS sequence 
LOCUS SAS_LS_GH68_(Ls2) 430 aa linear UNA 
FEATURES Location/Qualifiers 
Region 1..429 
/region_type=Extracellular 
/note="TMHMM2.0 OUTSIDE" 
/label=outside 
Region 2..410 
/Domain bit score=407.2 
/Domain bias=0.1 
/Accession=PF02435.11 
/Predicted by="HMMER 3.1b1 (May 2013)" 
/label=Glyco_hydro_68 
ORIGIN 
1 MTYETSAWTI ADALKVRADD PTTTMPVIAQ NFPVIDEALW QWDTGALRTI RGATVTFKGW 
61 YVMWALVANK ADTGATVEGW HNRNAFAYIG YYYSRDGLDW TFGGRLLDKS ADLRPDEWSG 
121 GLVMREGTEN VVDMFYTSVN TDTNQSVPSV SSGRILADAN GVWFDGFTST TEMFAADGVH 
181 YANADEDQYF DFRDPHPFLN PADGKIYCLF EGNVAGIRGQ FVISDRERGP TPPAYDVDAG 
241 AQYGAAAIGI ARLDGNYSKG EFDKWTLLPP LVTALGVNDQ TERPHVVFQD GRTYLFTISH 
301 HSTYTGNLSG PDGVYGFVSD KGIFGPYRPL NGSGLVLGNP SVAPYETYSH FVDPQGYVQS 
361 FIDTLPAPDT VDPQNPVTYR IGGTLAPTVR ILLDGERTFL TEVHGYGQIF VQGAWPVRNT 
421 PDVRPVATS* 
// 
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